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1.  Deutsche Zusammenfassung 
MHC (major histocompatibility complex class)-Klasse I-Moleküle  präsentieren 
den CD8
+-T-Lymphozyten intrazellulär prozessierte Antigene. Die Präsentation 
wird durch den makromolekularen Peptidbeladungskomplex (PLC) vermittelt. 
Dabei spielen das Glykoprotein Tapasin als auch TAP (transporter associated 
with antigen processing) eine essentielle Rolle in der Peptidbeladung der 
MHC-Klasse I-Moleküle. Die durch das Proteasom produzierten Peptide werden 
von TAP aus dem Zytoplasma in das Lumen des Endoplasmatischen 
Retikulums (ER) transportiert. Anschließend werden diese Peptide auf 
MHC-Klasse I-Moleküle  geladen  und über den Golgi-Apparat an die 
Zelloberfläche transportiert. Dabei spielt das ER-ständige  Glykoprotein    
Tapasin eine wichtige Rolle: Tapasin fördert die optimale Faltung und 
Assemblierung der MHC-Klasse  I-Peptid-Komplexe. Außerdem reguliert 
Tapasin das Expressionsniveau von TAP, indem es diesen stabilisiert. Sowohl 
die strukturelle Organisation des PLCs, einschließlich des antigenen TAP-
Komplexes, als auch die Funktion von Tapasin auf die Peptidbeladung von 
MHC-Klasse I-Molekülen ist Gegenstand intensiver Forschung.  
In der vorliegenden Arbeit wurden rekombinante Fv, scFv und Fab 
Antikörperfragmente ausgehend von einer Hybridomzelllinie, die einen 
TAP1-spezifischen monoklonalen Antikörper mAb148.3 exprimiert, generiert. 
Wie bereits durch Epitopkartierung identifiziert, besteht das Epitop aus den 
letzten fünf C-terminalen Aminosäuren von TAP1. Die rekombinanten 
Antikörper wurden zunächst heterolog in E. coli sowie in Insektenzellen 
exprimiert und mittels Affinitätschromatographie zur Homogenität gereinigt. 
Sowohl der monoklonale als auch die rekombinanten Antikörper zeigen eine 
Affinität im nanomolaren Bereich bezüglich der letzten fünf C-terminalen 
Aminosäuren von TAP1 wie in enzyme linked immunosorbent assay (ELISA) 
und mittels Oberflächen-Plasmonen-Resonanz-Spektroskopie (SPR) gezeigt. 
Überraschenderweise stabilisieren die rekombinanten Antikörper den 
heterodimeren TAP-Komplex bei erhöhter Temperatur. Gleichzeitig wird, in 
Anwesenheit der rekombinanten Antkörper, die Peptid-Translokation durch TAP 
drastisch inhibiert. Dabei wird die ATP- und Peptid-Bindung an TAP nicht Deutsche Zusammenfassung 
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beeinträchtigt. Die rekombinanten Antikörper wurden ebenfalls bei der 
Reinigung des Peptidbeladungskomplexes  aus einer humanen B-
lymphoblastoiden Zelllinie erfolgreich angewendet. Hierbei konnte mittels 
Matrix-assistierter Laserdesorptionsionisations-Massenspektrometrie (MALDI-
MS) eine neue Komponente des PLCs, die Proteindisulfidisomerase (PDI), 
identifiziert werden.  
Ein weiterer Aspekt dieser Arbeit war die Etablierung eines in vitro Systems für 
die Untersuchung der Tapasin-MHC-Klasse  I-Interaktion. Dazu wurde ein 
Verfahren zur heterologen Expression und Reinigung von funktionalen, 
löslichen single chain MHC-Klasse I-Molekülen aus Insektenzellen aufgestellt. 
Neben einem tapasin-abhängigem MHC-Klasse I-Allel, HLA-B4402, wurde auch 
ein tapasin-unabhängiges HLA-B4405 als single chain Konstrukt generiert. Im 
Gegensatz zu dem tapasin-abhängigem scB4402-β2m, wurde das tapasin-
unabhängige scB4405-β2m ins Medium sezerniert und konnte zur Homogenität 
gereinigt werden. In Peptid-Bindungsstudien, sowie in Anisotropie-Messungen 
wurde die Funktionalität des scB4405-β2m nachgewiesen. Bei Untersuchungen 
der Wechselwirkung zwischen Tapasin und scB4405-β2m-Molekülen konnte 
mittels SPR eine direkte Interaktion nachgewiesen werden, wobei Hintergrund-
Interaktion der scB4405-β2m mit der Sensor-Oberfläche und die transiente, 
niederaffine Interaktion eine kinetische Auswertung schwierig machten. Um 
detaillierte Untersuchungen zur Rolle von Tapasin als Peptid-Editor 
durchzuführen, wurden Tapasin und scB4405-β2m-Peptid-Komplexe auf einer 
Chelator-Lipid-Oberfläche co-immobilisiert. Die Verwendung einer Lipid-
Doppelschicht ermöglichte laterale Mobilität. Mittels TIRFS (Totalinterne 
Reflektions-Fluoreszenz-Spektroskopie) wurde nun der Einfluß von Tapasin auf 
die Peptid-Dissoziation beobachtet. Dabei stellte sich heraus, dass die 
Peptid-Dissoziation des tapasin-unabhängigen scB4405-β2m in An- bzw. 
Abwesenheit von Tapasin unverändert blieb.  
Mit dem in dieser Arbeit etablierten in vitro Untersuchungssystem ist die 
Grundlage zu detaillierten Studien der Funktion von Tapasin, sowie weiteren 
Chaperonen des Peptidbeladungskomplexes wie z.B. ERp57 bei der 
Peptidbeladung von MHC-Klasse I-Molekülen geschaffen. 
 Summary 
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2.  Summary 
Presentation of intracellular processed antigens by major histocompatibility 
(MHC) class I molecules to CD8
+ cytotoxic T lymphocytes is mediated by the 
macromolecular peptide loading complex (PLC). In particular accessory 
proteins, including the transporter associated with antigen processing (TAP) and 
tapasin, play a pivotal role in the MHC class I mediated antigen presentation 
pathway. TAP belongs to the ATP-binding cassette (ABC) superfamily and 
consists of TAP1 (ABCB2) and TAP2 (ABCB3), each of which possesses a 
transmembrane and a nucleotide-binding domain (NBD). The ER-resident 
glycoprotein tapasin promotes the optimal folding and assembly of MHC-peptide 
complexes, and independently stabilizes the steady state expression level of 
TAP.  
In the present thesis recombinant Fv, scFv and Fab antibody fragments to 
human TAP from a hybridoma cell line expressing the TAP1-specific 
monoclonal antibody mAb148.3, were generated. The epitope of the mAb148.3 
was mapped to the very last five C-terminal amino acid residues of TAP1 on 
solid-supported peptide arrays. The recombinant antibody fragments were 
heterologously expressed in E. coli and insect cells, and purified to homogeneity 
by affinity chromatography. The monoclonal and recombinant antibodies display 
nanomolar affinity to the last five C-terminal amino acid residues of TAP1 as 
demonstrated by enzyme linked immunosorbent assay (ELISA) and surface 
plasmon resonance (SPR). Surprisingly, the recombinant antibody fragments 
confer thermal stability to the heterodimeric TAP complex in insect cells when 
incubated at elevated temperature. At the same time, TAP is arrested in a 
peptide transport incompetent conformation, although ATP and peptide binding 
to TAP are not affected. Furthermore, the recombinant antibodies were 
successfully used in the purification of the PLC from a human B-lymphoblastoid 
cell line and a novel factor, protein disulfide isomerase (PDI), was identified by 
matrix assisted laser desorption/ionisation-mass spectrometry (MALDI-MS).  
In the second part of this thesis the  tapasin-MHC class I  interaction  was 
investigated. It is for this reason, that an in vitro assay had been established for Summary 
 
 
  4
direct measuring tapasin-MHC  class  I interactions. First, soluble single chain 
MHC  class  I molecules were engineered, choosing two MHC  class  I alleles: 
HLA-B4402 representing a highly tapasin-dependent allele and with 
HLA-B4405, a tapasin-independent allele was chosen. Tapasin as well as the 
two single chain MHC class I constructs, scB4402-β2m and scB4405-β2m, were 
expressed in insect cells and purified from insect cell supernatants by affinity 
chromatography. In contrast to the HLA-B4405 allele, which was expressed and 
secreted at moderate yield, the HLA-B4402 allele was expressed and trapped 
inside the insect cells instead of secreted into the medium. Peptide-binding and 
anisotropy measurements with fluorescein-labeled peptides verified the 
functionality of the scB4405-β2m. For further investigation of the tapasin-
MHC class I interaction an in vitro assay was established using surface plasmon 
resonance spectroscopy. Due to the transient nature of the interaction including 
the decreased affinity of both interaction partners, kinetic data acquisition was 
difficult to evaluate. Furthermore, interaction of the scB4405-β2m with the 
sensor surface itself contributed to the measured interaction. Additionally, to 
investigate tapasin editing function, tapasin as well as the scB4405-β2m-peptide 
complex were tethered on fluid chelator lipid bilayers and monitored by 
reflectance interference (RIf) and total internal reflection fluorescence 
spectroscopy (TIRFS). Stable immobilization of scB4405-β2m-peptide complex 
as well as of tapasin was observed, unfortunately no changes in peptide 
dissociation kinetics monitored in the TIRFS channel were detected. 
Presumably, the tapasin-independent HLA-B4405 already loaded with a high 
affinity peptide is not influenced by the peptide-editing function of tapasin. Here, 
for the first time an in vitro assay was established for direct probing interactions 
within the various proteins of the PLC. 
 Introduction 
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3.  Introduction 
3.1.  The immune system and the quest against invaders 
A major task of the immune system in higher vertebrates is the defense against 
invaders. Pathogenic microorganisms like bacteria, viruses and fungi, which 
differ greatly in their lifestyles and structures, have evolved manifold 
mechanisms to escape the immune system surveillance and to invade through 
external or internal epithelial surfaces: the respiratory tract mucosa provides a 
route of entry for airborne microorganisms, the gastrointestinal mucosa for 
microorganisms in food and water, insect bites and wounds allow 
microorganisms to penetrate the skin, and direct contact between individuals 
offers opportunities for infection of the skin, the gut, and the mucosa of the 
reproductive tract. Once a pathogenic agent succeeds in evading the immune 
system, unbiased defense mechanisms are alerted generally based on 
activation of tissue macrophages equipped with surface receptors that can bind 
and phagocytose many different types of pathogens. This leads to an 
inflammatory response, which causes the accumulation of phagocytic 
neutrophils and macrophages at the site of infection, the so-called innate 
immune response. In addition to the cellular innate immune response, plasma 
proteins accumulate at the site of infection, including the complement 
components that provide circulating or humoral innate immunity. Innate 
immunity provides a front line of host defense through effector mechanisms that 
engage the pathogen directly, act immediately on contact with it, and are 
unaltered in their ability to resist a subsequent challenge with either the same or 
a different pathogen. Since the innate responses often fail to clear the infection, 
dendritic cells, macrophages, and other cells activated in the early innate 
immune response help to initiate the development of an adaptive immune 
response. Generally, the reaction taking part in the adaptive immune response 
is initiated by ligand-receptor interactions. Pathogens displayed as antigenic 
peptides are recognized by receptors of certain immune cells, known as B- and Introduction 
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T lymphocytes, the main protagonists of the adaptive immune system 
(Janeway et al., “Immunbiology” 6
th edition. Garland Science Publishing, 2005). 
The cell-mediated immune response of the adaptive immunity begins with the 
activation of antigen-specific T cells by antigen-presenting cells (APCs) in the 
lymphoid tissues and organs (Dustin, 2003). The activation induces the 
proliferation and the differentiation of T cells into armed effector T cells: CD8
+ 
cytotoxic T cells, TH1 and TH2 cells. The process is mediated by the cytokine T 
cell growth factor IL-2, which binds to a high affinity receptor on the activated T 
cell. CD8
+ cytotoxic T cells target MHC class I-peptide complexes on the cell 
surface, which are recognized by their T cell receptors and activate the 
apoptotic pathway. Hence, preformed cytotoxins stored in specialized CD8
+ 
cytotoxic T cells lytic granules are released upon direct contact with an infected 
cell. The cytotoxins consist of the perforins, which polymerize in target-cell 
membranes to form transmembrane pores, the granzymes belonging to the 
serin proteases family and the granulysins, which induce apoptosis in target 
cells and have an antimicrobial activity. Another mechanism to induce apoptosis 
in the target cell is the interaction between Fas in the target-cell membrane and 
the Fas ligand, which is present in the membranes of activated cytotoxic T cells, 
TH1 and some TH2 cells. Ligation of Fas leads to the activation of caspases, 
which induce apoptosis in the target cell (Medana et al., 2000). Cytotoxic T cells 
also act by releasing cytokines IFN-γ, TNF-α, and TNF-β. IFN-γ inhibits viral 
replication but also induces the increased expression of MHC class I as well as 
other proteins involved in the peptide loading of MHC class I molecules (see 3.2 
for details). IFN-γ also activates macrophages by recruiting them to sites of 
infection both as effector and as antigen-presenting cells. IFN-γ also lowers the 
tryptophan concentration with cells carrying an IFN-γ receptor and thus can kill 
intracellular pathogens by starvation. TNF-α and TNF-β can synergize with 
IFN-γ in macrophage activation and in killing of some target cells 
(Tseng & Dustin, 2002).  
Taken together, CD8
+ T cells recognize antigens derived from intracellular 
pathogens (viruses, intracellular bacteria) and malignantly transformed cells 
(tumors), which are then proteolytically degraded by the cytosolic proteasom 
and presented by the MHC class I molecules. In contrast, the TH1 and the TH2 Introduction 
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cells, both expressing the CD4
+ co-receptor, recognize fragments of antigens 
degraded within intracellular vesicles and displayed at the cell surface by 
MHC class II molecules. TH1 cells activate macrophages by releasing IFN-γ as 
well as by docking to CD40 on macrophages via their CD40 ligand. TH2 cells 
are inefficient macrophage activators because they produce IL-10, a cytokine 
that can deactivate macrophages; they do not produce IFN-γ. They do express 
CD40 ligand, however, and can deliver the contact-dependent signal required to 
activate macrophages to respond to IFN-γ. Together with TNF-α produced by 
the activated macrophage and IFN-γ produced by TH1 effector cells the reactive 
nitrogen metabolite NO is induced, which has broad antimicrobial activity. 
Furthermore, by producing the hematopoietic growth factors IL-3 and GM-CSF, 
which in turn stimulate the production of new phagocytic cells in the bone 
marrow, TH1 cells recruit macrophages to the site of infection. Also, TNF-α and 
TNF-β, which are secreted by TH1 cells in case of an infection, change the 
surface properties of endothelial cells enabling phagocytes to adhere to them. 
Chemokines such as the macrophage chemotactic protein CCL2, which is 
produced by TH1 cells in the inflammatory response, direct these phagocytic 
cells through the vascular endothelium and to the site of infection 
(Underhill et al., 1999). 
The B lymphocytes are initiators of the humoral immune response, which is 
responsible for the protection of the extracellular spaces along which pathogens 
spread by moving from cell to cell. B cells internalize the antigens bound by their 
surface immunoglobulin receptors and then display peptide fragments of 
antigen as MHC class II-peptide complexes. The activation of B cells and their 
differentiation into antibody-secreting plasma cells and memory B cells is 
triggered by antigen and usually requires the TH2 class of CD4
+ T cells but also 
a subset of TH1 cells. B-cell activation takes place first when the B-cell antigen 
receptor cross-linked to an antigen transmits signals directly to the cell interior 
and at the same time the antigen is internalized and processed into peptides, 
which are subsequently presented by MHC  class II  molecules.  In  the  case        
of thymus-dependent antigens, the second signal represents helper T cells 
recognizing the MHC class II-peptide complex, which then transmits activating 
signals to the B cell. This activation is essentially driven by the interaction of the 
CD40 ligand on the T cell and CD40 on the B cell. For thymus-independent Introduction 
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antigens, the second signal is delivered solely by the antigen itself. TH2 cells 
secrete the B  cell stimulating cytokines IL-4 and IL-6 which promote the 
proliferation and differentiation of the B cell to antibody producing plasma cells 
(Liu et al., 1991). Binding of bacterial toxins by IgG antibodies or the binding of 
viruses by IgG and IgA antibodies neutralizes the toxins and protects the cell 
against toxic effects (Mandel, 1976). Antibodies that coat pathogens are 
recognized by Fc receptors on phagocytes, which are thereby triggered to 
engulf and destroy the pathogen. Antibodies can also initiate the destruction of 
pathogens by activating the complement system (opsonization) (Cooper, 1985). 
Furthermore, antibody-coated pathogens are also recognized by Fc receptors 
on NK cells (antibody-dependent cell-mediated cytotoxicity (ADCC)). The 
destruction of those antibody-coated pathogens is mediated by the release of 
cytoplasmic granules containing perforin and granzymes (Lanier et al., 1986).  
The antigens recognized by CD4
+ T cells derive from extracellular bacteria or 
toxins, which are endocytosed and are proteolytically digested in the 
endosomes. Thus MHC  class  II molecules display peptides derived from 
pathogens, which live in macrophage vesicles or which have been internalized 
by phagocytic cells and B cells. MHC  class  II molecules assemble in the 
endoplasmic reticulum (ER) with the invariant chain. The invariant chain inhibits 
peptide-binding in the ER as well as during the translocation to the endosomes. 
In  the  late  endosomes  the  invariant  chain  is  cleaved  by  various              
proteases leaving the remaining CLIP (class II-associated  invariant-chain 
peptide) fragment bound to the MHC  class  II molecule.  HLA-DM/HLA-2M              
interacts with the MHC class II-CLIP complex and catalyzes the exchange of 
CLIP for exogenous antigenic peptides  (Rocha & Neefjes, 2008).  The 
MHC class II-peptide complex is transported via the Golgi to the cell surface for 
screening by CD4
+-T-cells (Figure 3-1). 
Effector cells (B and T cells) have a limited life span. After the elimination of the 
antigen, part of the clonaly expanded cells differentiate to memory cells, which 
are circulating awaiting new confrontation with a pathogen. The other effector 
cells go through apoptosis. 
 Introduction 
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Figure 3-1. The MHC class II processing pathway. MHC class II αβ heterodimers assemble in 
the endoplasmic reticulum with Ii, which occupies the peptide-binding groove and contains an 
endosomal targeting signal. Ii chaperones MHC II either directly (route 1; black solid arrow) or 
indirectly after internalization from the cell surface (route 2; gray dashed arrows) into 
MHC class II-containing compartment (MIIC). In the MIIC, Ii is finally degraded by a series of 
endosomal proteases leaving the remaining CLIP fragment (orange). HLA-DM assists the 
exchange of CLIP for relevant exogenous antigenic fragments (red and yellow) in subdomains of 
MIIC (the internal vesicles) prior to transport for stable intergration in the plasma membrane 
(blue arrows in MIIC) unless internalization is induced by a process like ubiquitination (Ub) of the 
MHC II β-chain cytoplasmic tail (route 3; pink dashed arrow) (Rocha & Neefjes, 2008). 
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3.2.  MHC class I antigen processing and presentation pathway 
3.2.1.  The major histocompatibility complex (MHC)  
The main function of MHC molecules is the presentation of protein fragments 
derived from pathogens at the cell surface to the appropriate T cells. In order to 
respond to the multitude of different and rapidly evolving pathogens, the 
immune system possess as a prerequisite polygenic and polymorphic MHC. 
The MHC gene locus is subdivided into several  different  MHC class I  and 
MHC  class  II genes. This polygenic architecture of the MHC gene provides 
every individual with a set of MHC molecules with different ranges of peptide-
binding specificities. Furthermore, every individual holds additionally multiple 
variants of each gene within the population as a whole, meaning the MHC gene 
locus is highly polymorphic. 
3.2.1.1.  Genomic organization  
The major histocompatibility complex is located on chromosome 6 in humans 
and chromosome 17 in the mouse genome and spans at least 4 × 10
6 base 
pairs. Since the MHC genes were first discovered through antigenic differences 
between white blood cells from different individuals they are also called human 
leukocyte antigen or HLA genes. In humans there are three MHC  class  I 
α-chains, namely HLA-A, -B, and -C, and three pairs of MHC class II α- and 
β-chain genes, called HLA-DR, -DP, and -DQ (Figure 3-2). All nucleated cells 
express MHC  class  I molecules, whereas MHC  class  II molecules are 
expressed in epithelial thymus cells and in APCs. The HLA-DR cluster contains 
an extra β-chain gene whose product can pair with the DRα chain, meaning that 
the three sets of genes can give rise to four types of MHC class II molecules. 
Differences between the MHC  class  I and class  II subtypes are found in the 
presentation of a different range of peptide repertoire, including different peptide 
specificities, which are unique for every individual. Within the MHC gene cluster, 
the MHC genes are closely linked to genes involved in the degradation of 
proteins into peptides, formation of MHC-peptide complexes and the transport of 
these complexes to the cell surface. Introduction 
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Figure 3-2. Genomic organization of the human major histocompatibility complex (MHC) on 
chromosome 6. The MHC, also called HLA, is organized in clusters of MHC class I genes (red) 
and MHC class II genes (yellow). The MHC class I gene cluster is subdivided into three main 
class  I genes, namely HLA-A, -B, and -C. The gene for β2-microglobulin is located on 
chromosome 15 in humans. The MHC  class  II region consists of the α and β chains of the 
antigen-presenting MHC  class  II molecules HLA-DR, -DP, and -DQ, the genes for the 
TAP1/TAP2 complex, the LMP genes encoding proteasome subunits, the genes encoding the 
DMα and DMβ chains, the genes encoding the α and β chains of the DO molecule (DNα and 
DOβ, respectively), and the gene encoding tapasin (TAPBP). The class  III genes encode 
proteins of the complement including cytokines (after Janeway  et al., “Immunobiology”  6
th 
edition. Garland Science Publishing, 2005).  
3.2.1.2.  Structural organization 
MHC  class  I molecules consist of the membrane-spanning α heavy chain 
(45  kDa) encoded in the MHC gene locus and a noncovalently associated 
invariant  β2-microglobulin chain (12  kDa), which is not polymorphic and is 
encoded on chromosome 15 in humans. Since both of them derive their origin 
from the duplication of an original immunoglobulin fold, they belong to the 
immunoglobulin gene family. The heavy chain is composed of the α1, α2 and α3 
domains and includes intramolecular disulfide bridges as well as a membrane-
spanning region and a short cytoplasmic tail not resolved in the crystal structure 
(Figure 3-3). Together the α1 and α2 domains of the heavy chain consisting of 
two  α helices atop an extended eight antiparallel β strands form the 
peptide-binding cleft. The folded structure of the α3 domain and β2-microglobulin 
resembles an immunoglobulin fold. The α1  domain of human MHC  class  I 
molecules is N-glycosylated at position 86, in close proximity to the C-terminus 
of the bound peptide. Introduction 
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Figure 3-3. Structure of soluble MHC class I HLA-B44. Structure of soluble HLA-B44 produced 
in E. coli and refolded in the presence of epitope peptide EEFGRAYGF was solved by Zernich 
and colleagues (Zernich et al., 2004; PDB ID 1SYV). Ribbon diagram of the structure consisting 
of the α chain folded into three domains: α1 (green), α2 (magenta) and α3 (blue). The α3 domain 
and β2-microglobulin (yellow) show similarities in amino acid sequence to immunoglobulin C 
domains and have similar folded structures, whereas the α1 and α2 domains fold together into a 
single structure consisting of two segmented α helices lying on a sheet of eight antiparallel β 
strands. The α1 and α2 domains create a cleft, which is the site where antigenic peptides bind to 
MHC  class  I molecules. Right side at the bottom: a schematic representation of the soluble 
MHC class I molecule. 
 
3.2.1.3.  Peptide-binding cleft 
Resolving the crystal structure of a meanwhile abundant number of MHC class I 
molecules helped incredibly in the characterization of the MHC class I-peptide 
complexes. Prior to loading, MHC  class  I molecules associate with 
β2-microglobulin in the endoplasmic reticulum and are subsequently loaded with 
peptide-binding cleft 
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antigenic peptides of approximately 8-14 amino acids in length (Bouvier, 2003; 
Ellgaard & Helenius, 2003; Wright et al., 2004). Peptide-binding to MHC class I 
molecules takes place in a cleft  formed by two α-helices, α1 and α2, on top of an 
extended antiparallel β-sheet at the α1/α2 domain, site of the highest 
polymorphism (Madden, 1995) (Figure 3-4, b and c). The N- and C-terminus of 
the peptide backbone is deeply anchored in the peptide-binding cleft by a 
network of hydrogen bonds as well as by ionic interactions with conserved 
residues within the peptide-binding cleft (Figure 3-4, a). Side chains of specific 
residues point directly toward the β-sheet at the bottom of the α1/α2 domain 
forming hydrogen bonds with residues within the β-sheet as well as the 
surrounding α-helices. The main differences between the allelic MHC variants 
are found in the peptide binding cleft resulting in altered amino acid residues 
located at main positions of the peptide interaction sites in the different MHC 
alleles. Thus every MHC allele displays a different subset of peptide specificity. 
One can divide the different peptide-binding clefts into six subgroups (A, B, C, 
D, E and F). For instance, the HLA-B44 molecule holds a relatively deep 
peptide-binding groove of the F type, enabling binding of peptides with aromatic 
amino acids present at the C-terminus (DiBrino  et al., 1995) (Figure  3-4). 
MHC class I molecules are highly polymorphic. The polymorphic residues are 
located at the bottom and sideways of the peptide-binding cleft 
(Zhang et al., 1998). One example of the polymorhism of MHC class I molecules 
is demonstrated by the HLA-B44 allele: Only one amino acid substitution at 
position 116 turns a highly tapasin-dependent HLA-B4402 (D116) into a 
completely tapasin-independent HLA-B4405  (Y116)  (Figure 3-4, b and c). 
These various, polymorphic side chains determine the properties of the binding 
pockets in the peptide-binding cleft, which interacts with the peptide side chain. 
Further analysis of the peptide repertoire of different MHC  class  I alleles 
revealed the positioning of anchor residues specific for every MHC class I allele. 
These anchor positions lie at the C-terminus as well as at position 2 of the 
peptide. For HLA-B4402 the peptide-binding specificity is determined by the 
position 2 and 9, with glutamic acid and phenylalanine respectively, anchoring 
the N- and C-terminus of the peptide deeply in the peptide-binding cleft 
(Figure 3-4, a-c). Furthermore, not only the amino acid composition but also the 
structure of the bound peptide defines decisively the lifetime of the Introduction 
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MHC  class  I-peptide complexes. The structure of the MHC  class  I domain 
interacting with the N-terminus of the peptide is rather rigid in the absence of a 
peptide (Zacharias & Springer, 2004). Peptide-binding induces a rearrangement 
of the amino groups of the N-terminus of the peptide facing towards the bottom 
of the β-sheet and the formation of hydrogen bonds (Madden, 1995). Unlike the 
rigid N-terminal domain of the peptide-binding cleft, the peptide-binding cleft at 
the C-terminus of the peptide is rather flexible in the absence of a peptide 
(Zacharias & Springer, 2004). By the time of peptide-binding, the side chain of 
the peptide last C-terminal amino acid is anchored in a deep pocket (F-pocket). 
The terminal carboxyl group is facing outward and the hydrogen bonds are 
located on the surface of the MHC class I-peptide complex. As a result of the 
flexibility of the peptide-binding cleft at the C-terminus, peptides with an 
elongated C-terminus are able to bind more stably to the MHC class I binding 
cleft. Longer peptides are bound by kinking or looping out of the peptide 
backbone. Since the part of the α2 helix anchoring the C-terminus of the peptide, 
is very flexible and is located close to the tapasin interaction site, it is assumed 
that tapasin induces a conformational change in this region (Wright et al., 2004). 
The interaction of tapasin with the exposed α2 loop could cause an outward 
positioning of the α2-1 helix (Figure  3-2  (b)) (completely opened form of the 
MHC class I-peptide-binding cleft) resulting in the loss of the hydrogen bonds to 
the C-terminus of the peptide thus allowing peptide exchange 
(Elliott et al., 1997; Wright et al., 2004). Only high affinity peptides with a slow 
dissociation rate would be able to induce a mature conformation (closed form) 
and a stable ternary complex upon which tapasin is excluded and is not able to 
interact. Amino acid side chains, which do not interact but rather protrude out of 
the peptide-binding cleft, form together with the accessible elements of the α1- 
and α2- helices the epitope for the MHC class I-peptide-specific binding by the 
appropriate T cell receptor. 
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Figure 3-4. The peptide-binding cleft of MHC class I molecules anchors peptides tightly via their 
N- and C-terminal ends. Surface of the peptide-binding cleft of HLA-B4405 in complex with the 
epitope peptide EEFGRAYGF according to the α1 helix (green) and α2 helix (purple) is shown in 
(a). Looking down on the peptide-binding cleft from above, the sides of the cleft are formed from 
the inner faces of the two α helices. The antiparallel β strands building up the β sheet create the 
floor of the cleft. HLA-B4405 and HLA-B4402 differ only in one amino acid at position 116 as 
indicated in (b) and (c). From the crystal structure no prediction can be made about structural 
differences between those two alleles. Tyr as well as Asp do neither interact with the peptide nor 
do they have any other obvious function or interaction bonding. 
 
 
 
 
α2 helix 
N
B4405 B4402 α1 helix α1 helix 
α2 helix
Y116  D116
N
C  C
(b) 
(a) 
(c) 
B4405  α1 helix 
α2 helix 
α2-1 
α2-2 
α2-3 
α2 helix Introduction 
 
 
  16
3.2.2.  The antigen transporter TAP 
Supply of peptides in the ER and subsequent binding to MHC class I molecules 
is a crucial step in the assembly of stable MHC class I molecules. Studies of 
various mutant cell lines deficient in cell surface expression of MHC  class  I 
molecules, but proficient in normal MHC  class  I heavy chain and β2m 
expression, indicated for the first time the presence of peptide transporters 
(DeMars et al., 1992). Lacking peptides, the MHC class I molecules are held in 
a partly folded state in the ER. The genes responsible for this defective 
phenotype, tap1 and tap2, are located in the MHC class II gene locus of human 
chromosome 6 both comprising 11 exons (Trowsdale et al., 1991). Transfection 
of these cell lines with cDNA  of  TAP1  and  TAP2  could  restore  cell            
surface expression of the MHC  class  I molecules (Attaya  et al., 1992; 
Powis et al., 1991; Spies  et al., 1992;  Spies & DeMars, 1991).  Subsequent 
heterologous expression of TAP1 and TAP2 in insect cells and yeast showed a 
functional peptide translocation in the absence of factors of the adaptive                      
immune system (Meyer et al., 1994; Urlinger et al., 1997). Immunoelectron and 
immunofluorescence studies showed the localization of TAP1 and TAP2 in the 
ER or cis-Golgi membranes (Kleijmeer et al., 1992; Meyer et al., 1994).  
The functional peptide transporter is organized as a heterodimer consisting of 
TAP1 (ABCB2) and TAP2 (ABCB3), and belongs to the ATP-binding cassette 
(ABC) transporter superfamily (Kelly  et al., 1992; Spies  et al., 1992). As 
predicted by hydrophobicity analysis and sequence alignments with other 
known ABC transporters TAP1 and TAP2, the so-called half-size transporters, 
are composed of ten and nine hydrophobic transmembrane helices, 
respectively, followed by a highly conserved nucleotide-binding domain (NBD). 
The sequence identity within the NBDs resembles 60%, whereas for the TMDs 
of TAP only 30% are reached. The predicted topology of TAP1 was confirmed 
by applying cysteine scanning mutagenesis (Schrodt et al., 2006) (Figure 3-5). 
Single cysteines were introduced into putative loops between transmembrane 
segments following the analysis of hydrophobicity algorithms and sequence 
alignments of TAP from different species and other members of the ABC-B 
subfamily. The accessibility of single residues facing the cytosol or endoplasmic 
reticulum lumen was probed with membrane-impermeable, thiol-specific Introduction 
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fluorophores in semipermeabilized cells. Based on the results the authors 
conclude that the transporter core is formed by 6+6 TMs, which is common for 
most ABC transporters. In addition to the 6+6  TM core, TAP1 and TAP2 
comprise an extra N-terminal domain, consisting of four well predicted TMs, that 
is essential for the assembly of the peptide-loading complex (PLC), mediated by 
the adapter protein tapasin (Figure 3-5). Deletion of the N-terminal four (TAP1) 
or three (TAP2) putative TMHs, as predicted by the topological model 
(Figure 3-5), does not affect peptide transport. Instead they were proven to be 
essential for tapasin recruitment (Koch  et al., 2004; 2005; 2006).  Both 
transmembrane domains of human TAP1 and TAP2 contribute to the 
peptide-binding site (Androlewicz  et al., 1993; 1994).  Photo-crosslinking 
experiments mapped the peptide-binding site between the cytosolic loops of 
TM4 and TM5 and a C-terminal stretch of approximately 15 amino acids after 
TM6 (Nijenhuis & Hämmerling, 1996). Additionally, two further peptide sensing 
sites were mapped in TAP1 by modifying epitope peptides with a chemical iron-
dependent chemical protease and subsequent mass spectrometry and cysteine 
cross-linking experiments (Herget et al., 2007). One contact site was mapped to 
a stretch following TM6 of TAP1 and extends over the already identified 
peptide-binding pocket obtained by photo-crosslinking studies. The second 
peptide sensing site was identified in the cytosolic core loop 1 between TMH 2 
and TMH 3 of TAP1. Mechanistic questions regarding ATP binding to the non-
equivalent NBDs of TAP1 and TAP2 as well as ATP hydrolysis and subsequent 
translocation of the peptides across the hydrophobic lipid bilayer are heavily 
discussed. To date, proposed models of the transport cycle are based on 
biochemical studies as well as on high-resolution structures of isolated NBDs in 
various conformations (Janas et al., 2003; Smith et al., 2002). Based on these 
models, the key aspect of the transport cycle is the ATP-induced dimer 
formation and subsequent ATP hydrolysis by the head-to-tail sandwich dimer of 
the NBDs, following the dissociation of the NBDs dimer.  Introduction 
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Figure 3-5. Schematic model of the TAP complex. TAP is a heterodimer consisting of TAP1 and 
TAP2. Each subunit is subdiveded into a N-terminal transmembrane domain (TMD) and a 
C-terminal cytosolic nucleotide binding domain (NBD). The TMDs can be subdivided into a 
core-domain of six helices and an N-terminal extension of four and three helices for TAP1 and 
TAP2, respectively. The peptide binding region is depicted in yellow (Abele and  Tampé, 2005; 
Schrodt et al., 2006). 
3.2.3.  Tapasin 
In 1994 Ortmann and colleagues discribed for the first time a 48 kDa protein 
which was co-immunoprecipitated with the peptide transporter TAP from 
digitonin-solubilized B-lymphoblastoid cells (Ortmann  et al., 1994). This type I 
glycoprotein called TAP-associated protein tapasin was found to bridge 
MHC  class  I molecules, awaiting a suitable peptide, and TAP, the peptide 
transporter. High mRNA levels of tapasin are found in T cells, bone marrow, 
thymus, gut, lung and kidney. In carcinoma and melanoma  cell  lines                
the tapasin expression is often reduced, however it can be restored by 
treatment with IFN-γ or a combination of IFN-β and TNF-α (Ritz  et al., 2001; 
Seliger et al., 2001  a/b/c). The gene for human tapasin is encoded on 
chromosome 6 in the so-called extended MHC II domain (Herberg et al., 1998). 
The 8 exons encode a 448 amino acids long type I transmembrane protein. 
Tapasin is structurally divided into an ER-luminal domain (residues 1-392), Introduction 
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followed by a transmembrane helix (residues 393-417), and a short cytosolic tail 
(residues 418-428) bearing an ER retention signal (consensus sequence KKxx) 
(Figure 3-6). 
 
Figure 3-6. Structural organization of the type I transmembrane protein tapasin. (a) Schematic 
model of tapasin including  interaction sites with MHC  class  I and ERp  57 as well as 
N-glycosylation site are indicated (Koch and Tampé, 2005). (b) Modeled structure of the 
N-terminal Ig-fold domain of tapasin (residues 1-128). N and C-terminus indicated in bold. The 
amino acid Cys 95 and the disulfide bridge Cys7-Cys71 are indicated (structure modelled by 
Janusz Bujnicki, http://genesilico.pl/).  
 
The ER-luminal domain can be subdivided into at least two immunoglobulin (Ig) 
fold domains. Each domain is stabilized by a disulfide bond (Cys7-Cys71 and 
Cys292-Cys362). The cysteine at position 95 is essential for the disulfide 
formation to ERp57, thus recruiting tapasin into the PLC (Dick  et al., 2002; 
Peaper et al., 2005; Bangia et al., 2005). The asparagine residue at position 233 
(Asn233) is the site of N-core glycosylation with the consequence of slower 
electrophoretic mobility in SDS-PAGE (Li  et al., 1997; Turnquist  et al., 2001) 
(Figure  3-6). Mutagenesis studies have shown that the  N-terminal                     
50amino acids of tapasin as well as the two Ig folds are                                  
important for the recruitment of MHC  class  I molecules (Bangia  et al., 1999; 
(b)  (a) 
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Turnquist et al., 2001; Harris et al., 2001). Indications were provided that tapasin 
is associated with coat-protein complex (COP) I vesicles operating as a cargo 
receptor to transport incorrectly folded MHC class I molecules from the cis-Golgi 
network back to the ER lumen (Paulsson et al., 2002). The transport of peptide 
loaded  MHC class I  molecules from the ER to cis-Golgi network in COP  II 
vesicles is regulated presumably by the B cell associated protein (Bap) cargo 
receptor 31 (Spiliotis  et al., 2000; Paquet  et al., 2004). Bap 31 interacts, 
independently of MHC  class  I molecules with tapasin and recruits 
MHC  class  I  molecules to the ER exit site. Already in the PLC, Bap 31 is 
screening for potential cargo (Paquet et al., 2004).  
Tapasin plays an important role in the loading of MHC class I molecules with 
high-affinity peptides. It was shown that tapasin associates independently with 
TAP and MHC  class  I molecules respectively (Sadasivan  et al., 1996). 
Transfection of a tapasin-deficient B-lymphoblastoid cell line 721.220 (.220) with 
human tapasin restored the MHC class I association with TAP as well as the 
MHC  class  I  cell surface expression (Ortmann  et al., 1997; Lewis  et al., 1998; 
Tan et al., 2002). Thus tapasin bridges MHC  class  I molecules awaiting the 
appropriate peptides and the peptide supplier TAP. Investigating the 
stoichiometry of the PLC by blue native-PAGE in combination with antibody 
(Ab)-shift assays, Rufer and colleagues postulated very recently that the fully 
assembled PLC comprises two tapasin, two ERp57, but only one MHC class I 
and calreticulin, associated with the heterodimeric peptide transporter TAP 
(Rufer et al., 2007). Peptide photo-crosslinking experiments  showed               
that tapasin interacts only with one MHC  class  I molecule 
(Bangia & Cresswell,  2005). Both in .220 cells and in tapasin knockout mice a 
reduced MHC  class  I cell surface expression as well as MHC  class  I stability 
was observed (Sadasivan  et al., 1996; Ortmann  et al., 1997; Tan  et al., 2002; 
Greenwood et al., 1994; Barnden  et al., 2000; Purcell  et al., 2001; 
Williams et al., 2002; Garbi  et al., 2000; Grandea  et al., 2000). These 
MHC  class  I molecules are either empty or loaded with suboptimal peptides, 
rapidly fall apart on the cell surface, and are degraded. It was shown that 
tapasin also promotes the retention of MHC  class  I molecules in the ER, 
potentially increasing the efficiency of peptide loading (Schoenhals et al., 1999; 
Barnden et al., 2000; Grandea et al., 2000). Furthermore, it was suggested that Introduction 
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tapasin  optimizes  peptide-binding  to  MHC class I  molecules,  thus          
stabilizing the MHC class I complexes (Lewis & Elliott, 1998; Garbi et al., 2000; 
Purcell et al., 2001; Tan et al., 2002; Zarling et al., 2003; Howarth et al., 2004). It 
was suggested that tapasin would edit the repertoire of bound peptide to 
MHC  class  I molecules by exchanging low against high affinity peptides 
(Howarth et al., 2004). Binding of a high affinity peptide may stabilize the 
MHC class I molecule and induce a conformational change. This conformational 
change would probably cause the dissociation of the loading complex and the 
translocation of the MHC class I-peptide complexes to the cell surface. So far it 
is not apparent, which of the above mentioned functions of tapasin require, if at 
all, other components of the PLC. Recently, Wearsch and colleagues reported 
in a cell-free system, that although recombinant soluble tapasin (residues 
1-392) was ineffective in recruiting MHC class I  molecules  and  facilitating 
peptide binding, recombinant tapasin-ERp57 conjugates accomplished both of 
those functions and also edited the repertoire of bound peptides to increase 
their affinity (Wearsch and Cresswell, 2007). 
N-terminal tapasin deletion mutants lacking 50 to 300 amino acids still interact 
with TAP. But they are deficient in the association with HLA-B8 leading to 
reduced cell surface expression of HLA-B8 (Bangia et al., 1999). Additionally, 
no association of calreticulin with tapasin or the heavy chain of MHC class I was 
observed (Bangia et al., 1999). Deletion of N-terminal 19 amino acids resulted in 
loss of up-regulation of HLA-B8 molecules in .220 cells (Momburg & Tan, 2002). 
These results suggest the presence of structural elements located in the 
N-terminal domain of tapasin which are crucial for tapasin-MHC  class  I 
interactions. Mutation of Cys7 or Cys71, cysteine residues crucial for the 
formation of one of the two disulfide bridges, destabilizes tapasin and therefore 
impaires tapasin function (Dick et al., 2002). The surface exposed amino acids 
(residues 334-342) in the membrane proximal Ig-like domain of tapasin, are also 
involved in the interaction with MHC  class  I molecules (Turnquist  et al., 2001; 
2004). This region possibly interacts with an exposed loop (residues 222-229) 
with the acidic amino acids Asp227 and Glu229) in the α3 domain of the 
MHC  class  I (this loop also interacts with CD8) (Carreno  et al., 1995; 
Wright et al., 2004). An exposed loop of the MHC class I-α2 domain (residues 
128-137) interacts with the N-terminal domain of tapasin (Yu  et al., 1999). Introduction 
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Additionally, residues Gln115 and Asp122, which are located at the bottom of the 
peptide-binding cleft and contact β2m, participate in the interaction with the 
N-terminal domain of tapasin (these residues also interact with CD8) 
(Beissbarth et al., 2000). 
Murine MHC  class  I molecules are tapasin-dependent in respect to their cell 
surface expression and intrinsic stability, whereas allelic HLA molecules show 
discrete differences upon tapasin dependency. Interaction of the side group of 
the C-terminal amino acid of the peptide with the peptide-binding cleft is defined 
by the polymorphic MHC class I residues 114 and 116, which point from the 
bottom of the F-pocket towards the peptide (Bjorkman  et al., 1987). 
Peptide-binding by HLA-B4402 is highly tapasin-dependent, whereas 
peptide-binding by HLA-B8 is moderately and HLA-B2705 barely dependent on 
tapasin (Peh et al., 1998). Mutation of the residue Glu114 to His114 in the highly 
tapasin-dependent HLA-B4402 leads to loading with high affinity peptide and 
restoration of the cell surface expression even in the absence of tapasin. 
Substitution of His114 to Glu114 is sufficient to turn the otherwise tapasin-
independent HLA-B2705 into a tapasin-dependent one (Park et al., 2003). Also, 
it was shown that the presence of Ser116 (rather than Phe116 and Tyr116) in 
HLA-B subtypes goes along with an inefficient association with the PLC as well 
as a reduced MHC  class  I cell surface expression (Neisig  et al., 1996; 
Turnquist et al., 2000). Albeit, tapasin-independent MHC  class  I alleles 
efficiently bind and present peptides in the absence of tapasin, the bound 
peptide repertoire is edited, and the MHC class I maturation as well as intrinsic 
stability improves in the presence of tapasin (Peh  et al., 1998; 
Purcell et al., 2001; Zernich et al., 2004).  
The herpes simplex virus (HSV) type 1 and 2 encoding immediate early protein 
ICP47 blocks release of MHC class I molecules from the ER (Hill et al., 1994; 
York et al., 1994). ICP47 inhibits binding and translocation of peptides from the 
cytosol into the ER lumen without interfering with ATP binding 
(Früh et al., 1995). Interaction of ICP47 and TAP is species-specific, since 
murine TAP is not efficiently inhibited by ICP47 from human simplex virus 
(Ahn et al., 1996; Früh et al., 1995). Interestingly, the cell surface expression of 
the tapasin-independent allele HLA-B4405 (Tyr116), which is barely incorporated Introduction 
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into the PLC, was less affected by the viral TAP inhibitor ICP47 than the 
tapasin-dependent HLA-B4402 (Asn116) (Zernich  et al., 2004). This indicates 
that tapasin-independent alleles have developed during the evolution to sustain 
the antigen presentation in case the PLC is attacked by viruses.  
Tapasin interacts with MHC class I molecules as well as with TAP. A soluble 
tapasin variant lacking the TMD and the cytoplasmic tail fails to associate with 
TAP but displays normal association with HLA-B8 (Lehner  et al., 1998). This 
illustrates the necessity of the TMD and the cytoplasmic domain on the 
interaction of tapasin with TAP. Furthermore, tapasin upregulates the 
expression level of TAP (Lehner  et al., 1998; Li  et al., 2000; Tan  et al., 2002; 
Garbi et al., 2003). 
3.2.4.  Auxiliary factors 
3.2.4.1.  ERp57 
The co-chaperone ERp57 (57  kDa) is a thiol-dependent oxidoreductase 
belonging to the protein disulfide isomerase (PDI) family, promoting proper 
disulfide bond formation during the folding of newly synthesized glycoproteins 
(Garbi et al., 2007;  Ellgaard & Ruddock,  2005). ERp57 consists of four 
thioredoxin-like domains (abb’a’), with the a and a’ domains each having a 
canonical CxxC motif (x is any amino acid) within the active redox site including 
catalytic activity. The Lys-rich C-terminal domain of ERp57 is basic and bears a 
QDEL ER retention signal sequence. It was shown that the basic C-terminal b’ 
and a’ domains of ERp57 play a crucial role in the interaction with the acidic end 
of the P-domain of calnexin and calreticulin (Pollock  et al., 2004). Transient 
disulfide bonds are formed between the substrate and the amino-terminal 
cysteine residue within the motif and are resolved by an intramolecular attack of 
the carboxyl-terminal cysteine residue on the amino-terminal cysteine residue. 
Tapasin has been recognized as a unique substrate for ERp57 because it does 
not disengage from the oxidoreductase, trapping ERp57 in a stable 
intermolecular disulfide (Peaper et al., 2005). The disulfide linkage includes the 
Cys57 residue of ERp57 (amino-terminal cysteine residue of the a-domain active Introduction 
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site) and the Cys95 residue of tapasin. In ERp57-deficient mouse B cells as well 
as in human cells, replacement of Cys95 in tapasin and consequent inhibition of 
disulfide bonding with ERp57, resulted in a decrease of MHC class I-recruitment 
into the PLC as well as lower thermostability of MHC  class  I-β2m dimers 
(Dick et al., 2002; Garbi et al., 2006; Wearsch & Cresswell, 2007). It was shown 
that heavy chains which associate with tapasin Cys95 to Ala95 mutant devoid of 
ERp57 interaction site, are reduced in the α2 peptide-binding domain 
(Dick et al., 2002). This indicates that the ERp57-tapasin conjugate might be 
involved in maintaining the oxidized redox state of the α2 peptide-binding 
domain during peptide loading. Kienast and colleagues reported an explanation 
for the formation of the ERp57-tapasin conjugate (Kienast  et al., 2007). They 
found that in the absence of tapasin, MHC class I molecules were sensitive to 
disulfide bond reduction in the peptide-binding cleft. Tapasin, by forming the 
disulfide conjugate with ERp57, protected the empty peptide-binding groove 
against  α2 disulfide reduction until ligand peptide was bound. A 
tapasin-dependent allele (HLA-B4402) was sensitive to α2 disulfide reduction, 
whereas a tapasin-independent allele (HLA-B4405) was insensitive to α2 
disulfide reduction. Furthermore, they showed that when not conjugated to 
tapasin, ERp57 was able to act directly on the α2 disulfide bond in the 
peptide-binding groove. Recently, Wearsch and Cresswell showed in vitro the 
necessity of the ERp57-tapasin conjugate, unlike soluble tapasin alone, on the 
reassembly of the subcomplex (Wearsch & Cresswell, 2007). Furthermore, they 
verified functionality of the ERp57-tapasin heterodimer in respect to stabilization 
of empty MHC class I molecules, to catalysis of peptide binding and to selection 
of high-affinity peptides.  
3.2.4.2.  Calnexin and calreticulin  
Calnexin and calreticulin are homologous ER resident glycoproteins which 
assist in the folding of newly synthesized glycoproteins. Calnexin (65  kDa; 
apparent molecular mass  90  kDa (Ortmann  et al., 1997)) is a type I 
transmembrane protein, whereas calreticulin (46 kDa) is a soluble protein in the 
ER lumen. Both lectins possess an N-terminal domain, a globular β sandwich 
structure, followed by a proline rich arm domain (P domain) (Schrag et al., 2001; Introduction 
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Leach et al., 2002). The C-terminal domain of calnexin and calreticulin is rich in 
acidic amino acids. The C-terminal domain of calnexin ends with an KxRRx ER 
retention signal sequence, whereas in the case of calreticulin  a  KDEL             
ER retention signal sequence is found (Bergeron  et al., 1994; 
Helenius & Aebi, 2004). Both, the P domain as well as the C-terminal domain 
represent calcium binding sites. 
Calnexin and calreticulin form complexes with ERp57 and play a crucial role in 
the ER glycoprotein quality control (Hebert  et al., 2005). Nascent polypeptide 
chains are co-translationally translocated into the ER and subsequently N-core 
glycosylated (Glc3Man9GlcNAc2). After trimming of the core oligosaccharide to 
the monoglycosylated form (Glc1Man9GlcNAc2), calnexin and calreticulin 
interact via their N-terminal domains with the sugar moieties of the polypeptide 
chain (Hammond et al., 1994). The chaperones calnexin and calreticulin prevent 
aggregation, followed by degradation and export of incompletely or incorrectly 
folded nascent polypeptide chains. Furthermore, calnexin and calreticulin recruit 
ERp57, which forms transient intermolecular disulfide bonds with the newly 
synthesized glycoproteins and interacts with the P domain of the chaperones, to 
the complex (Frickel  et al., 2002; Oliver  et al., 1999; Morrice  &  Powis, 1998). 
Following correct folding of the nascent polypeptide chain, the third glucose 
moiety is removed by glucosidase  II leading to dissociation of 
calnexin/calreticulin. The released, correctly folded glycoprotein, is trimmed by 
mannosidase I and II and recognized by the mannose-binding lectin ER-Golgi 
intermediate compartiment (ERGIC)-53, following packaging into COP  II 
vesicles and transported from the ER to the Golgi. The transport receptor 
ERGIC-53 recycles between the ER and Golgi. Partially folded substrates are 
reglycosylated by the UDP-glucose:glycoprotein-glucosyltransferase and 
rebound by calnexin and calreticulin. Incorrectly folded proteins lose a mannose 
residue by action of mannosidase I resulting in the dissociation of calnexin and 
calreticulin and subsequent binding by the lectin ER degradation enhancing α-
mannosidase like protein (EDEM) (Jakob  et al., 2001; Hosokawa  et al., 2001). 
EDEM bound substrates are transported via the Sec61 complex from the ER to 
the cytosol for degradation.  Introduction 
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Calnexin interacts via its N-terminus and P domain with the heavy                  
chain of MHC  class  I molecules (Zhang  et al., 1995; Leach  et al., 2002; 
Leach & Williams, 2004). However, calnexin seems to be dispensable for the 
early folding, peptide loading as well as the ER export of MHC  class I 
molecules. In calnexin-deficient cell lines, MHC  class  I folding, as well as 
peptide loading and peptide presentation were not disturbed 
(Sadasivan et al., 1995;  Scott & Dawson, 1995).  However,  in  glucosidase II 
deficient cells binding of calnexin to the heavy chain of MHC  class  I was 
abolished. At the same time an increased interaction of BiP was observed 
leading to the assumption that BiP takes over the role of calnexin 
(Balow et al., 1995). In the early calnexin-associated state ERp57 is recruited 
and interacts with the incompletely oxidized heavy chain of MHC  class  I 
(Farmery et al., 2000). Association of β2m with the fully oxidized heavy chain 
induces the exchange of calnexin by calreticulin. In mice and humans 
calreticulin binding occurs at Asn86-linked carbohydrate present in the α1 helix of 
the heavy chain (Sadasivan et al., 1996). In tapasin deficient .220 cells or in the 
presence of tapasin variants lacking N- or C-terminal domains, interaction 
between MHC  class  I and calreticulin was significantly diminished 
(Lewis & Elliott, 1998; Harris et al., 2001; Bangia et al., 1999; Tan et al., 2002). 
Thus tapasin promotes the recruitment of calreticulin. The interaction of 
TAP-tapasin complexes with MHC  class  I variants, lacking the docking site 
Asn86 for calreticulin, was drastically decreased (Sadasivan  et al., 1996; 
Yu et al., 1999; Harris et al., 2001). Hence, it is assumed that the recruitment of 
heavy chain/β2m dimer by tapasin into the TAP-tapasin complex is calreticulin 
dependent. Analysis of calreticulin deficient murine cells revealed that 
calreticulin plays an important role in peptide loading (Gao et al., 2002). The cell 
surface expression of MHC  class  I was 70-75% reduced in the absence of 
calreticulin. Furthermore, the presentation of certain T  cell epitopes was 
drastically affected, although at the same time the ER export of MHC class I 
molecules was up regulated, indicating the crucial role of calreticulin and 
tapasin onto ER retention of empty or suboptimal loaded heavy chain/β2m 
dimers.  Introduction 
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3.2.4.3.  The immunoglobulin binding protein (BiP) 
BiP is a member of the heat shock protein family 70. Its function is to stabilize 
synthesized polypeptide chains during folding processes as well as to mediate 
their ER retention, to prevent aggregate formation and to avoid non-native 
disulfide bonds formation (Gething  &  Sambrook, 1992). Furthermore, BiP is 
involved in the translocation of newly synthesized proteins to the ER and in the 
degradation of misfolded proteins. 
3.2.5.  Peptide translocation to the ER 
Peptide translocation from the cytosol to the ER lumen by TAP is divided into 
several steps. Analysis of peptide transport in the presence of the viral protein 
ICP47, which inhibits peptide binding to TAP, proved that peptide binding is not 
a prerequisite for ATP binding (Tomazin et al., 1996). Peptides and nucleotides 
bind independently of each other to TAP. Peptide translocation is energized by 
ATP hydrolysis in the NBDs. The NBDs are L-shaped with the long arm I formed 
by  α-β-structures and include Walker A and B motifs, as well as the highly 
conserved D- and H-loop (also called switch region). The shorter arm II consists 
of an α-helical domain including Q- and C-loop. ATP binding induces the 
formation of the NBD sandwich dimer (Smith  et al., 2002), a prerequisite for 
ATP hydrolysis and subsequent peptide translocation (Hopfner  et al., 2000; 
Smith et al., 2002). Kinetic data provided a two step mechanism for peptide 
binding to TAP: a fast association step followed by slow isomerization of the 
TAP complex (Neumann  &  Tampé, 1999). The isomerization step includes a 
conformational change in TAP (Neumann et al., 2002). It is proposed that the 
molecular switch, which basically induces ATP hydrolysis, is a consequence of 
structural rearrangement. Stimulation of ATP hydrolysis was shown to be 
correlated with peptide binding (Gorbulev  et al., 2001). Sterically unfavoured 
peptides bound to TAP do not stimulate ATP hydrolysis (Gorbulev et al., 2001).  
During a translocation cycle ATP hydrolysis takes place in both NBDs 
(Chen et al., 2003). The non-equivalence of both subunits was determined by 
mutagenesis studies. Mutation of the highly conserved Lys residue at Walker A 
motif of TAP2 resulted in the loss  of  peptide  transport  activity,  while  the          
same mutation in TAP1 led to a minor reduction of peptide transport Introduction 
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(Karttunen et al., 2001; Lapinski et al., 2001). Peptide transport by TAP requires 
ATP hydrolysis, however also GTP, CTP and UTP can energize the transporter 
(Müller et al., 1994). The non-equivalence of both NBDs is reflected in sequence 
alignments of highly conserved regions of ABC transporters. Sequence 
alignments of the ATP-binding regions of NBD1 and NBD2 with other NBDs 
revealed major differences in the ATP-binding region of TAP1. In TAP1 
sequences, the conserved Glu following directly the Walker  B motif, is 
exchanged to Asp. This Asp residue is thought to be involed in ATP hydrolysis 
as the catalytic base. Furthermore, the TAP1 sequence contains a Gln residue 
instead of a His residue in the H-loop. This His residue contacts the γ-phosphate 
of ATP and is essential for the substrate transport in different ABC transporters 
(Shyamala et al., 1991; Hung  et al., 1998). The C-loop sequences in TAP2 of 
humans and gorillas are LAAGQ in comparison to LSGGQ in other species. 
Two critical residues (Leu and Gly) are highly conserved and are often 
substituted by other amino acids forming an irregular sequence xSxGQ. 
Therefore, this type of C-signature motif is usually called “degenerated C-loop”. 
Based on this, it was proposed that one NBD in the complex hydrolyzes ATP to 
provide the energy for translocation, while the other one only binds ATP as a 
regulatory domain (Yang et al., 2003).  
Peptides of 8-12 amino acids were observed to be transported most efficiently 
by TAP (Koopmann et al., 1996), however the optimal length for peptide binding 
is 8-16 amino acids (Van Endert et al., 1994). Nevertheless, peptides of 6 or 40 
amino acids in length are also transported by TAP, however with considerable 
lower efficiency (Koopmann et al., 1996). Since the optimal length of peptides 
for loading onto MHC class I is 8-10 amino acids and TAP transports peptides 
with slightly larger length, the ER-resident aminopeptidase  associated            
with antigen processing (ERAAP) is essential for  further  peptide                
trimming  (Falk & Rotzschke, 2002;  Saric et al., 2002; Serwold  et al., 2002; 
York et al., 2002). The sequence specificity of TAP was determined by 
screening combinatorial peptide libraries (Uebel  et al., 1997). The first three 
N-terminal and the last C-terminal residues were found as determinants for 
peptide-binding specificity. At the N-terminus, human TAP generally displays 
preferences for peptides with Lys, Asn and Arg in the first, Arg in the second, 
and Trp and Tyr in the third position. In the case of human TAP the C-terminal Introduction 
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residue is preferred to be a hydrophobic or basic residue. The peptide-binding 
spectrum of TAP and MHC class I molecules overlap in their C-terminal residue, 
suggesting that the binding principle of TAP and MHC class I molecules 
coevolved. Furthermore, it was shown that the substrate recognition by TAP is 
also strictly stereospecific. Interestingly, the introduction of D-amino acids at the 
termini of peptides causes complete abrogation of peptide transport 
(Gromme et al., 1997; Uebel  et al., 1997). Acetylation or methylation of the 
N-terminus or conversion of the C-terminal carboxyl  group  of  a  peptide              
to an amide decreases its translocation efficiency considerably 
(Momburg et al., 1994; Schumacher et al., 1994). Circular peptides, which lack 
free termini generally, do not represent a substrate for TAP. Indicated by the 
structure of MHC  class  I molecules, the hydrogen bonds between the two 
termini and MHC  class  I molecules contribute largely to the free energy of 
binding. Therefore, TAP was expected to apply an analogous strategy for 
peptide binding. The residues in the center of the peptide have only little or no 
effect on the substrate specificity of TAP. Interestingly, these residues are 
responsible for the detection of the MHC class I-peptide complex by the T cell 
receptor which interacts mainly with the residues 5-8 of MHC  class  I bound 
peptide. In conclusion, TAP binds peptides through the N- and C-termini and 
transports them with maximal diversity in the center of the peptide for T cell 
recognition.  
MHC class I molecules are unstable in the absence of peptides. Hence, TAP1-
deficient mice exhibit approximately 90-fold reduced MHC  class I cell-surface 
expression as well as a 20-fold reduced CD8
+ T cell number, in comparison to 
TAP1-proficient mice (Garbi et al., 2005). The CD8
+ cytotoxic T cell response is 
as well reduced similar to the CD8
+ T  cell number (Van Kaer  et al., 1992; 
Garbi et al., 2000). Also the CD8
+ T cell repertoire is impaired in TAP1-deficient 
mice. These data demonstrate that peptides translocated by TAP are important 
for a positive influence on the selection in the thymus. Since even in TAP1-
deficient mice an altered CD8
+ T  cell repertoire as well as a reduced CD8
+ 
cytotoxic T cell response is found, indicates the existence of TAP-independent 
pathways. However, these pathways play a minor role in the MHC  class  I 
antigen presentation. Secreted proteins including their ER signal sequences are 
translocated to the ER via the Sec61 complex, and the signal sequences are Introduction 
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cleaved off by an ER-resident endopeptidase. This leads to the TAP-
independent release of hydrophobic peptides in the ER lumen and subsequent 
loading onto HLA-A2 molecules in a human TAP-deficient cell line (T2; 
Wei  &  Cresswell, 1992). Another TAP-independent peptide source is the 
degradation of antigens by endosomal proteases in dendritic cells. These 
peptides are loaded onto recycled MHC class I  molecules  in  vesicular 
compartments (Ackermann  et al. 2005). 
3.2.6  Assembly of the peptide loading complex 
A prerequisite for the assembly of the ternary MHC class I complex, consisting 
of the MHC  class  I heavy chain, β2-microglobulin and the peptide, is the 
effective interplay between multiple ER-resident proteins and chaperones of the 
peptide loading complex (PLC) (Figure 3-7). The MHC class I heavy chain and 
β2-microglobulin are synthesized at the rough ER and are subsequently co-
translationally translocated into the ER via the Sec61 complex. During the 
translocation, the ER signal sequence is cleaved off and the heavy chain is co-
translationally N-core glycosylated. Then, the newly synthesized and unfolded 
heavy chain assembles with the ER-resident folding chaperone BiP and the 
lectin chaperone calnexin (Paulsson  &  Wang, 2003). Calnexin assists in the 
folding of the heavy chain as well as its assembly with β2m. The thiol-dependent 
oxidoreductase ERp57 interacts with the incompletely oxidized β2m-free 
MHC class I heavy chain and is together with tapasin involved in the correct 
folding as well as in the formation of proper intramolecular disulfide bridges 
(Dick et al., 2002). Binding of ERp57 induces the dissociation of BiP. After the 
pre-assembly of the MHC class I molecule, calnexin is exchanged by another 
lectin calreticulin. Subsequently, tapasin recruits the pre-assembled 
MHC  class  I molecules into the proximity of the TAP complex, where 
MHC class I molecules await their loading with high affinity peptides. The TAP 
complex translocates peptides of 8-16 amino acids in length across the ER 
membrane energized by ATP hydrolysis. Several N-terminally elongated 
precursor peptides display even a higher affinity for TAP than the final epitope 
(Neisig et al., 1995; Lauvau et al., 1999). Peptides with a Pro residue at position 
2 or 3 are transported less efficiently by TAP but are often ligands of human and Introduction 
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murine MHC class I molecules (Rammensee et al., 1993). Since longer peptides 
than are presented by MHC  class  I, are translocated in the ER lumen, ER 
resident exopeptidases are needed for subsequent trimming. Experiments in 
TAP-deficient cells with minigene-encoded N-terminally elongated precursor 
peptides bearing an ER signal sequence are imported to the ER and confirm 
N-terminal trimming (Powis  et al., 1996; Serwold  et al., 2001). However, 
carboxypeptidase activity in the ER could not be detected (Lobigs et al., 2000). 
An aminopeptidase was independently identified by two groups but named 
differently, ER-aminopeptidase 1 (ERAP1; Saric  et al., 2002) and ER-
associated aminopeptidase (ERAAP; Serwold et al., 2002). The IFN-γ induced 
zinc-dependent aminopeptidase ERAP1 has a broad tissue distribution and 
exhibits a special characteristic by preferring peptides with 9-16 amino acids in 
length and a hydrophobic C-terminal residue (Serwold  et al., 2002; 
Chang et al., 2005). The preference corresponds to the substrate length and 
sequence preference of TAP. The blockage of ERAP1 function leads to reduced 
antigen presentation (Serwold  et al., 2002; York  et al., 2002). A second ER-
localized aminopeptidase, ER-aminopeptidase 2 (ERAP2) a homolog of 
ERAP1, also seems to be involved in peptide processing (Tanioka et al., 2003). 
ERAP2 is cleaving preferentially units of basic dipeptides (Lys and Arg) 
(Tanioka et al., 2003). The molecular mechanism of tapasin as a peptide editor 
is still under debate, and it is speculated how peptide binding to MHC class I 
molecules occurs. It was shown by conformation-specific antibodies that 
immature, peptide-receptive MHC  class  I molecules are prevalent in the 
peptide-loading complex (Carreno  et al., 1995; Yu  et al., 1999). Presumably 
tapasin interacts with MHC class I molecules in a conformation where the α2 
loop (residues 128-123) as well as the contact site to β2m are involved. Upon 
optimal loading, the peptide-MHC  class I molecules are released from the 
tapasin-TAP complex. The highly sophisticated molecular complex consisting of 
the TAP complex, MHC  class  I molecules, tapasin, ERp57 and calreticulin is 
known as the PLC. The fully assembled PLC is essential for the loading of high 
affinity peptides, thus generating kinetically stable MHC class I complexes with 
increased half lifes. These MHC class I complexes display an increased stability 
on the cell surface, avoiding the loss of antigenic peptides before encounter with 
effector cells. The optimally loaded MHC  class  I molecules are further Introduction 
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translocated to the cell surface via the Golgi for presentation to effector cells of 
the immune system. 
 
Figure 3-7. The MHC class I antigen presentation pathway. The MHC class I heavy chain and 
β2-microglobulin are co-translationally translocated into the ER. Following folding and assembly 
of MHC  class  I heavy chain and β2-microglobulin which are assisted by calnexin and 
immunoglobulin binding protein (BiP), the MHC  class  I molecules are recruited into a 
macromolecular peptide-loading complex (PLC) consisting of calreticulin, ERp57, tapasin, TAP1 
and TAP2. Cytosolic peptides are translocated by TAP into the ER lumen, where they are 
loaded onto pre-assembled MHC class I molecules. MHC class I-peptide complexes dissociate 
from the PLC and are then transported via the Golgi to the cell surface where cytotoxic T cells 
screen the cell surface for infected or malignantly transformed cells. Once identified as foreign, 
T cell receptor and CD8 co-receptor bind to the MHC class I-peptide complex and trigger the 
killing of the target cell (Schölz & Tampé, 2005). 
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3.3.  Objectives 
An optimal immune surveillance is a prerequisite for the survival of higher 
vertebrates. However, herpes- and adenoviruses have evolved sophisticated 
strategies to circumvent the immune surveillance by interacting and at the same 
time modulating especially proteins of the macromolecular PLC. Predominantly 
TAP, tapasin and MHC  class  I molecules,  represent  a  major  target                   
for viral effector proteins (Loch  et al., 2008;  Loch & Tampé, 2005; 
McCluskey et al., 2004). Besides the manifold strategies of viral evasion, 
synthetic or protein engineered modulators have not been described so far. In 
the current work the production and purification of TAP-specific recombinant 
antibodies such as Fv, scFv and Fab fragments (Figure  3-8,  a) in pro- and 
eukaryotic expression systems has to be established and evaluated. 
Furthermore, cell-based assays were applied for functional characterization of 
the generated recombinant antibody fragments.  
The X-ray crystal structures of soluble MHC class I molecules as well as of the 
soluble TAP1 NBD have been solved. However, no structural information about 
the organization of the macromolecular PLC is available so far. Here, the 
generated recombinant antibody fragments were used for the purification of the 
endogenous PLC from a human B-lymphoblastoid Raji cell line. Subsequently, 
the composition of the PLC was investigated using electrophoretic methods in 
combination with mass spectrometry as well as single particle analysis.  
To get a better mechanistic understanding of the transient assembly and 
disassembly of the PLC as well as the highly sophisticated interplay of the 
diverse components of the PLC and their defined functions, it was necessary to 
establish an in vitro platform for measuring single interaction and their 
immediate interplay with other proteins of the PLC as well as their modulating 
function on those. The following questions are heavily discussed in the field: 
how is peptide translocation, peptide loading and dissociation of the trimeric 
MHC class I-peptide complex synchronized? And what is the precise function of 
the chaperone tapasin and the oxidoreductase ERp57 in the peptide transfer 
onto MHC class I molecules? Since the molecular events during peptide loading 
onto MHC class I molecules are not well defined, it was necessary to establish 
an  in vitro method for direct measuring interaction between the single Introduction 
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components of the PLC as well as changes in peptide kinetics in the presence 
or absence of certain PLC components, which provide a more detailed 
mechanistic understanding of the transient assembly and disassembly of the 
PLC. My aim was to engineer single chain MHC  class  I molecules 
(Figure 3-8, b),  precisely  two  different alleles, the HLA-B4405 a tapasin-
independent, and HLA-B4402 highly tapasin-dependent allele, and to 
functionally produce those in insect cells. For the analysis of individual 
interactions between MHC  class  I molecules and tapasin, soluble tapasin as 
well was expressed and purified from insect cell supernatants. The 
tapasin-MHC  class  I interaction was first investigated by surface plasmon 
resonance (SPR) spectroscopy. To investigate the differences in peptide 
kinetics in presence and absence of tapasin, both MHC class I molecules and 
tapasin were co-immobilized on a solid-supported lipid bilayer mimicking the 
lateral mobility of the cell membrane. The proteins were tethered via their 
C-terminal His6-tags onto a lipid functionalized with a multivalent chelator head 
group. The co-immobilization of both proteins in combination with surface-
sensitive fluorescence detection allowed the investigation of changes in peptide 
kinetics. Thus reconstitution of the interaction partners in vitro should help to 
narrow the functions of tapasin in regard to the interaction with MHC  class  I 
molecules and peptide kinetics. Introduction 
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Figure 3-8. Structure of an antibody and schematic model of soluble single chain MHC class I 
molecule. Ribbon diagram based on the X-ray crystallographic structure of an IgG1 antibody is 
shown in (a). Three globular regions form a Y shape. The two antigen-binding sites are at the 
tips of the arms, which are tethered to the trunk (=Fc domain) of the Y by a flexible hinge region. 
The protease papain cleaves antibody molecules into two Fab and one Fc fragment. (c) The Fab 
(Fragment antigen binding) fragment contain the antigen-binding site and consists of a complete 
light chain (VLCL, light magenta) paired with the VH and CH1 domains of the heavy chain. (b) 
Genetic engineering technique permits the construction of a truncated Fab comprising only the 
V domain of the heavy chain (VH in blue) and light chain (VL light blue), named Fv (fragment 
variable). By tethering the VH and VL by a (SG4)3 spacer produces a single chain Fv (scFv) 
fragment (not shown). The Fc (fragment crystallizable) fragment consists of the paired CH2 and 
CH3 domains and is the part of the antibody interacting with effector molecules and cells. (d) 
Schematic representation of an engineered soluble MHC  class  I molecule. Heavy chain 
MHC  class  I, lacking the membrane-spanning domain as well the short cytosolic domain, is 
linked via a (SG4)3 spacer to β2m and expressed as a single polypeptide chain. 
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4.  Material 
4.1.  Microorganisms  
Strain  Genetic markers  Source 
DH5α  F
- gyrA96 (NaI
r) recA1 endA1 thi-1 hsdR17 
(rk
-mk
+)  glnV44 deoR  Δ(lacZYA-argF)U169 
[Φ80d Δ(lacZ)M15] 
 
Hanahan, 1983 
Invitrogen 
XL1-Blue  F’Tn 10 (Tet
r) proA
+B
+ lacI
q Δ(lacZ)M15 I rec 
A1 endA1 gyrA96 (NaI
r) thi-1 hsdR17 (rk
-mk
-) 
glnV44 relA 1 lac 
 
Stratagene 
JM83  F
- ara Δ(lac-proAB) rpsL (Str
r) thi  
[Φ80d Δ(lacZ)M15] 
Vieira & Messing, 
1982; 
35607 
(ATCC number) 
 
DH10Bac  F
- mcrA D(mrr-hsdRMS-mcrBC) 
φ80lacZM15  ΔlacX74 deoR recA1 endA1 
araD139  Δ(ara,leu)7697 galU galK λ
-rpsL 
nupG / bMON14272 / pMON7124 
Invitrogen 
4.2.  Plasmids 
Plasmid  Provider/Company 
pCRScript Stratagene 
pSL1180 Pharmacia 
pASK68  Arne Skerra / IBA 
pASK85  Arne Skerra / IBA 
pFastBac1 Invitrogen 
pFastBacDual Invitrogen 
pGAMZ – B4402  Sebastian Springer 
(Jacobs University Bremen) 
pGAMZ – B4405  Sebastian Springer 
(Jacobs University Bremen) 
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4.3.  Eukaryotic cell lines 
Cell lines  Provider/Company 
Raji (Human Burkitt Lymphoma)  CCL-86 (ATCC number) 
Sf9 (Spodoptera frugiperda) CRL-1711  (ATCC  number) 
Tn5 (High Five, BTI-Tn-5B1-4,  
Trichoplusia ni) 
Invitrogen 
.720  kindly provided by Kajsa Paulsson 
(Panum Institute, Copenhagen) 
.721  kindly provided by Kajsa Paulsson 
(Panum Institute, Copenhagen) 
4.4.  Antibodies 
Antibodies  Type  Specificity 
148.3  monoclonal (mouse)  TAP1  
429.3 monoclonal  (mouse)  TAP2 
435.4 monoclonal  (mouse)  TAP2 
7F6 monoclonal  (rat)  tapasin 
HC10  monoclonal (mouse)  MHC class I 
9E10 monoclonal  (mouse)  c-myc-epitope 
 
Commercially available antibodies 
Specificity                           Type                                     Company 
ERp57 monoclonal  (mouse)  Abcam 
calreticulin polyclonal Sigma-Aldrich 
β2m polyclonal  (rabbit)  Sigma-Aldrich 
α-His6 monoclonal  (mouse)  Novagen 
Streptactin-HRP HRP  conjugate  IBA 
goat-α-mouse-HRP HRP  conjugate  Sigma-Aldrich 
goat-α-rat-HRP HRP  conjugate  Sigma-Aldrich 
goat-α-rabbit-HRP HRP  conjugate  Sigma-Aldrich 
 Material 
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4.5.  Oligonucleotides 
Primers for pASK68 
and pASK85 
5‘ – sequence – 3’ 
 (restriction site highlighted) 
forVH148 (PstI)  AGGTGAAGCTGCAGGAGACTG 
revVH (BstEII)  GGAGACGGTGACCGAGGTTCCTTGAC 
forVL148 (SacI)  TTGAGCTCACTCAGGCTGCACCCTCTG 
pASK68/85 for 
(sequencing primer) 
TCTAGATAACGAGGGCAAAA 
pASK68/85 rev 
(sequencing primer) 
TCACTTCACAGGTCAAGCTTA 
dT15 (cDNA synthesis)  TTTTTTTTTTTTTTT 
 
Primers for pFB1 and 
pFBD 
5‘ – sequence – 3’  
(restriction site highlighted) 
PH forward primer 
(BamHI) 
(melittin signal 
sequence) 
CCGGATCCTAAAAAACCGCCACCATGA 
AATTCTTAGTCAACGTTGCCCTTGTTTT 
TATGGTCG  
PH reverse primer 
(SacI) 
(melittin signal 
sequence) 
CCGAGCTCGATGTCGGCCGCATAGATG 
TAAGAAATGTATACGACCATAAAAACAA GGGC 
p10 forward primer 
(melittin signal 
sequence) 
TAATCCCGGGTAAAAAACCGCCACCAT 
GAAATTCTTAGTCAACGTTGCCCTTGTT 
TTTATGGTCG 
p10 reverse primer 
(melittin signal 
sequence) 
TTCTGCAGTTTAACTTCGGCCGCATAG 
ATGTAAGAAATGTATACGACCATAAAAA 
CAAGGGC 
(SG4)3 linker forward 
(SacI, XhoI) 
AAGAGCTCGAATTCCTCGAGATCAAAC 
GGTCTGGTGGCGGTGGCTCGGGTGGC 
GGCGGTTCGGGCGG 
(SG4)3 linker reverse 
(HindIII, NcoI, PstI) 
 
ATTAAGCTTCCATGGGTGACCCTGCAG 
TTTAACTTCAGAACCGCCACCGCCCGA 
ACCGCCGCC 
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Primers for MHC I in 
pFB1 
5‘ – sequence – 3’  
(restriction site highlighted) 
NgoMIVstrepfor   TTAATTGCCGGCTGGAGTCATCCACAGTTTG 
NgoMIVβ2mfor   TTAATTGCCGGCATCCAGCGTACTCCAAAG 
tevhisrev  TAATTAACCGGTAAGCTTTCATTAGTGATGG 
TGATGGTGATGAGACTGGAAGTACAGGTTC 
TCGTCGACCGGCTCCCATC 
 
Sequencing primers   5‘ – sequence – 3’  
pFBD_PH_REV GTAACCATTATAAGCTGC 
pFBD_PH_FOR AAATGATAACCATCTCGC 
pFBD_p10_REV GTATTGTCTCCTTCCGTG 
pFBD_p10_FOR CCTTTAATTCAACCCAAC 
M13_FOR GTAAAACGACGGCCAGT 
M13_REV CAGGAAACAGCTATGAC 
4.6.  Peptides 
Peptides  Sequence 
C4F RRY(C)
FluoresceinKSTEL 
NSTCL RRYQNST(C)
FluoresceinL 
NSTEL RRYQNSTEL 
R9LQK RRYQKSTEL 
ICP47 (2-34)  SWALEMADTFLDTMRVGPRTYADVRDEINKRGR 
EEFGRAFSF EEFGRAFSF 
CAFSF EEFG(C)
FluoresceinAFSF 
CFSF EEFGR(C)
FluoresceinFSF 
CSF EEFGRA(C)
FluoresceinSF 
CF EEFGRAF(C)
FluoresceinF 
 
 
 
 Material 
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4.7.  Chemicals 
Chemicals  Company 
Acetic acid (99%)  Carl Roth  
Acrylamide 30% (w/v)  Carl Roth  
Agar  Carl Roth  
Agarose   Carl Roth  
Ampicillin  Carl Roth  
APS (Ammonium persulfate)  Carl Roth  
Ammonium sulfate  Carl Roth  
Anhydrotetracycline IBA 
Avidin IBA 
Benzonase Nuclease  Merck 
Bromophenol Blue  Sigma-Aldrich 
BSA (Bovine Serum Albumin)  Carl Roth  
Chloramine T  Riedel de Haen  
Coomassie Brilliant Blue R  Sigma-Aldrich  
Desthiobiotin Sigma-Aldrich 
Disodium hydrogenphosphate  Carl Roth  
DMF (N,N-Dimethylformamide)  Fluka Chemie  
DMSO (Dimethylsulfoxide)  Merck 
dNTP-Mix MBI  Fermentas 
DTT (Dithiothreitol)  Merck 
EDTA (Ethylenediaminetetraacetic acid)  Carl Roth  
Ethanol, p.a.  Carl Roth  
Ethanol, denatured  Carl Roth  
Ethidium bromide  Merck  
Formaldehyde  Carl Roth  
Glycerol  Carl Roth  
Glycine  Carl Roth  
Guanidine hydrochloride  Carl Roth  
Hydrochloric acid, 37%  Carl Roth 
HABA (2-(4-Hydroxyphenylazo)benzoic acid)  Sigma-Aldrich 
Imidazole  Carl Roth  
IPTG (Isopropyl-β-D-1-thiogalactopyranoside) MBI  Fermentas Material 
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Methanol  Carl Roth  
Ponceau S red  Sigma-Aldrich 
Potassium chloride   Carl Roth 
Sodium carbonate  Carl Roth 
Sodium chloride  Carl Roth 
Sodium dihydrogen phosphate  Carl Roth 
SDS (Sodium dodecyl sulfate)  Carl Roth  
Sodium hydroxide  Carl Roth 
Sodium thiosulfate  Carl Roth 
Strep-Tactin-HRP conjugate  IBA 
Streptomycine Sigma 
TEMED (N,N,N,N-Tetramethylethylenediamine)  Carl Roth  
TRIS (Tris(hydroxymethyl)aminomethane)  Carl Roth  
Triton X-100  Sigma-Aldrich 
Tryptone  Carl Roth  
Tween 20  Sigma 
Yeast-Extract  Carl Roth  
X-Gal (5-Bromo-4-chloro-3-indolyl β-D-galactopyranoside) MBI  Fermentas 
Xylene cyanole  Sigma-Aldrich 
4.8.  Enzymes  
Enzymes  Company 
Cfr9I (isoschizomer of XmaI)  MBI Fermentas 
DpnI MBI  Fermentas 
Eco9I (isoschizomer of BstEII)  MBI Fermentas 
EcoRI MBI  Fermentas 
HindIII MBI  Fermentas 
Mph1103I (isoschizomer of NsiI)  MBI Fermentas 
NsiI NEB  Biolabs 
NgoMIV NEB  Biolabs 
Pfu polymerase  Promega 
PowerScript DNA polymerase  PAN Biotech  
PstI NEB  Biolabs 
Reverse Transcriptase SuperScript II  Invitrogen Material 
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SacI MBI  Fermentas 
Taq polymerase  MBI-Fermentas 
T4 DNA ligase  NEB Biolabs 
T4-Polynucleotide kinase  MBI Fermentas 
XbaI   MBI Fermentas 
XhoI NEB  Biolabs 
 
Kits  Company 
Maus-Hybridoma-Subtyping Kit  Roche 
RNeasy Kit  Qiagen 
QIAquick PCR Purification Kit  Qiagen 
QIAquick Gel Extraction Kit  Qiagen 
Nucleospin Plasmid  Macherey & Nagel 
PCR-Purification Kit  Macherey & Nagel 
Gel-Extraction Kit  Macherey & Nagel 
QIAprep Spin Miniprep Kit  Qiagen 
QIAGEN PCR Cloning Kit   Qiagen 
QuikChange Multi site-directed Mutagenesis Kit  Stratagene 
4.9.  Equipment 
Apparatus  Company 
Autoclave 5075 ELVC  Systec  
BIAcore T100  GE Healthcare 
Cary 50 Bio UV Vis spectrophotometer  Varian 
Douncer (30 mL)  Braun Melsungen 
Eppendorf centrifuge 5417R  Eppendorf 
Fluorescence spectrometer  Instruments S.A., 
France 
Gilson pipettes: P-2, -10, -20, -200, -1000  Abimed 
Incubator Kelvitron   Heraeus 
Incubator Innova 4330  New Brunswick 
Scientific 
Ino Lab pH-meter  WTW 
Lumi Imager F1  Roche Material 
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Milli Q-Plus water system  Millipore 
Multipipette Eppendorf 
Multiscreen filtration system  Millipore 
Polarstar Galaxy (ELISA reader)  BMG 
Rotors for ultracentrifugation 
(SW 28, Ti60, Ti70, TLA100, TLA110, TLA55) 
Beckmann 
Instruments 
Semidry blotting apparatus  BioRad 
SDS-PAGE gel apparatus  BioRad 
Sepatec Megafuge  Heraeus 
Speed Vac evaporator  Buchofer 
Sorvall centrifuge RC 3C Plus  Kendro 
Sorvall centrifuge RC 5B Plus  Kendro 
Thermomixer Eppendorf 
Thermocyler T-personal  Whatman 
Biometra 
Ultracentrifuge Beckmann L-50  Beckmann 
Instruments 
Ultracentrifuge Beckmann TLX 100  Beckmann 
Instruments 
UV-Vis spectrometer, nanodrop  PEQlab 
Vortexer Scientific 
Industries 
 
4.10.  Chromatography material 
Material  Company 
Aekta Explorer  GE Healthcare 
Activated CH-Sepharose 4B  GE Healthcare 
ATP-Agarose ((A2767))  Sigma  
ETTAN GE  Healthcare 
HiTrap Chelating (1 mL) GE  Healthcare 
Ni-NTA Agarose  Qiagen 
SMART Chromatography System  GE Healthcare 
Superdex 200 PC 3.2/30  GE Healthcare 
Superdex 75 PC 3.2/30  GE Healthcare Material 
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4.11.  Supplementary material 
Material  Company 
Cuvette (plastic)  Fischer Scientific 
Cuvette (quartz glass)  Hellma 
Eppendorf tubes  Greiner 
Filter paper  Whatman 
Microliter syringe  Hamilton 
Multiwellplates Greiner 
Multiwellplates MaxiSorb  Nunc 
Spin Concentrator (Amicon)  Millipore 
Spin Columns  BioRad 
Sterile filter  Millipore 
CM5 chip  Biacore 
SA chip  Biacore Methods 
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5.  Methods 
5.1.  Molecular biology 
5.1.1.  Mini preparation of plasmid DNA 
A 2 mL culture of E. coli containing the plasmid and the appropriate antibiotic 
were incubated for 8-12  h at 37°C with sufficient aeration following 
centrifugation for 1  min at 14,000  g to form a pellet. For the isolation and 
purification of pure and low salt DNA, the alkaline denaturation method was 
applied using Nucleospin Plasmid Kit (Macherey & Nagel)  following  the 
manufacturer’s instructions. The cell pellet was resuspended in 300  µL TE 
buffer, resulting in a homogenous suspension. 300 µL of alkaline lysis buffer 
was added and the capped tube was inverted several times and subsequently 
incubated for 5 min at RT. The solution was then mixed with 300 µL of low acidic 
neutralization buffer and incubated for 5 min on ice. The coagulated white mass 
of detergent and denatured genomic DNA which coprecipitates was centrifuged 
for 10 min at 14,000 g and 4°C. The supernatant was transferred to a microfuge 
tube and mixed with 800 µL of isopropanol. After centrifugation for 15 min at 
14,000 g and 4°C the DNA pellet was washed with 80% EtOH and dried at RT. 
The pellet was finally resuspended in 20-50 µL autoclaved dH2O. 
 
5.1.2.  Restriction enzyme digestion 
Restriction analysis was performed following standard protocols and using 
restriction endonucleases from New England Biolabs or MBI Fermentas. The 
reaction was preformed in 20  µL volume containing the appropriate 1  x 
restriction endonuclease buffer, the restriction endonuclease itself (1 U/µg DNA) 
and the plasmid DNA. The digestion was performed for 1  h at 37°C and 
terminated by incubation for 20  min at 65-80°C if needed for subsequent Methods 
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reaction. The digestion was analyzed by agarose gel electrophoresis (see 
5.1.4). 
5.1.3.  Ligation 
The ligation reaction was performed in a volume of 10 µL using T4 DNA ligase 
(New England Biolabs) for 12 h at 16°C. 50 - 100 ng DNA and 10 U T4 DNA 
ligase were used in the ligation reaction. For the transformation of E. coli DH5α 
10 µL of the ligation reaction was used. 
5.1.4.  Nucleic acid electrophoresis and DNA recovery 
Nucleic acids are separated and visualized in agarose gels after 
electrophoresis. Electrophoresis is defined as the movement of ions and 
charged macromolecules through a medium when an electric current is applied. 
Agarose and polyacrylamide are the primary stabilizing media used in the 
electrophoresis of macromolecules. Macromolecules are separated through the 
matrix based on their size, charge distribution, and structure. In general, nucleic 
acids migrate through a gel based on size, with no influence from base 
composition or sequence. The appropriate amount of agarose powder was 
weighed, resuspended in 1  x TAE buffer and heated in a microwave. The 
agarose solution was thouroughly mixed and while cooling, the gel casting tray 
was assembled. Subsequently the agarose solution was poured into the gel 
tray, the comb was inserted and the agarose was left to gel at room 
temperature. The 0.8  –  2% agarose gels were then transferred into an 
electrophoresis chamber filled with 1 x TAE buffer. Prior to loading, the DNA 
was resuspended in 6 x DNA loading buffer and electrophoresed at 20-150 mA. 
After separation of the DNA, the agarose gel was removed from the 
electrophoresis chamber and submerged for 20  min in the ethidium bromide 
solution and visualized subsequently by UV radiation (312 nm). The ethidium 
bromide intercalates between the bases of DNA, resulting in an increase in 
fluorescence yield when the DNA/ethidium bromide complex is exposed to UV 
radiation. Methods 
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For further purpose DNA was recovered from an agarose gel by cutting the DNA 
out with a steril scalpel. The DNA was recovered using QIAquick Gel Extraction 
Kit (Qiagen) following manufacturer’s instructions.  
 
TAE (50 x)  DNA loading buffer (6 x)  Ethidium bromide solution 
2 M TrisAc, pH 8.0  60% glycerol  5 µg/mL in dH2O 
50 mM EDTA  60 mM EDTA   
  0.09% bromophenol blue   
  0.09% xylene cyanole   
5.1.5.  Photometric concentration determination of nucleic acids 
The concentration of nucleic acids was determined by measuring the 
absorbance of UV light at 260 nm. An OD unit corresponds to the amount of 
nucleic acid in µg in 1 mL volume using 1 cm length quartz cuvette resulting in 
OD260 nm = 1 = 50µg / mL. For the concentration determination the DNA solution 
was diluted 1:100 and the OD was measured in a spectrophotometer.  
factor dilution absorption ng ion concentrat nm × × = 260 50 ] L [ μ  
5.1.6.  Amplification of VH and VL genes of mAb 148.3 
The variable heavy (VH) and variable light (VL) genes were amplified from a 
hybridoma cell line 148.3 (Meyer et al., 1994).  
5.1.6.1.  Poly-mRNA isolation 
In general there are two strategies to isolate mRNA: 1) isolation of total RNA, 2) 
isolation of messenger RNA (mRNA). Almost all eukaryotic mRNA are 
monocystronic and contain a post-transcriptionally added, poly-adenylic acid 
(poly A) at their 3’ terminal. This poly-A tail permits separation and isolation of 
mRNA from the total pool of RNA. Hybridoma cells 148.3 (1-2 x 10
8 cells) were 
harvested at 500 g for 5 min at 4°C and the supernatant was discarded. Cell 
pellet was washed twice with ice-cold PBS and the RNA isolation was continued 
by using RNeasy Mini Kit (Qiagen) following the manufacturer’s instructions.  Methods 
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Usually 1 to 3% of the total RNA pool represent the mRNA level. The 
purification of mRNA is based on the hybridization of poly-A
+-RNA tail to 
oligo-dT-nucleotides immobilised on a matrix under high salt concentration. The 
poly-A-mRNA was isolated by using Oligotex Direct mRNA Mini Kit (Qiagen) 
following the manufacturer’s instructions.  
5.1.6.2.  cDNA synthesis 
For the synthesis of single stranded DNA the enzyme SuperScript II Reverse 
Transcriptase (from E. coli) (Invitrogen) was used following the manufacturer’s 
instructions. The following reaction mixture was prepared: 
 
4 µL  first strand buffer (5x) 
1 µL  RNasin (20 U/µL), RNase inhibitor 
1 µL  dNTP (10 mM) 
1 µL  DTT (0.1 M) 
4 µL  dT15 primer (10 pmol/µL) 
1-5 µg  RNA 
ad 19 µL  RNase-free dH2O 
 
The reaction mixture was incubated for 1  min at 42°C. 1  µL of the reverse 
transcriptase was added and the reaction was continued for 1 hour at 42°C, 
followed by a 15 min incubation at 70°C to terminate the reaction. The reaction 
mixture was transferred on ice and centrifuged for 5 min at 18,000 g and 4°C. 
Supernatant was transferred to a fresh 1.5 mL tube and stored at -80°C. 
5.1.6.3.  Polymerase chain reaction (PCR)  
DNA fragments are amplified sequence specifically by using polymerase chain 
reaction (PCR) (Saiki et al., 1985; Mullis et al., 1986). DNA templates flanked by 
two oligonucleotides hybridized to opposite strands of the template are 
synthesized by DNA polymerase starting from the 3’  end of each 
oligonucleotide. Following repeating cycles of heat denaturation of the template, 
annealing of the primers and extension of the annealed primers by DNA 
polymerase, the DNA fragment is synthesized and amplified. These newly Methods 
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synthesized DNA strands are used again as DNA templates in a new cycle. To 
amplify the VH and VL chain genes cDNA (see 3.1.1.2) template and degenerate 
primers (Hunte & Müncke 2004) specific for antibody genes were used in the 
following reaction mixture of 100 µL: 
 
1 µL   cDNA (10 ng) 
10 µL  Polymerase buffer (10 x) 
3 µL  MgCl2 (50 mM) 
20 µL  Optizym enhancer (5 x) 
2 µL  forward primer (10 pmol/µL) 
2 µL  reverse primer (10 pmol/µL) 
2 µL  dNTPs (10 mM) 
1 µL  PowerScript DNA polymerase 
59 µL  dH2O 
 
The thermal cycling profile looked as follows: 
 
94°C 1  min 
94°C   1 min 
50°C  90 sec             30 x 
72°C 2  min 
72°C 10  min 
4°C break 
 
The resulting PCR products were cloned into pDrive vector (Invitrogen) 
following the manufacturer’s instructions and sequenced.  
To introduce restriction sites into the antibody and HLA-B44 genes, Pfu DNA 
polymerase (Lundberg  et al.,  1991) with 3’  →  5’ exonuclease activity 
(proofreading) was used. The following reaction components in a volume of 
50 µL were used in a standard PCR: Methods 
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1 µL   DNA (10 ng) 
5 µL  Pfu buffer (10 x) 
2.5 µL  forward primer 
2.5 µL  reverse primer  
5 µL  dNTPs (2 mM) 
0.5 µL  Pfu polymerase (2.5 U/µL) 
33.5 µL  dH2O 
 
The following thermal cycling profile was used for the antibody genes: 
 
95°C 3  min 
95°C   30 sec 
60°C  30 sec             30 x 
72°C 2  min 
72°C 10  min 
4°C break 
 
To introduce restriction sites into the HLA-B44 genes the following reaction 
mixture in a total volume of 100 µL was prepared: 
 
1 µL   DNA (10 ng) 
20 µL  Phusion buffer (5 x) 
2.5 µL  forward primer 
2.5 µL  reverse primer  
10 µL  dNTPs (2 mM) 
1 µL  Phusion polymerase (2.5 U/µL) 
5 µL  DMSO 
58 µL  dH2O 
 
The following thermal cycling profile was used for the HLA-B44 genes: 
 
95°C 3  min 
95°C   1 min 
55°C  1 min             30 x 
72°C 45  sec 
72°C 10  min 
4°C break 
 
The PCR products were analyzed by agarose gel electrophoresis. Methods 
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5.1.6.4.  Colony PCR 
Instead of plasmid preparation and subsequent restriction analysis, colony PCR 
was used to screen E. coli colonies directly from LB plates for their DNA with 
insert specific primers. E. coli colony was resuspended in 50 µL sterile water 
and incubated for 10 min at 95°C following centrifugation for 2 min at 20,000 g. 
10  µL of the supernatant was transferred into an appropriate PCR tube and 
following reaction components were added: 
 
5 µL   Taq buffer (10 x) 
5 µL  MgCl2 (50 mM) 
0.25 µL  forward primer (10 pmol/µL) 
0.25 µL  reverse primer (10 pmol/µL) 
5 µL  dNTPs (2 mM) 
0.25 µL  Taq polymerase (5 U/µL) 
34.25 µL  dH2O 
 
The following thermal cycling program was used: 
 
95°C 4  min 
95°C   4 min 
55°C  30 sec             30 x 
72°C 90  sec 
72°C 10  min 
4°C break 
5.1.6.5.  Bacmid PCR 
To proof the transposition of the pFB1 or pFBD in DH10Bac cells, a PCR with 
sequence specific and M13 standard primers was performed. DH10Bac colony 
was resuspended in 50  µL sterile water and incubated for 10  min at 95°C 
following centrifugation for 2  min at 20,000  g. 10  µL of the supernatant were 
transferred to a PCR tube and following reaction components were added: Methods 
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5 µL   Taq buffer (10 x) 
5 µL  MgCl2 (50 mM) 
0.5 µL  DMSO 
0.25 µL  forward primer (10 pmol/µL) 
0.25 µL  reverse primer (10 pmol/µL) 
5 µL  dNTPs (2 mM) 
0.25 µL  Taq polymerase (5 U/µL) 
33.75 µL  dH2O 
 
95°C 3  min 
95°C   30 sec 
50°C  30 sec             30 x 
72°C 4  min 
72°C 10  min 
4°C break 
5.1.7.  Construction of expression plasmids  
5.1.7.1.  Bacterial expression plasmids for recombinant antibodies 
The isolated and sequenced VH and VL chain genes were PCR amplified to 
introduce restriction sites PstI (NsiI) and BstEII into the VH gene and SacI and 
XhoI into the VL chain gene (Kleymann et al., 1995). Following PCR, PCR 
products and the plasmids pASK68 (Fv expression) and pASK85 (Fab 
Expression) were cut with the appropriate set of restriction endonucleases (see 
also 5.1.2) and ligated (see also 5.1.3). The genes inserted into the expression 
vectors were verified by sequencing.  
5.1.7.2.  Insect cell expression plasmids for recombinant antibodies 
For the expression of scFv148.3 and Fab148.3 in insect cells, a pro-melittin 
signal sequence from honeybee (www.expasy.ch, UniProt data base, accession 
number P01501) together with a (SG4)3 spacer sequence was synthesized by 
GenScript (GenScript Corporation, New Yersey, U.S.A.) and cloned into pUC57. 
The antibody heavy (VHCH1) and light (VLCL) chains of the Fab fragment in 
pASK85 were cut with SacI, HindIII and PstI, NcoI respectively and cloned into Methods 
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the pUC57 including the melittin signal sequence. The light chain (VLCL) of the 
Fab fragment including the melittin signal sequence was subsequently cloned 
into pFasBacDual with BamHI and HindIII. Afterwards the heavy chain (VHCH1) 
of the Fab fragment including the melittin signal sequence was cloned into 
pFastBacDual using XmaI and NcoI. The variable heavy (VH) and variable light 
(VL) chains in the pASK68 were cut with PstI, NcoI and SacI, XhoI, respectively, 
and ligated into pUC57 including the melittin signal sequence and the (SG4)3 
linker. The antibody genes including the melittin signal sequence were cut from 
the pUC57 and ligated into pFastBac1 (scFv) via BamHI and HindIII restriction 
sites. 
5.1.7.3.  Insect cell expression plasmids for HLA-B4402 and HLA-B4405  
The single chain MHC class I B4402-β2m (scB4402-β2m) and single chain MHC 
class I B4405-β2m (scB4405-β2m) genes were PCR-amplified from the pGAPZ 
plasmid (kindly provided by Sebastian Springer, Jacobs University Bremen) with 
NgoMIVstrepfor, with a N-terminal strep tag, or with NgoMIVβ2mfor, without 
N-terminal strep tag and tevhisrev, introducing a TEV cleavage site and a His6- 
tag. PCR products were cut with NgoMIV and HindIII, following ligation into 
pFastBac1 already bearing the melittin signal sequence gene. Ligation products 
were checked via restriction analysis and verified by DNA sequencing (Scientific 
Research & Development GmbH, Germany). 
5.2.  Microbiology 
5.2.1.  Preparation of competent E. coli cells 
An overnight culture of E. coli DH5α cells was diluted 1:200 in 200 mL of LB 
medium and grown at 37°C to an OD550 of 0.5. The culture was incubated on ice 
for 10 min and harvested at 2,000 × g for 10 min at 4°C. The cell pellet was 
carefully resuspended in 35 mL of sterile, ice-cold TFB I buffer and incubated on 
ice for 1 h. After centrifugation at 3,000 × g for 10 min at 4°C, the cell pellet was 
resuspended in 6 mL of ice-cold TFB II buffer. Cell aliquots of 100 µL were Methods 
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frozen in liquid nitrogen and stored at -80°C. To make E.coli DH10Bac 
competent cells, the same procedure was applied except for LB medium 
containing 50 µg/mL kanamycin and 10 µg/mL tetracycline. 
 
TFB I solution  TFB II solution 
30 mM KAc  10 mM MOPS 
10 mM CaCl2  10 mM RbCl2 
50 mM MnCl2  75 mM CaCl2 
100 mM RbCl2  15% (v/v) glycerol 
15% (v/v) glycerol  adjusted pH 6.8 with 1 M KOH 
adjusted pH 5.8 with 1 M acetic acid   
5.2.2.  Transformation of competent E. coli cells 
100 µL of E. coli BL21, DH5α or JM83 competent cells were incubated with 1 µL 
plasmid DNA on ice for 30 min. Heat shock was performed for 1 min at 42°C 
and subsequently cells were incubated for 1 min on ice. 900 µL of SOC medium 
were added and regeneration was carried out for 45 min at 37°C in a 
thermomixer. 100 µL of the regenerated cells were plated on LB-agar plates 
containing the appropriate antibiotic and incubated overnight at 37°C.  
 
LB-agar  SOC medium 
10 g/L peptone/tryptone  20 g/L peptone/tryptone 
5 g/L yeast extract  5 g/L yeast extract 
5 g/L NaCl  10 mM NaCl 
15 g/L agar  2.5 mM KCl 
  10 mM MgCl2 
20 mM glucose  
5.2.3.  Transformation of competent DH10 Bac cells 
1 µL of DNA (100 ng) was added to 100 µL of competent DH10Bac cells thawed 
on ice and the transformation mixture was incubated on ice for 15-20  min. 
Following a heat shock at 42°C for 1 min and a 2 min incubation on ice, 1 mL of 
SOC medium was added and the transformed cells were subsequently 
incubated at 37°C for 4 h. The transformation mixture was then plated onto LB Methods 
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agar plates containing 50  µg/mL kanamycin, 7  µg/mL gentamicin, 10  µg/mL 
tetracycline, 100 µg/mL Bluo-Gal and 40 µg/mL IPTG. Plates were incubated at 
37°C for at least 36  h. The white colonies were amplified to isolate the 
recombinant bacmids for transfection of insect cells. 
5.3.  Cell culture 
5.3.1.  Expression of recombinant antibodies in E. coli 
Recombinant antibodies were expressed in E. coli (strain JM83) as described by 
Skerra (Skerra, 1988). An overnight culture, grown at 30°C in 2 x YT medium 
supplemented with 100  µg/mL ampicillin and 30  µg/mL streptomycin, was 
diluted 40-fold in 2 L of the same medium without streptomycin and grown at 
22.5°C till mid exponential phase (A550 nm=0.5). Protein expression was induced 
by adding 1 mM IPTG (pASK68) or 0.2 mg/L AHT (pASK85). After 3 h the cells 
were harvested by centrifugation at 5,000 g for 15 min at 4°C, resuspended in 
20  mL of periplasmic extraction buffer, and incubated on ice for 30  min. 
Spheroblasts were removed at 5,000 g for 45 min at 4°C and the periplasmic 
fraction was stored at -20°C.  
 
YT medium (2 x)  Periplasmic extraction buffer 
16 g/L peptone/tryptone  100 mM Tris/HCl, pH 8.0 
10 g/L yeast extract  500 mM sucrose 
5 g/L NaCl  1 mM EDTA 
5.3.2.  Monolayer culture of Sf9 insect cells 
Monolayer cultures of Spodoptera frugiperda (Sf9) insect cells were cultured       
at 27°C in Sf900  II medium (including 10 units/mL penicillin, 0.1  mg/mL 
streptomycin, 0.2% pluronic acid and 5% fetal calf serum). For passaging, 
medium and floating cells from a confluent monolayer were discarded and 
replaced by pre-warmed medium.  Methods 
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5.3.3.  Monolayer culture of Tn5 insect cells 
Monolayer cultures of Trichoplusia ni cell line (BTI-Tn-5B1-4), commercially 
known as High Five insect cells, were cultured in Express Five SFM medium 
(supplemented with 18 mM L-glutamine and 10 units/mL penicillin, 0.1 mg/mL 
streptomycin). Before passaging of a confluent culture (T75, 75  cm
2  growth 
surface) non-adherent, floating cells were removed and pre-warmed medium 
was added. 
5.3.4.  Shaker culture of Sf9 and Tn5 insect cells 
Insect cells were subcultured from monolayer cultures at a cell density of 
0.4-4 x 10
6 cells/mL to a volume of up to 600  mL under defined shaking 
conditions (<200 mL at 110 rpm, >200 mL at 60 rpm). 
5.3.5.  Transfection of Sf9 insect cells 
2 x 10
6 Sf9 cells were seeded onto a 35-mm tissue culture plate and incubated 
for one hour at 27°C. The cell densitiy should be 50-70% confluent before 
proceeding with the transfection. The transfection was carried out as described 
in the Baculogold manual (BD Bioscience Pharmingen) using the Baculogold 
Transfection Kit (BD Bioscience Pharmingen). After seeding the cells the culture 
medium was removed and 1  mL of transfection buffer A (BaculoGold) was 
added. 5 µg bacmid DNA were mixed with 1 mL transfection buffer B and was 
immediately added dropwise to the transfection mixture. After incubation at 
27°C for 4 h the transfection medium was discarded and 3 mL of fresh Sf900 
medium were added. The plate was incubated for 5-7 days at 27°C before the 
recombinant virus (P0) was harvested. 
5.3.6.  Amplification of virus 
For the amplification of virus P1 (10 mL), 1.2 x 10
6 cells/mL seeded in a T75 
flask and incubated at 27°C for 1 h were infected with 2 mL recombinant virus 
P0 (P0 has typically a titer of 1  x  10
7 pfu (plaque forming units)/mL). 
Recombinant virus P1 was harvested after 5-7 days. 15 mL P2 were harvested Methods 
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from infection of 3 x 10
7 cells with 2 mL of P1 for 5-7 days. Following 5-7 days 
infection of 1  x  10
9 cells with 15  mL P2, recombinant virus P3 (500  mL) was 
harvested and stored at 4°C.  
5.3.7.  Infection of Sf9 and Tn5 cells for protein production 
500 - 700 mL  shaker  culture  of  Sf9 or Tn5 cells were grown at 27°C in a 
Fernbach flask to a density of 3-3.5 x 10
6 cells/mL. 30-50 mL of virus stock P3 
were added and the culture was incubated until a cell death rate of 30% was 
achieved (usually after 3  –  4 days). Subsequently cells were harvested by 
centrifugation at 200  g for 5  min and the supernatant was kept at 4°C until 
protein purification proceeded. 
5.3.8.  Raji cells 
Human Burkitt lymphoma cells (Raji cells) were propagated in roller bottles at 
37°C and 95% humidity in RPMI medium 1640 supplemented with 10% FCS, 
1 mM sodium pyruvate, and each 40 units/mL penicillin and streptomycin. The 
cell density of the culture was generally maintained at 1.5-3 x 10
6 cells/mL. 
5.4.  Biochemical methods 
5.4.1.  Preparation of microsomes 
For the preparation of microsomes (Ehses, 2005; van Endert, 1994), Raji cell 
pellets (10
9 cells from 400 mL culture) were thawed and resuspended in 50 mL 
of cavitation buffer. All steps were performed at 4°C. Cells were then 
homogenized by a glass douncer and centrifuged at 800 g for 5 min. The pellet 
was discarded and 25  mL of 1.3  M sucrose buffer were added to the 
supernatant and another centrifugation step at 800 g, for 10 min was started. 
The resulting supernatant was then centrifuged at 20,000  g for 30  min. The 
pellet was carefully resuspended in 4  mL of 0.25  M sucrose buffer and 
supplemented with 28 mL of 2.5 M sucrose buffer, before dispensing the cell Methods 
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sucrose suspension on ultracentrifuge tubes. A sucrose gradient containing 
3  mL of 2  M sucrose buffer, 3  mL 1.3  M sucrose buffer and 0.8  mL 250  mM 
sucrose buffer on top was poured and centrifuged at 100,000 g overnight in a 
SW-28 rotor. The microsomes were harvested from the 2.0 M / 1.3 M sucrose 
interphase and diluted with 2 volumes of 1 x PBS and centrifuged at 20,000 g 
for 20 min. The pellet was resuspended in 2 mL of 1 x PBS and aliquots were 
frozen in liquid nitrogen and stored at -80°C. Protein concentration was 
determined by BCA (Pierce). 
 
Cavitation buffer  PBS (10 x) 
10 mM Tris/HCl, pH 7.5  90 mM Na2HPO4 
2.5 mM benzamidine  18 mM KH2PO4 
1 mM PMSF  1.4 M NaCl 
  27 mM KCl 
  ad pH 6.86 
 
0.25 M sucrose 
buffer 
1.3 M sucrose  
buffer 
2.0 M sucrose  
buffer 
2.5 M sucrose 
buffer 
20 mM HEPES, 
pH 7.5 
20 mM HEPES, 
pH 7.5 
20 mM HEPES, 
pH 7.5 
20 mM HEPES, 
pH 7.5 
25 mM KAc  25 mM KAc  25 mM KAc  25 mM KAc 
5 mM MgAc  5 mM MgAc  5 mM MgAc  5 mM MgAc 
0.25 M sucrose  1.3 M sucrose  2.0 M sucrose  2.5 M sucrose 
5.4.2.  Preparation of membranes 
For preparation of membranes Sf9 cell pellets (10
9 cells) were carefully thawed 
on ice by adding 3 volumes of cavitation buffer. All steps were performed at 4°C. 
Using a glas douncer cells were homogenized and cell debris was removed by a 
two step centrifugation: at 200  g for 4  min, at 700  g for another 8  min. The 
supernatant was then centrifuged at 20,000  g for 30  min and the pellet was 
resuspended in 1 x PBS. Aliquots were frozen in liquid nitrogen and stored at 
-80°C.  Methods 
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5.4.3.  SDS-polyacrylamide-gelelectrophoresis 
The discontinuous sodium dodecyl sulfate polyacrylamid gel electrophoresis 
(SDS-PAGE, Lämmli, 1970) is used for the electrophoretic separation of 
proteins based on their molecular weight. Treatment with SDS, an anionic 
detergent, disrupts non-covalent interactions in native proteins and gives a 
denatured protein a large net-negative charge due to the deprotonated sulfate 
group, which is roughly proportional to the mass of the protein. Reducing agents 
like DTT or β-Mercaptoethanol (2-thioethanol) are necessary to break disulfide 
bonds. After assembling the Mini-Protean 3 casting chamber (BioRad) of a mid-
size gel 10.1 x 8.2 mm and a gel thickness of 0.75 mm, first the running gel and 
after 10 min of polymerization the stacking gel was poured and a comb was 
inserted. 
 
     Stacking gel 
5% 
Separating gel 
            10%                             12% 
30% acrylamide  650.00 µL  3.10 mL  3.76 mL 
collecting gel 
buffer 
1.10 mL  -  - 
separating gel 
buffer 
-  3.95 mL  2.82 mL 
dH2O  2.70 mL  3.95 mL  2.82 mL 
10% APS  30.00 µL  40.00 µL  40.00 µL 
TEMED  10.00 µL  20.00 µL  20.00 µL 
 
Prior to electrophoresis proteins were denatured in 2  x sample buffer and 
incubated for 10 min at 95°C. SDS electrophoresis was performed at 25 mA per 
gel for 1-1.5 h in electrophoresis buffer. Prestained Protein Marker (Fermentas) 
was used as a standard. Methods 
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Stacking gel buffer Separating gel buffer  SDS sample buffer 
(2x) 
Running buffer 
(10x) 
0.5 M Tris/HCl, 
pH 6.8 
1.5 M Tris/HCl, 
pH 8.8 
0.1 M Tris/HCl, 
pH 6.5 
0.25 M Tris/HCl, 
pH 8.8 
0.4% SDS (w/v)  0.4% SDS (w/v)  4% SDS (w/v)  2 M glycine 
  
0.2% bromophenol- 
blue (w/v) 
10% SDS (w/v) 
    20% glycerol (v/v)   
   0.9 M 
β-mercaptoethanol   
5.4.4.  Tricine-SDS-polyacrylamide-gelelectrophoresis  
Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(Tricine-SDS-PAGE) is used for the separation of proteins in a broader range 
from 1 to 100 kDa resulting in a higher resolution of protein complexes 
(Schägger, 1987). The stacking and separating gel composition as well as the 
gel and running buffers are listed in the following tables. 
 
  Stacking gel 
4.5% 
Separating gel 
            12%                             16% 
30% acrylamide   650 µL  2.92 mL  3.90 mL 
3 x gel buffer  1.50 mL  2.50 mL  2.50 mL 
dH2O  2.30 mL  1.18 mL  0.20 mL 
10% APS  30.00 µL  25.00 µL  25.00 µL 
TEMED  10.00 µL  2.50 µL  2.50 µL 
 
Cathode buffer (5 x)  Anode buffer (5 x)  Gel buffer (3 x) 
0.5 M Tris  1 M Tris/HCl, pH 8.9  3 M Tris/HCl, pH 8.5 
0.5 M Tricine    0.3% (w/v) SDS 
0.5% (w/v) SDS     
5.4.5.  Coomassie and silver staining 
Proteins separated on an SDS-PAGE were visualized by staining with a solution 
of Coomassie Blue for 30 min. After staining, the excessive dye was removed 
by incubating the gel in a destain solution (10% acetic acid, 20% methanol) until Methods 
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distinct protein bands were visible. The detection limit is approximately 400 ng 
protein per lane. 
 
Stain solution  Destain solution 
40% (v/v) methanol  40% (v/v) methanol 
10% (v/v) acetic acid  10% (v/v) acetic acid 
0.25% (w/v) Coomassie Blue G250   
 
Silver staining is far more sensitive than Coomassie and can detect 10 ng 
protein per lane. For silver staining the SDS gel was incubated for at least 1 h in 
50  mL fixation solution and rinsed two times for 10 min with water before 
incubating the gel for 1 min in thiosulfate buffer. Afterwards the gel was rinsed 
two times with water for 1 min. For staining it was incubated for 20 min in 50 mL 
silver nitrate solution. After rinsing the gel two times with water for 1 min, 50 mL 
of the developing solution was added and the gel was incubated for 20 min. 
Again, the gel was rinsed two times with water following incubation in 
developing solution until protein staining became visible.  
 
Fixation solution  Thiosulphate buffer 
Silver nitrate  
solution 
Developing 
solution 
40% EtOH (v/v)  0.02% (w/v) NaS2O3 0.1%  (w/v)  AgNO3  2% (w/v) Na2CO3 
10% HAc (v/v)    
0.04% (v/v) form- 
aldehyde 
0.04% (v/v) form- 
aldehyde 
5.4.6.  Immunoblotting 
After the electrophoretic separation of a protein sample on an SDS-
polyacrylamide gel, the proteins were transferred onto a nitrocellulose 
membrane by electroblotting. The gel was placed on a nitrocellulose membrane 
and sandwiched by Whatmann paper soaked in blotting buffer in a Semidry 
blotting apparatus (Bio-Rad Laboratories GmbH, Germany) with the 
nitrocellulose facing the anode. The transfer ran for 1 h with a current of 75 mA 
per membrane. Methods 
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Blotting buffer  Blocking buffer  Wash buffer  TBS (10 x) 
25 mM Tris/HCl 
pH 7.5 
1 x TBS, pH 8.0  1 x TBS, pH 8.0  200 mM Tris/HCl, 
pH 8.0 
192 mM glycine  0.05% Tween-20  0.05% Tween-20  2.5 M NaCl 
0.03% (w/v) SDS  5% (w/v) skim milk     
20% methanol  or 3% (w/v) BSA     
 
To determine the transfer efficiency, the membrane was stained with Ponceau 
Red (0.1% Ponceau S red (w/v), 5% (v/v) acetic acid) for 1 min and washed with 
water until background stain was removed and protein bands became visible. 
For immunodetection the membrane was incubated with blocking buffer for at 
least 30 min at room temperature or overnight at 4°C. After blocking, the 
membrane was incubated at room temperature for 1 h or overnight at 4°C with 
the primary antibody (dilutions given below), subsequently washed three times 
for 5 min with washing buffer and finally incubated with horseradish peroxidase 
conjugated secondary antibody for 1 h at room temperature. Afterwards, the 
membrane was washed again three times for 5 min and incubated with a 
mixture of 10 mL each ECL solution 1 and ECL solution 2 for 1 min. The 
chemiluminescent signal was detected by a LumiImager. 
 
Antibody  Dilution  Directed against 
148.3 1:10  TAP1 
435.3 1:5  TAP2 
429.4 1:5  TAP2 
7F6 1:20  tapasin 
HC10  1:20  MHC class I 
α-His 1:2,000  His-tag 
streptactin-HRP 1:20,000  Strep-tag 
goat-α-mouse-HRP 1:20,000  mouse-IgG 
goat-α-rabbit-HRP 1:20,000  rabbit-IgG 
    
ECL solution 1  ECL solution 2 
100 mM Tris/HCl, pH 8.5  100 mM Tris/HCl, pH 8.5 
0.4 mM coumaric acid  0.12% (v/v) H2O2 
2.5 mM luminol sodium salt   Methods 
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5.4.7.  Stripping of immunoblots 
To remove antibodies from already developed western blots, membranes were 
stripped with stripping buffer for 20 min at RT and washed afterwards 3 x with 
TBS-T for at least 5 min following blocking for at least 1 h and incubation with 
the next antibody. 
 
Stripping buffer  Washing buffer 
0.1 M glycin/HCl, pH 2.7  1 x TBS 
 0.05%  Tween-20 
5.4.8.  Protein G affinity chromatography 
The hybridoma supernatant containing the monoclonal antibody was adjusted to 
0.02 M  NaH2PO4, pH  7.0 with 1.0  M NaHPO4. Protein G column (1  mL bed 
volume) was equlibrated with 5 column volumes of binding buffer. Hybridoma 
supernatant was applied to the protein G column which was subsequently 
washed with 5-10 column volumes of the binding buffer. The antibody was 
eluted with 5 column volumes of elution buffer and immediately neutralized with 
60-200  µL of the neutralization buffer per mL elution fraction. The protein G 
column was re-equilibrated with 5-10 column volumes of the binding buffer, 
washed with 5-10 column volumes of dH2O and finally stored in 20% EtOH at 
4°C. 
 
Binding buffer  Elution buffer  Neutralization buffer 
20 mM NaH2PO4, pH 7.0  0.1 M glycine/HCl, pH 2.7  1.0 M Tris/HCl, pH 9.0 
150 mM NaCl     
5.4.9.  Epitope coupled affinity chromatography 
The peptide CYWAMVQAPADAPE corresponding to the C-terminus of human 
TAP1 was coupled to Ultralink Iodoacetyl Gel (Pierce) via the N-terminal 
cysteine according to the manufacturer’s instructions. After equlibration of the 
column with running buffer, 50  mL of hybridoma supernatant (mAb148.3, 
adjusted to pH  7.0) or periplasmic fractions or insect cell supernatant of the Methods 
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recombinant antibodies (Fv, scFv and Fab fragments, dialyzed against running 
buffer) were loaded. After washing, bound antibodies were eluted with the 
elution buffer. The antibodies were immediately buffered to neutral pH with the 
neutralization buffer, concentrated by ultrafiltration (Amicon, Millipore) and 
quantified by Micro BCA Protein Assay (Pierce). 
 
Running and washing 
buffer  Elution buffer  Neutralization buffer 
50 mM Na-phosphate 
buffer, pH 7.0 
100 mM glycine/HCl, pH 2.7 1 M Tris/HCl, pH 9.0 
150 mM NaCl     
5.4.10.  Streptavidin affinity chromatography 
The Strep-tag I, an eight amino acid peptide (WRHPQFGG) has been originally 
selected from a genetic random library (Schmidt & Skerra, 1993), which binds 
specifically to core streptavidin (proteolytically truncated version of the natural 
bacterial protein). The Strep-tag binds reversibly to the same pocket as the 
natural ligand D-biotin and can be eluted under mild conditions with D-
desthiobiotin, which is a derivative of D-biotin with less strong affinity. An 
optimized  Strep-tag II exists, which can be placed at the N- or C-terminus 
whereas the Strep-tag I is placed only at the C-terminus. An engineered 
streptavidin variant, called Strep-Tactin, with improved peptide-binding capacity 
has been developed and is commerically distributed by IBA. 
5.4.10.1.  Refolding of core streptavidin 
Inclusion bodies derived from 1 L cell culture were dissolved in 8 mL ice-cold 
6 M guanidium/HCl and dialyzed in 10-fold volume (1:10) for 2 x 4 h against 6 M 
guanidium/HCl at 4°C to remove biotin. Dialyzate was poured in a steady, 
nearly dropwise stream in stirring ice-cold PBS at a ratio of 1:25 and incubated 
at least 3  h or overnight at 4°C without stirring. Non-dissolved protein was 
sedimented for 30  min at 20,000  g and fractionated ammonium sulfate 
precipitation was performed to remove protein contaminations. In the first step 
0-40% (taken from 25°C table, Arne Skerra), 243 g/L, were dissolved, stirred Methods 
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further for 10 min and incubated for 3 h without stirring. The precipitated protein 
was removed by centrifugation for 30 min at 20,000 g and the supernatant was 
carefully decanted. The ammonium sulfate concentration was increased to 
40-70%, 205 g/L, and after dissolving it was incubated overnight without stirring. 
The precipitated streptavidin was recovered by centrifugation for 1 h at 20,000 g 
and the pellet was resuspended in 10 mL 2.2 M of ammonium sulfate / L cell 
culture and incubated for 2-3 h following centrifugation for 30 min at 20,000 g. 
Again, the protein pellet was resupended in 10 mL 1 x PBS / L cell culture and 
non dissolved protein was sedimented for 30 min at 20,000 g. The supernatant 
was sterile filtered (0.22 µm filter) and aliquots were stored at 4°C. If not used 
for coupling immediately, the filtered supernatant was dialyzed twice 1:100 
against 1 x PBS to remove ammonium sulfate and stored in 1 x PBS including 
1 mM EDTA and 0.01% NaN3.  
 
Guanidiumhydrochlorid  PBS (10 x)  Ammoniumsulfate 
6 M guanidium/HCl, pH 1.5  40 mM KH2PO4  2.2 M ammoniumsulfate 
  160 mM Na2HPO4  in 1 x PBS 
  1150 mM NaCl   
 pH  7.0   
 
To quantify the refolded streptavidin, the sample was diluted in 1 x PBS and 
absorption at 280 nm was measured. The following equation was used: 
1
280 ) (
− × × = ε factor dilution x M E w nm  
E280 nm = measured extinction at 280 nm 
M = molar mass (13310 g/mol for monomeric streptavidin) 
ε = extinction coefficient at 280 nm (35600 M
-1 cm
-1 for monomeric streptavidin) 
5.4.10.2.  Preparation of streptavidin sepharose 
Activated CH Sepharose 4B (GE Healthcare) was suspended in 1  mM HCl 
following the manufacturer’s instructions and washed for 15 min with 1 mM HCl 
on a sintered glass filter. About 200  mL of 1  mM HCl per gram freeze-dried 
sepharose powder were used, added in several aliquots. The core streptavidin Methods 
 
 
  66
was dialyzed 12-16  h against coupling buffer in a ratio 1:100. The dialyzed 
streptavidin solution (10  mg/mL) was mixed with the already washed gel 
suspension in a stoppered vessel. The mixture was rotated end-over-end for 
1-2 h at RT. Excess of ligand was washed out with at least 5 gel volumes of 
coupling buffer. Remaining active groups were blocked by incubating the gel for 
1 h in 0.1 M Tris/HCl, pH 8.0. The gel suspension was washed thoroughly with 
three cycles of alternating pH. Each cycle consisted of a wash with 0.1  M 
acetate buffer pH  4.0 containing 0.5  M NaCl followed by a wash with 0.1  M 
Tris/HCl buffer pH  8.0 containing 0.5  M NaCl. The coupled gel matrix was 
stored in 0.1 M Tris/HCl, pH 8.0 including 0.01% NaN3 at 4°C.  
 
Coupling buffer  Blocking buffer  Washing buffer 1  Washing buffer 2 
0.1 M NaHCO3, 
pH 8.0 
0.1 M Tris/HCl, 
pH 8.0 
0.1 M Ac, pH 4.0  0.1 M Tris/HCl, 
pH 8.0 
0.5 M NaCl    0.5 M NaCl  0.5 M NaCl 
5.4.10.3.  Immobilized streptavidin affinity chromatography 
A streptavidin sepharose column with a bed volume of 2 mL was prepared and 
equlibrated with 10 column volumes of binding buffer. The periplasmic extracts 
were dialyzed for 12-16  h against 100-fold (1:100) binding buffer. After the 
addition of avidin to a final concentration of 20 µg/mL, the dialyzed periplasmic 
extracts were applied on the streptavidin column. The column was washed with 
5 column volumes of binding buffer and the Fv fragments were eluted with 5 
column volumes of elution buffer, concentrated, and stored in 50 mM Tris/HCl, 
pH  8.0, 150  mM NaCl at 4°C. The streptavidin column was washed with 5 
column volumes of regeneration buffer followed by 5 column volumes of binding 
buffer and stored at 4°C. 
 
Binding buffer  Elution buffer  Regeneration buffer 
20 mM Tris/HCl, pH 8.0  20 mM Tris/HCl, pH 8.0   20 mM Tris/HCl, pH 8.0 
150 mM NaCl  150 mM NaCl  150 mM NaCl 
1 mM EDTA  1 mM EDTA  1 mM EDTA 
  2.5 mM desthiobiotin  1 mM HABA Methods 
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5.4.11.  Immobilized metal chelate affinity chromatography 
Immobilized metal chelate affinity chromatography (IMAC) was first used to 
purify proteins in 1975 (Porath et al., 1975) and is based on the chelating ligand 
iminodiacetic acid (IDA) or nitrilotriacetic acid (NTA). NTA occupies four of the 
six ligand binding sites in the coordination sphere of the nickel ion, leaving two 
sites free to interact with His6-tag. Since insect cell medium contains several 
ingredients acting as chelators, which are removing metal ions from the IMAC-
columns, the supernatants were dialyzed three times against 15 L dialysis buffer 
given below. 
 
Dialysis and running buffer 
20 mM Tris/HCl, pH 8.0 
200 mM NaCl 
 
Ni-NTA Agarose (Qiagen) or the IDA-column (1  mL HiTrap Chelating, 
Amersham Pharmacia) were used for protein purification. The IDA-column was 
conditioned with 10  mL of stripping buffer, 10  mL of water, 10  mL of ZnSO4 
(20 mM) and 10 mL of running buffer. The resin was loaded with a flow rate of 
1  mL/min. In the case of Ni-NTA agarose (1  mL bed volume), the resin was 
equilibrated with 10  mL of running buffer before applying the dialyzed 
supernatant adjusted to 500 mM NaCl. After loading, the column was washed 
with 50 mL of buffer A, 50 mL of buffer B, 25 mL of buffer C and finally eluted 
with the elution buffer. Protein-containing samples were identified by SDS-
PAGE, pooled, concentrated in a centricon device (Millipore), and stored at 4°C 
until size exclusion chromatography.  
 
Stripping 
buffer 
 Buffer A  Buffer B  Buffer C  Elution buffer 
50 mM EDTA, 
pH 8.0 
20 mM,Tris/HCl, 
pH 8.0 
20 mM,Tris/HCl, 
pH 8.0 
20 mM,Tris/HCl, 
pH 8.0 
20 mM,Tris/HCl, 
pH 8.0 
  200 mM NaCl   200 mM NaCl  200 mM NaCl  200 mM NaCl 
  5 mM histidine  10 mM histidine 20 mM histidine 200 mM histidineMethods 
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5.4.12.  Immobilized antibody fragment affinity chromatography 
Recombinant antibody fragments are widely used to purify membrane proteins 
including multisubunit membrane protein complexes. To co-purify the antigenic 
TAP complex together with associated factors the Fab148.3 expressed in Tn5 
cells was used as capture agent. Microsomes prepared from 3.2 L Raji cells 
were centrifuged for 2 min at 14,000 g and the pellet was washed with PBS and 
centrifuged again for 2 min at 14,000 g. The microsome pellet was resuspended 
in solubilization buffer adjusting the total protein concentration to 5 mg/mL and 
digitonin was added to a final concentration of 1% (v/v). The solubilizate was 
incubated for 45 min on ice and subsequently centrifuged for 30 min at 98,000 g 
to remove unsoluble cell material. Purified Fab148.3 was added to the 
supernatant in a stoichiometry of 2:1 (Fab148.3:TAP complex, assuming the 
expressed TAP level is 1% of the total protein content present) and incubated 
for 30 min at 4°C. 1 mL of Ni-NTA agarose beads equilibrated with solubilization 
buffer were added to the solubilizate including Fab148.3 and incubated for 2 h 
at 4°C. Following washing with each 10 column volumes of wash buffer 1, 2, 3 
and 4, the TAP complex including Fab148.3 was either eluted with 5 column 
volumes of elution buffer or 50 µM of the 5mer epitope peptide Ac–ADAPE–OH in 
wash buffer 1. The purified protein complex was precipitated by incubating the 
elution fraction with 10-50 µL of Strataclean beads (Stratagene), centrifuged for 
1 min at 1,000 g, and the beads were resuspended in 30 µL of 2 x SDS sample 
buffer. 
 
Solubilization buffer  Wash buffer 1  Wash buffer 2 
20 mM Tris/HCl, pH 7.4  20 mM Tris/HCl, pH 7.4  20 mM Tris/HCl, pH 7.4 
100 mM NaCl  100 mM NaCl  100 mM NaCl 
1% (v/v) PMSF (0.1 M)  1% (v/v) PMSF (0.1 M)  1% (v/v) PMSF (0.1 M) 
1% (v/v) benzamidine 
(0.3 M) 
1% (v/v) benzamidine 
(0.3 M) 
1% (v/v) benzamidine 
(0.3 M) 
15% glycerol (v/v)  15% glycerol (v/v)  15% glycerol (v/v) 
1% digitonin  1% digitonin  1% digitonin 
  5 mM histidine  10 mM histidine 
 Methods 
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Wash buffer 3  Wash buffer 4  Elution buffer 
20 mM Tris/HCl, pH 7.4  20 mM Tris/HCl, pH 7.4  20 mM Tris/HCl, pH 7.4 
100 mM NaCl  100 mM NaCl  100 mM NaCl 
1% (v/v) PMSF (0.1 M)  1% (v/v) PMSF (0.1 M)  1% (v/v) PMSF (0.1 M) 
1% (v/v) benzamidine 
(0.3 M) 
1% (v/v) benzamidine 
(0.3 M) 
1% (v/v) benzamidine 
(0.3 M) 
15% glycerol (v/v)  15% glycerol (v/v)  15% glycerol (v/v) 
1% digitonin  1% digitonin  1% digitonin 
20 mM histidine  40 mM histidine  200 mM histidine 
5.4.13.  Size exclusion chromatography 
Size exclusion chromatography (SEC) was performed on a Superdex 200 
PC 3.2/30 column (GE Healthcare) in running buffer (20 mM HEPES, pH 8.0, 
140 mM NaCl) with a flow rate of 50 µL/min at 4°C.      
5.4.14.  Generation of proteolytic Fab fragments 
Papain cleavage of the mAb148.3 was carried out as described by Parham 
(Parham, 1986)
 
with some modification. Digestion was performed in 50  μL 
aliquots with 10 µM mAb in reaction buffer. To activate the protease, 500 ng 
papain (Sigma) were pre-incubated in reaction buffer supplemented with 
100  mM cysteine (Sigma) for 15 min at 20°C. The reaction was started by 
adding the mAb and continued for 16 h at 35°C. The digest was terminated with 
70 mM iodoacetamide for 30 min at 20°C. After the addition of neutralization 
buffer the mixture was loaded onto Protein G Sepharose (GE Healthcare) pre-
equilibrated with ten column volumes of running buffer and subsequently 
washed with ten column volumes of the same buffer. The Fab fragments were 
eluted with ten column volumes of the elution buffer, immediately buffered to 
neutral pH with the neutralization buffer, and concentrated by ultrafiltration 
(Amicon,Millipore). 
 
Reaction buffer  Neutralization buffer Running buffer  Elution buffer 
100 mM NaOAc, 
pH 5.5  1 M Tris/HCl, pH 9.0 50 mM Na-
phosphate, pH 7.0 
100 mM 
glycine/HCl, pH 2.7
1 mM EDTA       Methods 
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5.4.15.  Protein concentration determination 
5.4.15.1.  UV/Vis spectroscopy 
Protein concentration is determined by UV/Vis spectroscopy taking the 
theoretical extinction coefficients (determined with ProtParam Software, from 
www.expasy.ch) into account. 
                                               factor dilution d c A × × × =ε 280  
 
A280  = Absorption at 280 nm 
ε  = extinction coefficient (M
-1 cm
-1) 
d  = pathway (1 cm) 
5.4.15.2.  Bicinchonin acid (BCA) 
The BCA assay is based on the reduction of Cu
2+ to Cu
+ by reducing agents like 
peptide bonds in proteins. Bicinchonin acid forms specifically a complex with 
Cu
+ with an absorption maximum at 562 nm. For protein determination the Micro 
BCA Protein Assay Kit (Pierce) was used.  
5.4.16.  Peptide iodination with Na
125I 
For iodination of peptides the chloramin T method was used 
(Hunter  &  Greenwood, 1964). 10  µL of the peptide (500  µM) in 40  µL PBS 
(pH 7.0) together with 10 µL chloramin T (1 mg/mL) and 1 µL (100 µCi) Na
125I 
were incubated for 5  min. The reaction was terminated by adding 120  µL 
NaS2O5 (0.17  mg/mL). Free iodine was removed by anion exchange 
chromatography using Dowex 1 x 8 material. 10 mg of Dowex were equilibrated 
in PBS (pH  7.0) containing 0.2% dialyzed BSA and washed twice with PBS 
without BSA. 220 µL of the Dowex suspension were added to the radio-labeled 
reaction mix, carefully resuspended and incubated for 5 min at RT. To separate 
the radiolabeled peptide (2.3 µM) from free iodine, the suspension was applied Methods 
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to an empty spin column (BioRad) and centrifuged for 30  s at 1,000  g. The 
radio-labeled peptide containing flow-through was kept at 4°C.   
5.4.17.  Peptide labeling with iodoacetamidofluorescein 
50 mM iodoacetamidofluorescein stock solution was prepared in DMF. Peptides 
containing one single cysteine were dissolved in PBS, pH 6.5, 20% DMF to a 
concentration of 10 mM. The labeling reaction was initiated by adding 1.2 molar 
excess of iodoacetamidofluorescein to the peptide solutions. Following 90 min 
incubation at RT, the labeling solution was applied onto a C18 column (Vydac-
218TP510-C18 protein and peptide, 10  x  250  mm) equlibrated with 0.1% 
trifluoroacetic acid. Free fluorescein was separated from peptides with an 
acetonitrile gradient running from 15%  -  38% within 30  min (for peptides 
EEFGRAFCF, EEFGRACSF, EEFGCAFSF) and with an acetonitrile gradient 
running from 26%  -  33% within 28  min at a flow rate of 1  mL/min. The 
absorption at 455 nm was monitored to localize the fluorescein and peptides. 
The peak containing fluorescein-labeled peptide was pooled and lyophilized 
peptides were dissolved in water supplemented with 20% DMF. The peptide 
concentration was determined by absorption at 492 nm in tricine buffer, pH 9.0 
(molar extinction coefficient at pH 9.0 75,000 cm
-1 M
-1). Purity of the fluorescein-
labeled peptides was verified by MS spectrometry. 
5.4.18.  Generation of "empty" MHC class I molecules 
To investigate peptide association to recombinant soluble MHC class I 
molecules it was necessary to remove any bound peptide. To generate "empty" 
MHC class I molecules the pH shock method was used (Shields,  1998; 
Sugawara, 1987; van der Burg, 1995). Decreasing pH of purified MHC class I 
molecules by 0.1 M citric acid to a pH of 2.5 led the bound peptide dissociate 
and left the MHC class I in an "empty" state. The sample was incubated on ice 
for 2 min and the reaction was terminated by neutralizing the protein sample 
with  1 M Tris/HCl,  pH 9.0.  After neutralization the unbound peptide was 
removed from the sample by gelfiltration, applying the sample on a pre-
equilibrated size ecxlusion chromatography Micro-Spin column (BioRad) with a Methods 
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cut-off of 30 kDa. The sample was centrifuged at 1,000 g for 4 min and the flow-
through containing "empty" MHC class I molecules was immediately used for 
peptide-binding experiments.  
5.4.19.  Peptide-binding assay with "empty" MHC class I molecules 
"Empty" MHC class I molecules (500 nM) were mixed with fluorescein-labeled 
peptide EEFGRCAFSF (500 nM) in 50 µL of 20 mM Tris/HCl, pH 7.5, 120 mM 
NaCl. The protein sample was incubated overnight at 18°C in a shaker. 
Background binding was determined by adding a 500-fold excess of unlabeled 
peptide (competitor). To remove unbound peptide the protein mixture was 
applied on a pre-equilibrated size exclusion chromatography Micro-Spin column 
(BioRad) and the peptide loaded  MHC class I  molecules in the flow-through 
were quantified with a fluorescence plate reader (λex/em=485/520 nm).  
5.4.20.  Peptide-binding assay 
Peptide binding to TAP was measured in filter assays using a multiple filtration 
manifold (Multiscreen Assay System, Millipore). TAP-containing microsomes 
(15 µg total protein) were pre-incubated in the absence of ATP, with 3 mM ATP 
or 5  µM Fv fragment for different periods at 27°C. Subsequently 1  µM 
radiolabeled peptide RR(
125I)YQKSTEL was added to a final volume of 50 µL in 
AP-buffer. After 15 min on ice the samples were transferred onto a multiscreen 
filter (Multiscreen Plates with glass fiber filter, pore size 1.0 µm, Millipore), pre-
incubated with 100  µL of polyethylene imine, followed by 100  µL of 0.2% 
dialyzed BSA. Unbound peptide was removed by washing the filter plates three 
times with 100 µL of 1 x PBS. Peptides bound to the filters were quantified by 
γ-counting. The data were corrected for background binding determined in the 
presence of a 100-fold molar excess of unlabeled peptide.  
5.4.21.  Peptide transport assay with semipermeabilized cells 
2.5 x 10
6 Sf9 cells were semi-permeabilized in 50 µL of AP-buffer supplemented 
with 0.05% saponin (w/v) for 1 min at 20°C. After washing with AP-buffer, the Methods 
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cells were pre-incubated with 10 µM mAb148.3, 10 µM mAb435.3 or different 
concentrations of the Fv fragment for 20 min at 4°C. After incubation protein 
samples were mixed with 500 nM fluorescein-labeled peptide RRYQNSTC
(F)L 
and 10 mM ATP in 100 µL of AP-buffer. The transport assay was performed for 
3 min at 32°C and terminated by adding 1 mL of ice-cold PBS supplemented 
with 10  mM EDTA. After centrifugation for 8  min at 20,000  g, the cells were 
solubilized in 1 mL lysis buffer for 15 min at 20°C. Insoluble debris was removed 
by centrifugation. N-core glycosylated and therefore transported peptides were 
bound to 60 µL of concanavalin A Sepharose (50% (v/v)) overnight at 4°C. After 
three times washing of the beads with 1 mL of lysis buffer, peptides were eluted 
with 200 mM methyl α-D-mannopyranoside for 30 min at 4°C and quantified with 
a fluorescence plate reader (λex/em=485/520 nm). Background transport activity 
was determined by replacing ATP with 1 unit of apyrase. Specific inhibition of 
the Fv fragment was determined in the presence of a 1,000-fold molar excess of 
5mer epitope peptide (Ac-ADAPE-OH). ICP47 was used as a control at identical 
conditions as described for the Fv fragment.  
 
AP-buffer  Lysis buffer 
1 x PBS, pH 7.0  50 mM Tris/HCl, pH 7.5 
5 mM MgCl2  150 mM NaCl 
  5 mM KCl 
  1 mM CaCl2 
  1 mM MnCl2 
  1% (v/v) NP-40 
5.4.22.  Peptide transport with membranes or microsomes 
Membranes or microsomes (100 – 250 µg total protein) were incubated together 
with 3  mM ATP and 0.5  µM radio-labeled RRY(
125I)QNSTEL in 50  µL of AP 
buffer for 3 min at 32°C. The reaction was stopped by adding 1 mL of ice-cold 
stop buffer. After centrifugation, the pellets were solubilized in 900 µL of lysis 
buffer and incubated for 20  min at RT. After removing insoluble material by 
centrifugation at 20,000 g for 8 min, the supernatant was incubated with 70 µL 
of concanavalin A Sepharose (50%, v/v) overnight. After three washing steps, 
the radioactivity associated with the ConA-Sepharose was quantified by 
γ-counting.  Methods 
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AP buffer  Stop buffer  Lysis buffer 
1 x PBS, pH 7.0  1 x PBS, pH 7.0  50 mM Tris/HCl, pH 7.5 
5 mM MgCl2  10 mM EDTA  150 mM NaCl 
    5 mM KCl 
    1 mM CaCl2 
    1 mM MnCl2 
    1% (v/v) NP-40 
5.4.23.  Nucleotide-binding assay 
The ATP-binding activity of TAP was analyzed based on published procedures 
(Knittler et al., 1999). All solutions and centrifuges were pre-cooled to 4°C. The 
ATP-agarose was prepared following the manufacturer’s instructions. 400 µL of 
Raji microsomes (5 mg/mL) were digitonin-solubilized in solubilization buffer for 
30 min at 4°C. Insoluble material was removed at 100,000 g for 30 min at 4°C. 
The supernatant was pre-incubated with 10 µM Fv148.3 following 1 h incubation 
with pre-equilibrated ATP-agarose beads. The ATP-agarose beads were 
washed three times with 500 µL of washing buffer. Bound proteins were eluted 
with MgATP (10 mM) and analyzed by SDS-PAGE and immunoblotting using 
the TAP1-specific monoclonal antibody 148.3. 
 
Solubilization buffer  Washing buffer  Elution buffer 
20 mM HEPES, pH 7.4  20 mM HEPES, pH 7.4  20 mM HEPES, pH 7.4 
150 mM NaCl  150 mM NaCl  150 mM NaCl 
1 mM KCl  1 mM KCl  1 mM KCl 
1.5 mM MgCl2  1.5 mM MgCl2  5 mM MgCl2 
2% digitonin  0.2% digitonin  0.2% digitonin 
15% glycerol  15% glycerol  15% glycerol 
    5 mM ATP 
5.4.24.  Enzyme-linked immunosorbent assay (ELISA) 
96-well plates (MaxiSorb, Nunc) were coated with 1 µg of soluble NBD of TAP1 
in coating buffer (100 µL/well) for 16 h at 4°C. After saturation of non-specific 
binding sites with blocking buffer, the mAb148.3 or the antibody fragments were 
bound for 1 h at 25°C and detected with a goat anti-mouse HRP-conjugated 
antibody (Sigma). Bound antibodies were visualized with Methods 
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3,3’,5,5’-tetramethylbenzidine (TMB, Progen) and quantified in an ELISA reader 
at a wavelength of 450 nm.  
 
Coating buffer  Blocking buffer  Washing buffer 
1 M NaHCO3, pH 9.0  3% (w/v) BSA 
1 x TBS 
0.05% (v/v) Tween-20 
1 x TBS 
   0.05%  (v/v)  Tween-20 
5.4.25.  Fluorescence polarization 
To investigate rotational diffusion of fluorophores within the fluorescence life 
time in fluid solution the polarization or anisotropy of the emission is measured. 
Anisotropy measurements are based on the excitation of fluorophores by 
polarized light. The absorption is maximal when the transition dipole of the 
fluorophore is parallel to the electric vector of the light, the so-called 
photoselection. Since in homogenous solution the ground-state fluorophores are 
oriented randomly, only those fluorophores, which have their absorption 
transition moments oriented along the electric vector of the light, are excited 
upon exposure to polarized light. Measuring the fluorescence intensities of the 
vertically and horizontally polarized emission of a sample which is excited with 
vertically polarized light, one can calculate the fluorescence anisotropy (R) and 
polarization (P): 
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Equation 3-1: Calculation of the anisotropy. IVV – emission parallel to vertical excitation,  
IVH – emission orthogonal to vertical excitation 
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Equation 3-2: Calculation of the polarisation. IVV – emission parallel to vertical excitation,  
IVH – emission orthogonal to vertical excitation 
 
Anisotropy is dimensionless and independent of the total intensity of the 
sample. Two methods are used for steady state measurements: the L-format Methods 
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method, which uses a single emission channel, and the T-format method, which 
uses two emission channels (parallel and perpendicular). The FLUOLOG-3 
uses the single-channel method. Since the monochromator or the emission filter 
used in these measurements have different transmission efficiency for vertically 
and horizontally polarized light, rotation of the emission polarizer changes the 
measured parallel and perpendicular intensities. For this reason it is necessary 
to determine the G-factor, which is the ratio of the sensitivities of the detection 
system for vertically and horizontally polarized light: 
H
V
S
S
G =  
Equation 3-3: Definition of the G-Factor. SV – sensitivity for vertically polarized light, SH-
sensitivity for horizontally polarized light 
 
The G-factor is dependent on the emission wavelength and also on the 
bandpass of the monochromator. Filters generally do not have any polarizing 
effect (G = 1.0). Nonetheless the G-factor should always be determined since 
the rotation of the emission polarizer can cause the focussed image of the 
fluorescence to change the position, changing the effective sensitivity. The G-
factor is measured using horizontally polarized excitation where both 
horizontally and vertically polarized components are equal because both 
polarizer orientations are perpendicular to the polarization of the excitation. 
Thus any measured differences between IHV and IHH are due to the properties of 
the detection system. 
HH
HV
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Equation 3-4: Determination of the G-factor 
 
The anisotropy measurements were carried out at 20°C with 1  µM peptide-
deficient scB4405-β2m (see 5.4.18) and 20  nM fluorescein-labeled peptide in 
200 µL of HBS buffer. The reassociation of the fluorescein-labeled peptides with 
the peptide-deficient scB4405-β2m conjugate was investigated by recording the 
changes in the anisotropy using the FLUOLOG-3 spectrometer (Instruments 
S.A., France) with an excitation wavelength of 470  nm and an emission 
wavelength at 515 nm of the fluorophore. The time-dependent changes in the Methods 
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anisotropy were fitted by a monoexponential function yielding the association 
and dissociation rate constants, ka and kd, based on pseudo first-order reaction.  
 
HBS buffer 
20 mM HEPES/HCl, pH 7.5 
140 mM NaCl 
5.4.26.  Fluorescence emission 
Fluorescence quenching is the decrease of fluorescence emission which takes 
place for instance in case of fluorescein, which senses alteration in the polarity 
or pH of the environment. Time-dependent change of fluorescence emission 
was analyzed during the binding and dissociation of fluorescein-labeled peptide 
to TAP in presence or absence of Fab148.3. 80 nM fluorescein-labeled peptide 
(C4F) were preincubated in 170 µL HBS (pH 7.5) buffer at 10°C. After reaching 
a stable fluorescence emission signal, 30 µL of purified TAP1/TAP2 heterodimer 
or purified TAP1/TAP2 heterodimer preincubated with 10 µM Fab148.3, were 
injected into the cuvette. When binding reached equilibrium as indicated by a 
stable fluorescent emission signal, a 100-fold molar excess of non-labeled 
peptide (RRYQKSTEL) was added to induce the dissociation of the peptide. The 
fluorophore was excited at a wavelength of 470 nm and the emission signal at 
515 nm was recorded using the FLUOLOG-3 spectrometer (Instruments S.A., 
France) equipped with a microstirring device. 
 
HBS buffer 
20 mM HEPES/HCl, pH 7.5 
140 mM NaCl 
0.1% digitonin 
5.4.27.  Surface plasmon resonance 
5.4.27.1.  Binding kinetics of recombinant antibodies 
Binding kinetics were determined on a CM5 chip using the Biacore T100 
(Biacore) surface plasmon spectrometer (GE Healthcare). The peptide epitope Methods 
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CYWAMVQAPADAPE was coupled to the dextran matrix in citric acid buffer 
using a thiol coupling kit (GE Healthcare). All experiments were carried out at a 
flow rate of 30 µL/min using HBS buffer. Different concentrations of recombinant 
antibody were injected onto the chip and dissociation was followed in a constant 
flow of HBS buffer without antibody. The surface was regenerated using 
regeneration buffer with a low pH. The analysis of the binding data was carried 
out using the BIAevaluation software (Biacore) and Origin (OriginalLab 
Corporation, Northhampton, U.  S.  A.) based on a standard model for 1:1 
interaction. 
 
Coupling buffer  HBS buffer  Regeneration buffer 
0.1 M citric acid, pH 2.5  20 mM HEPES, pH 7.5  0.1 M glycine/HCl, pH 2.7 
  150 mM NaCl   
  0.05% surfactant P20   
5.4.27.  Interaction of soluble tapasin and MHC class I molecules 
Interaction studies by SPR were carried out using the Biacore T100 instrument 
(GE Healthcare). Biacore experiments were carried out in HBS buffer on a 
streptavidin-functionalized surface (sensor chip SA, GE Healthcare). For 
functionalization 
BTtris-NTA (1 µM) in HBS buffer was injected on a single flow 
channel for 60 s, following conditioning of the surface with imidazole, EDTA and 
divalent cations (Ni
2+). Subsequently soluble tapasin (100  nM) in HBS buffer 
with a flow rate of 10 µL/min was immobilized on the 
BTtris-NTA-functionalized 
flow channel. All samples of MHC class I molecules (B2709, B2705, B4405) 
were injected over this channel and an adjacent flow channel for referencing. 
Finally the surface was regenerated with imidazol and EDTA. The analysis of 
the binding data was carried out using the BIAevaluation software (Biacore) and 
Origin (OriginalLab Corporation, Northhampton, U. S. A.) based on a standard 
model for 1:1 interaction. 
 
Imidazol  EDTA  NiSO4  HBS buffer 
250 mM  imidazol  250 mM EDTA  10 mM NiSO4  20 mM Hepes, 
pH 7.5 
      140 mM NaCl 
     0.01%  Tween-20 Methods 
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5.4.28.  Total internal reflectance fluorescence spectroscopy (TIRFS) 
For vesicle preparation, SOPC and Tris-NTA-SOA chelator lipid (75% SOPC, 
25% tris-NTA-SOA), resuspended in chloroform, were mixed, dried by a gentle 
stream of nitrogen and rehydrated with HBS buffer. Subsequently small 
unilaminar vesicles (SUV) were prepared by sonification (15 min on ice). The 
transducer surface was incubated for at least 20  min in a freshly prepared 
mixture of one part of 30% (v/v) hydrogen peroxide and two parts of 
concentrated sulfuric acid. After extensive washing with water, the transducer 
was mounted immediately into the flow cell. SUV’s at a concentration of 250 µM 
were injected and bilayer formation was followed by reflectance interference 
detection (RIf). Vesicle fusion should appear rapidly with a signal intensity 
corresponding to 5 ng/mm
2. For every measurement the bilayer was conditioned 
by sequential 50 sec injections of 500 nM imidazole, 200 mM EDTA and 10 mM 
NiSO4 (in HBS), 270 µL each. Bilayers were used for one day of measurements 
or until an air bubble destroyed the bilayer.  
To investigate the influence of tapasin on peptide dissociation of MHC class I 
molecules, both proteins were immobilized subsequently on a lipid bilayer to 
achieve lateral mobility of the individual proteins in plane of the membrane. 
Protein immobilization was monitored by RIf, and the fluorescence labeled 
peptide bound to MHC class I molecule was simultaneously detected by TIRFS. 
After loading of MHC class I molecules with a fluorescein-labeled peptide 
overnight, 150 nM of the loaded MHC class I molecule (in 250 µL) was injected 
for 36 s. Proper immobilization of the MHC class I molecule on the surface was 
checked by washing for 150 s. After probing the surface with 500 nM of soluble 
tapasin for 36 s, again the surface was washed and finally 100 µM non-labeled 
peptide was injected for 435 s, following 10 s washing of the surface. After every 
binding experiment, the surface was conditioned with imidazole, EDTA and 
NiSO4 as described above. 
 
Imidazole  EDTA  NiSO4  HBS buffer 
500 mM  imidazole  250 mM EDTA  10 mM NiSO4  20 mM HEPES, 
pH 7.5 
      140 mM NaCl 
 Results 
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6.  Results 
6.1.  Recombinant antibodies as extrinsic modulators of the 
antigen peptide transporter TAP 
6.1.1.  The mAb148.3 binds to the very last five C-terminal amino acid 
residues of human TAP1 
The mAb148.3, which is specific for human TAP1 is an important diagnostic tool 
to investigate the antigen processing machinery in tumor development and viral 
escape mechanisms (Kyritsis et al., 2001; Seliger et al., 2001). Moreover, the 
mAb148.3 has led to the identification and subunit mapping of the 
macromolecular peptide-loading complex in the ER membrane 
(Bangia et al., 2005; Ortmann et al., 1997). 
The mAb148.3 belongs to the immunoglobulin G1 (IgG1) κ-chain subtype, 
which I determined by immunological subtyping.  
6.1.2.  Cloning, expression, and purification of recombinant antibody 
fragments of mAb148.3 from E. coli 
In order to convert the TAP1-specific mAb148.3 into Fv and Fab formats, cDNA 
was prepared from hybridoma cells, and the VH and VL chain genes were PCR 
amplified using a set of degenerate primers. Not all the PCR-amplified gene 
segments were functional, since part of them accumulated mutations that 
prevent them from encoding a functional protein. These pseudogenes were 
excluded by sequencing and the complementarity determining regions (CDRs) 
and framework regions (FR) of the functional antibody chains were assigned as 
described by Kabat and colleagues (Kabat et al., 1987) (Figure 6-1).  
The genes of the identified VH and VL chains were subsequently cloned into the 
expression vectors pASK68 and pASK85 for periplasmic production of Fv and 
Fab fragments, respectively. Recombinant Fv and Fab fragments were Results 
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produced at different levels in E. coli (Figure 6-2). Both antibody fragments were 
detected after 1 h of induction as shown by SDS-PAGE and immunoblotting with 
tag-specific antibodies (Figure 6-2). 
Figure 6-1. Amino acid sequence of the variable heavy and variable light chains of the 
mAb148.3.  The complementarity determining regions (CDRs), which are involved in epitope 
recognition, are annotated as described (Kabat  et al., 1987) (yellow boxes). Interspersed 
β-sheets, responsible for the stability of the scaffold of the antigen-binding site, are indicated by 
arrows. The variable region of the heavy (VH) and light (VL) chain consists of 130 and 124 amino 
acid residues, respectively. The intramolecular disulfide bonds between Cys22 and Cys98, and 
between Cys23 and Cys93, respectively, are indicated with an asterisk. 
 
 
 
VH 
VL Results 
 
 
  82
 
Figure 6-2. Expression of recombinant antibodies. E. coli were transformed with the expression 
vectors pASK68 (Fv) or pASK85 (Fab). Expression was induced with IPTG (pASK68) or AHT 
(pASK85) for 3  h. Aliquots of the bacterial cell lysates (0, 1, 2, 3  h), the supernatant after 
harvesting (sn), the periplasmic fraction (pp, 1/25 aliquot), and the cytoplasmic fraction (cp) 
were analyzed by reducing Tricine-SDS-PAGE ((a), 16%, expression of Fv; (d), 12%, 
expression of Fab). The VH (b) and VL (c) chains of the Fv fragment were detected with tag-
specific antibodies at 14.4 kDa and 13.8 kDa, respectively. The heavy chain (VHCH1) of the Fab 
fragment at 25 kDa (e). Molecular mass standard in kDa.  
 
The recombinant antibody fragments were initially purified via the C-terminal 
Strep-tag of the Fv-VH chain and the C-terminal His6-tag of the Fab-VHCH1 
chain. However, the Fv fragment displayed a tendency to dimerize, leading to 
reduced affinity to its epitope. Therefore, the recombinant antibody fragments 
were purified by affinity chromatography employing the peptide 
CWAVQPADAPE (epitope underlined). The Fv fragment was purified to 
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homogeneity in a single affinity chromatography step as shown by silver-
staining of an SDS-PAGE and immunoblotting using a Streptactin-HRP 
conjugate (Figure 6-3 (a)). By contrast, the purity as well as the total amount of 
purified Fab fragment was considerably lower than for the Fv fragment 
(Figure  6-3 (b)). The Fab fragment was however clearly detectable by 
immunoblotting using an Fab-specific antibody  (Figure 6-3 (b)).  Heterodimer 
assembly of the purified Fab fragment was confirmed by SDS-PAGE under 
oxidizing conditions. The Fab fragment has an apparent molecular mass of 
50 kDa due to the intermolecular disulfide bridge at the C-termini of the constant 
regions (between CH1 and CL) (Figure 6-3 (c)). The yields of purified Fv and Fab 
fragments were 100  µg and 20  µg per liter of E. coli culture, respectively. 
Comparable amounts of the Fab fragment were purified also by IMAC. Correct 
folding and monodispersity of the purified Fv fragment was demonstrated by 
analytical size exclusion chromatography (Figure 6-3 (d)). The Fv fragment 
appears as a single peak with a molecular mass of 28 kDa. A proteolytic Fab 
fragment (50  kDa), which was generated by papain digestion of mAb148.3, 
eluted shortly before the Fv fragment and was used as an internal standard 
(Figure 6-3 (d)). The proteolytic  Fab fragment appears as a monomeric peak 
with an additional sub-fraction corresponding to an (Fab)2 fragment as 
described for other antibodies (Better et al., 1988). 
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Figure 6-3. Affinity purification of recombinant antibody fragments. Fv and Fab fragments were 
affinity-purified  via the epitope peptide CYWAMVQAPADAPE of TAP1. Aliquots of the 
periplasmic fraction (pp), the flow through (ft), the washing step (w), and the elution fractions 
(1-5) were analyzed. (a) Purification profile of the Fv fragment analyzed by Tricine-SDS-PAGE 
(16%, silver-stained). The VH chain was detected with a Streptactin-HRP conjugate. (b) 
Purification of the Fab fragment was monitored by Tricine-SDS-PAGE (12%, silver-stained). The 
Fab fragment was detected with a Fab-specific antibody. (c) Heterodimer assembly of the 
purified Fab fragment (200 ng) analyzed by Tricine-SDS-PAGE (12%, silver-stained) under non-
reducing conditions. Molecular mass standard in kDa. (d) The affinity-purified Fv and proteolytic 
Fab fragments were separated by size exclusion chromatography (Superdex 200 PC3.2/30). 
Proteins (0.3 mg total protein) were monitored at 280 nm. The void volume (V0 = 0.85 mL) and 
the total volume (Vt = 2.3 mL) are indicated by arrows in the chromatogram.  
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6.1.3.  Cloning, expression and purification of scFv and Fab fragments of 
mAb148.3 from insect cells 
Eukaryotic expression systems have been widely used for the expression of 
recombinant antibodies (Verma et al., 1998). Since the periplasmic expression 
of the Fv and Fab fragment resulted in an over all low expression and 
purification yield, the genes of the recombinant antibody fragments were 
subcloned into pFastBac1 and pFastBacDual for production and secretion of 
scFv and Fab fragments, respectively, in insect cells. Briefly, a secretion signal 
sequence (pro-melittin sequence from honeybee) was introduced into the 
pFastBac1 and pFastBacDual. The VHCH1 and VLCL antibody chain genes were 
cloned in the pFastBacDual for expression and secretion of the Fab fragment. 
For the expression of the scFv fragment the VH and VL chain genes were 
amplified and linked via a (SG4)3 linker following ligation in pFastBac1.  
After generation of recombinant baculoviruses by using the Bac-to-Bac System 
(Invitrogen) a Sf9 shaking culture was infected with 10% (v/v) of the respective 
virus. Supernatants were collected after 72-96  h of infection and dialyzed 
extensively against buffer containing 20 mM Tris/HCl, pH 8.0, 150 mM NaCl at 
4°C. Purification of His6-tagged scFv and Fab fragments was performed with 
either nickel-nitrilotriacetic acid (Ni-NTA) or epitope-coupled affinity 
chromatography employing the peptide CYWAMVQAPADAPE (epitope 
underlined). Both scFv and Fab fragments were purified to homogeneity by a 
single affinity chromatography step (Figure  6-4 (a) and (b)) with a molecular 
weight of approximately 25  kDa for the VHCH1 and VLCL, respectively, and 
28 kDa for the scFv due to the (G4S)3 linker bridging the VH and VL chain. The 
heterodimer assembly of the Fab fragment was analyzed by SDS-PAGE 
(coomassie-stained) under reducing and oxidizing conditions (Figure 6-4 (a)). 
Here, the Fab fragment had an apparent molecular mass of 50 kDa due to the 
intermolecular disulfide bridge at the C-termini of the constant regions (between 
CH1 and CL). Analytical size exclusion chromatography demonstrated 
monomeric scFv and Fab fragments after a single-step purification 
(Figure 6-4 (c)). Results 
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Figure 6-4. Affinity purification of scFv and Fab fragments secreted from insect cells. scFv and 
Fab fragments were affinity-purified via the epitope peptide CYWAMVQAPADAPE of TAP1 and 
the elution fraction was analyzed by SDS-PAGE (12%, coomassie-stained). (a) 2  µg Fab 
fragment were analyzed under reducing (with β-mercaptoethanol, red) or non-reducing (without 
β-mercaptoethanol, oxid) conditions to prove proper heterodimer assembly. (b) The purity of the 
purified scFv fragment (1 µg) was estimated by SDS-PAGE (12%, coomassie-stained) under 
reducing conditions (red). (c) The affinity-purified scFv and Fab fragments were separated by 
size exclusion chromatography (Superdex 200 PC3.2/30) monitoring proteins (20 µg) at 280 nm. 
The void volume (V0=0.85 mL) and the total volume (Vt=2.3 mL) are indicated by arrows in the 
chromatogram. Molecular mass standard in kDa. 
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6.1.4.  Recombinant antibody fragments bind with nanomolar affinity to the 
TAP1 epitope 
The binding affinity of the recombinant antibody fragments was analyzed by 
ELISA using the NBD of TAP1 as antigen (Müller et al., 1994). The equilibrium 
binding constants (KD) for the monovalent recombinant Fv (31.8±2.7 nM) and 
the Fab fragment (39.5±2.7  nM) are very similar (Figure  6-5  (a) and (b)), 
however they differed drastically by two orders of magnitude from the KD value 
of the mAb148.3 (0.42±0.04 nM) (Figure 6-6. (d)). To investigate whether this 
difference is based on avidity effects of the bivalent IgG molecules, I generated 
proteolytic Fab fragments by papain cleavage of the mAb148.3. The resulting 
Fab fragments were purified on Protein G Sepharose and analyzed by SDS-
PAGE under oxidizing conditions and immunoblotting using Fab- and Fc-
specific antibodies (Figure 6-6 (a) and (b)). In addition to the monovalent Fab 
fragment a small amount of the bivalent (Fab)2 fragment was detected with the 
Fab-specific antibody. The proteolytic Fab fragment displays a KD value of 
14.8±0.8 nM (Figure 6-6 (c)), demonstrating that the KD values of the isolated 
paratopes of the bivalent mAb148.3 for binding to the TAP1-NBD are 
comparable with those of the recombinant Fv and Fab fragments.  
 
Figure 6-5. Affinity binding constants of the recombinant antibodies. ELISA plates were coated 
with purified TAP1-NBD (10  µg/mL) and probed with various concentrations of the 
affinity-purified Fv (a) and Fab fragments (b). The experimental data were fitted to a 1:1 
Langmuir binding model. 
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Figure 6-6. Affinity binding constant of the proteolytic Fab fragment. After papain cleavage, the 
proteolytic Fab fragment was affinity-purified on Protein G Sepharose and analyzed by non-
reducing SDS-PAGE (10%). The Fab (a) and Fc fragments (b) were detected with specific 
antibodies. The binding constants of the proteolytic Fab fragment (c) and the mAb148.3 (d) for 
the NBD of TAP1 were determined by ELISA. The experimental data were fitted to a 1:1 
Langmuir binding model. Molecular mass standard in kDa. 
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The association and dissociation kinetics of the Fv fragment were analyzed by 
surface plasmon resonance (SPR) spectroscopy using the epitope peptide 
CYWAMVQAPADAPE immobilized on a CM5 biosensor chip (Figure 6-7 (a)). 
Rate constants and equilibrium binding constants were determined based on a 
standard model for 1:1 interaction and are summarized in Table 6-1.  
 
Table 6-1. Association and dissociation rate constants at 4°C.  
Fv (nM)  ka (10
4×M
-1×s
-1)
  kd (10
-3×s
-1)  KD, kin (nM) 
15.6 12.76 1.40 11.00 
31.3 8.12 1.42  17.50 
62.5 8.27 1.43  17.30 
125.0 8.33  1.45 17.40 
 
The association rate constant derived from the various concentrations 
(arithmetic mean) of Fv fragments was determined to 
ka = (8.57 ± 0.31) × 10
4 M
-1s
-1 (4°C). The dissociation rate constant was 
kd = (1.43 ± 0.06) × 10
-3 s
-1 (4°C). Diffusion limitation and multivalency effects 
(crowding at the sensor interface) could be excluded by investigating the rate 
constants at different flow rates as well as at different concentrations of the 
immoblized epitope peptide. The KD (arithmetic mean) derived from these rate 
constants was 16.80 (± 0.69) nM. The KD value calculated from the resonance 
units at equilibrium binding of the Fv fragment to the surface (Req) is 
32.1 (± 1.10) nM  (Figure 6-7 (b)).  The  Req value deduced from binding 
experiments at 25°C is 35.4  (±  2.20)  nM. These results prove the self-
consistency of the data and confirm the nanomolar affinity of the recombinant 
antibody fragments for TAP1 as determined by ELISA. 
 Results 
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Figure 6-7. Determination of the affinity binding constant of the Fv fragment by surface plasmon 
resonance (SPR). (a) The binding kinetics of the Fv fragment to the epitope peptide 
CYWAMVQAPADAPE were analyzed with concentrations of 15.6  nM, 31.2  nM, 62.5  nM and 
125 nM at 4°C. (b) Determination of the thermodynamic KD value calculated from the plasmon 
shifts at equilibrium binding of the Fv fragment to the surface (Req).  Rate constants and 
equilibrium binding constants were determined based on a standard model for a 1:1 interaction. 
 
The kinetic rate constants of Fv148.3 for binding to the epitope peptide 
CYWAMVQAPADAPE immobilized on a CM5 biosensor chip were also 
compared at several temperatures between 5 and 25°C (Figure 6-8). Both, ka 
and kd of Fv148.3 increased with the temperature. However, the kd increases 
moderately between 5 and 20°C and rises suddenly at 25°C. The reason for this 
difference may lie in the reduced stability of the Fv fragment at higher 
temperature. Since both, the ka  and kd  rate constants increased with the 
temperature, the corresponding binding constant of the Fv148.3 for epitope 
peptide CYWAMVQAPADAPE decreased (Figure  6-9). The fact that the 
temperature dependence on the binding constant decreases as the temperature 
rises, is an indication for an exothermic reaction. This temperature-dependent 
decrease in binding affinity of the Fv148.3 to the epitope peptide may have 
several reasons: (1) increase in temperature may result in rearrangement of the 
paratope, subsequently leading to a decrease in affinity, and (2) elevated 
temperatures may affect the functionality of the Fv fragment, since both VH and 
VL are non-covalently associated and may fall apart.  
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Figure 6-8. The kinetic rate constants for the Fv148.3 monitored at several temperatures. The 
association (a) and dissociation (b) rate constants of Fv148.3, for binding to the epitope peptide 
CYWAMVQAPADAPE immobilized on a CM5 biosensor chip, were analyzed at several 
temperatures between 5 and 25°C. 
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Figure 6-9. Affinity binding constants determined by kinetic measurements for Fv148.3 observed 
at several temperatures. 
 
The association and dissociation rate constants measured at temperatures 
between 5 and 25°C allowed determining thermodynamic characteristics such 
as the enthalpy and the entropy changes of the reaction. The graphical 
representations carried out are summarized in Figure  6-9, Figure 6-10,  and Results 
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Figure  6-11. The results obtained from graphical representations are 
summarized in Table 6-2. 
To investigate the temperature effect on the interaction between the Fv148.3 
and the epitope peptide, precisely the effect of temperature on the binding 
constant, the van’t Hoff equation was used. Under certain conditions the binding 
constant is linked to the standard Gibbs free energy change of the interaction 
(∆G
0) as stated in the van’t Hoff equation:  
D
1
D
0 K ln RT ) K ln( RT G × = × − = Δ
−  
with  
∆G
0  standard free energy change 
R  universal gas constant 
T  absolute temperature (K) 
KD  equilibrium dissociation constant 
Substitution of the following expression with the van’t Hoff equation 
0 0 0 S T H G Δ − Δ = Δ  
and rearranging gives finally  
R
S
RT
H
K D
0 0
ln
Δ
−
Δ
=  
with 
   ∆H
0  standard enthalpy change 
   ∆S
0  standard entropy change 
 
In case of ∆H
0 < 0, corresponding to an exothermic reaction, the entire term on 
the right of the equation is negative and as shown in Figure 6-10, the equilibrium 
constant of an exothermic reaction decreases with an increase in temperature.  
 Results 
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Figure 6-10. Van’t Hoff presentation of lnKD as a function of the inverse of the temperature. 
 
The linear regression of lnKD as a function of the inverse of the temperature 
gives a slope of -9,304  (±  1,300) and an intercept value of 15  (±  5), with a 
correlation coefficient (R) of -0.97. The slope is defined as ∆H
0/R and the 
intercept of the y-axis as ∆S
0/R. 
The increase of the association and dissociation rate constants with the 
temperature is explained by the Arrhenius and the Eyring equations. Both the 
Arrhenius and the Eyring equation describe a temperature dependence of the 
reaction rates. The linear regression for lnka  and lnkd as a function of the 
temperature gave a slope of -4,781 (± 842) with R = -0.96 and an intercept of 
-14,084 (± 480) with R = -0.99, respectively. The slopes allowed to calculate the 
energy of activation (∆Ea) by implementing the Arrhenius equation: 
A ln
RT
E
k ln
a +
Δ
− =  
With -∆Ea/R defined as the slope and lnA as the intercept of the linear 
regression. A high activation energy (∆E) corresponds to a reaction rate that is 
very sensitive to temperature (the Arrhenius plot has a steep slope). On the 
contrary, Arrhenius plot with a shallow slope, suggesting a small activation 
energy, indicates a reaction rate that varies slightly with the temperature. In this 
case, the corresponding activation energy (Ea,d; Table 6-2)  indicates  that  the Results 
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dissociation rate constant of the Fv148.3 from the epitope peptide is more 
dependent on the changes in temperature than the association rate constant. 
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Figure 6-11. Temperature dependence demonstrated by the Arrhenius plot: lnka and lnkd as a 
function of the inverse of the temperature. 
 
The Eyring equation is based on the transition state model which implies that 
the reaction includes an unsteady intermediate state on the reaction pathway. 
The kinetic rates are dependent on the variation of enthalpy and entropy of 
association and dissociation of the activated complex: 
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with 
  ∆H
*  enthalpy change of the activated complex 
  ∆S
*  entropy change of the activated complex 
  h  Planck’s constant (6.6262 × 10
-34 J × s) 
kB  Boltzmann’s constant (1.3806 × 10
-23 J × K
-1) 
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Thus the thermodynamic transition state constants for the forward and 
backward reactions can be obtained from plots of ln(ka/T) and ln(kd/T) 
respectively against 1/T. The linear regression of ln(ka/T) and ln(kd/T) as a 
function of the inverse of the temperature gives for ka a slope of -4,378 (± 810) 
and an intercept value of 23 (± 3), with a correlation coefficient of -0.95, and for 
kd a slope equal to -13,416  (±  531), an intercept value of 36  (±  2) with a 
correlation coefficient of -0.99. The change of enthalpy of the activated complex 
(∆H*) is given by the slope (-∆H/R), whereas the entropy of the activated 
complex (∆S*) is calculated from the intercept value (ln(kB/h)+(∆S*/R)). 
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Figure 6-12. Temperature dependence demonstrated by the Eyring plot: ln(ka/T) and ln(kd/T) as 
a function of the inverse of the temperature. 
The differences between the association (ka) and dissociation (kd) values of the 
entropy and enthalpy of the activated complex give the changes of the entropy 
and enthalpy of the reactions: 
*
d
*
a
0 H H H Δ − Δ = Δ  
*
d
*
a
0 S S S Δ − Δ = Δ  
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Table 6-2. Summary of the thermodynamical data of the interaction of the Fv fragment and the 
epitope peptide CYWAMVQAPADAPE. 
  Fv148.3 
∆H
0 (kJ / mol)  -77.4 (± 0.2) 
∆S
0 (J × (K × mol)
-1)   -121.3 (± 37.4) 
∆G
0 (kJ / mol)  -41.2 (± 0.2) 
∆Ea;a (kJ / mol)  39.7 (± 7.0) 
∆Ea;d (kJ / mol)  117.1 (± 4.0) 
∆H*a (kJ / mol)  36.4 (± 6.7) 
∆H*d (kJ / mol)  111.5 (± 4.4) 
∆S*a (J × (K × mol)
-1)   -10.3 (± 2.8) 
∆S*d (J × (K × mol)
-1)   103.1 (± 1.8) 
 
In conclusion, moving from free Fv148.3 fragment to the transition state is 
enthalpically opposed yet entropically favored, whereas going from the 
transition state of the bound Fv148.3 fragment to the epitope peptide is favored 
both enthalpically and entropically. The transition state thermodynamics of 
Fv148.3 fragment binding to the epitope peptide is largely entropy-driven since 
-T×∆S
0 is higher than ∆H
0: 36.1 (kJ / mol) > -77.4 (kJ / mol) at 298 K. This is 
consistent with the significant hydrophobic character of the Fv148.3 paratope. 
The enthalpic barrier to binding may result from the stripping of water from 
partial and full charges on the Fv148.3 fragment paratope as well es the epitope 
peptide (Baker & Murphy, 1998). As the transition state settles into the bound 
state, some favorable enthalpy is regained as paratope-epitope hydrogen bonds 
and salt bridges are formed (Gabdoulline & Wade, 2002). If one assumes the 
interface at the transition state is partially dehydrated, then entropically, 
formation of the transition state from the unbound components again reflects the 
hydrophobic effect as waters are released. Forming the bound state from the 
transition state requires release of further water, giving rise to additional 
entropy. Entropy also plays a significant role in influencing the kinetics of the 
paratope-epitope reaction. It is also evident from Table  6-2 how the entropy 
component of the transition state thermodynamics simultaneously reduces the 
activation barrier for binding (∆Ea;a) and increases the barrier for dissociation 
(∆Ea;d). This demonstrates an entropic component of the paratope-epitope 
interaction by which tight paratope-epitope binding and slow dissociation are 
achieved. Results 
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6.1.5.  Fv binding to the C-terminus of TAP1 arrests the TAP complex in a 
peptide transport incompetent state 
It was recently shown that the NBDs of TAP1 and TAP2 have non-equivalent C-
terminal tails, which may account for functional differences in ATP binding and 
hydrolysis at both NBDs (Bouabe & Knittler, 2003). Moreover, the C-terminus of 
the dimeric HlyB-NBD, the closest homologue of a dimer NBD structure, is 
involved in stabilization of the dimer interface (Zaitseva et al., 2005). Based on 
this information I speculated that the Fv fragment modulates peptide 
translocation into the ER lumen by binding to the C-terminus of TAP1. I 
performed transport inhibition studies in semipermeabilized cells after pre-
incubation with graded amounts of recombinant antibodies. Strikingly, the Fv 
fragment inhibits TAP-dependent peptide transport in a concentration 
dependent manner (Figure 6-13). The inhibitory effect is fully reversible in the 
presence of a 1000-fold molar excess of the 5mer epitope (Ac-ADAPE-OH), 
demonstrating that the translocation arrest is specifically linked to the C-
terminus of TAP1. Since the 5mer peptide is too short and is also blocked at its 
N-terminus, it cannot be recognized and transported by TAP 
(Uebel et al., 1997). In the presence of 10 µM of mAb148.3, peptide transport 
was blocked to a similar extent when compared to the Fv fragment. By contrast, 
the same amount of the TAP2-specific mAb435.3 did not inhibit peptide 
transport. The epitope of the mAb435.3 is localized within a sequence stretch C-
terminal of the TMD of TAP2 (
469KFQDVSFAYPNR
480) as determined by epitope 
mapping. These findings argue against simple steric hinderance by the Fv 
fragment or the mAb148.3. In the absence of either ATP or in the presence of 
the TAP-specific inhibitor ICP47 (10  µM with ATP), peptide transport was 
reduced to background level.   Results 
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Figure 6-13. Inhibition of intracellular peptide transport in semipermeabilized cells. Transport 
assays were performed in semipermeabilized cells with fluorescein-labeled peptide (500 nM of 
RRYQNSTC
(F)L) for 3 min at 32°C in the presence of ATP (10 mM). For inhibition studies the 
samples were pre-incubated with either ICP47 (10 µM), Fv fragment (10 µM) together with the 
competitor peptide Ac-ADAPE-OH (10  mM), different concentrations of Fv fragment 
(0.01-10  µM), mAb148.3 (10  µM) or mAb435.3 (10  µM). After cell lysis, N-core glycosylated 
(transported) peptides were bound to Concanavalin A-Sepharose and quantified after specific 
elution. Background transport activity was determined by replacing ATP with apyrase (one unit). 
Data represent the arithmetic mean of triplicate measurements after subtraction of background 
transport activity. 
6.1.6.  The TAP complex is stabilized by antibody fragments 
Since the C-terminal tails of TAP1 and TAP2 control nucleotide interaction 
(Bouabe & Knittler, 2003), I investigated whether binding of the Fv fragment to 
the C-terminus of the TAP1-NBD influences the ATP-binding properties of TAP. 
However, ATP-agarose binding experiments in the absence and presence of 
10  µM of Fv fragment revealed that ATP binding to the heterodimeric TAP 
complex as well as TAP1 alone was not altered by the recombinant antibodies 
(Figure 6-14 (a)). Furthermore, peptide binding experiments at non-saturating 
conditions revealed no effect of the Fv fragment on peptide binding by TAP 
(Figure 6-14 (b)). 
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Figure 6-14. ATP and peptide binding to TAP in the presence of recombinant antibodies. (a) 
Microsomes containing either the heterodimeric TAP1/2 complex or the TAP1-subunit alone 
(both 3.75 mg total protein) were solubilized with digitonin (1%) and split into three vials (250 µL 
each). One of the samples was pre-incubated in the presence of Fv fragment. TAP was bound 
to C8-coupled ATP-Agarose (Sigma) and washed with buffer (one sample with buffer 
supplemented with Fv fragment (10 µM)). TAP was specifically eluted with 50 µL of Mg-ATP 
(5  mM) and analyzed by SDS-PAGE (solubilisate, 5  µL/lane; eluate, 10  µL/lane) and 
subsequent immunoblotting. Solubilizate (sol.), sample without Fv (1), sample pre-incubated 
with Fv (2), sample washed with Fv (3), minor degradation product of TAP1 (*). Molecular mass 
standard in kDa. (b) Peptide binding to the TAP complex at half-maximal peptide 
concentrations. TAP-containing Raji microsomes (25 µg protein) were pre-incubated with 10 µM 
of Fv fragment or without additives for 15  min at 4°C. Peptide binding was performed with 
250  nM of radiolabeled peptide R9LQK for 20  min at 4°C. TAP-associated peptides were 
quantified by γ-counting. Data represent the arithmetic mean of triplicate measurements. 
 
Peptides and ATP bind independently from each other to TAP 
(Androlewicz et al., 1993; Uebel et al., 1995; van Endert et al., 1994). Moreover, 
the heterodimeric TAP complex is highly unstable in the absence of ATP or ADP 
(van Endert et al., 1999). Based on these data I speculated that the Fv fragment 
could compensate for the absence of nucleotides. TAP-containing microsomes 
were preincubated in the absence of ATP and in the presence of either ATP 
(3  mM) or Fv fragment (5  µM) for up to 120  min at 27°C and subjected to 
peptide binding experiments (at  4°C) with the radiolabeled peptide 
anti-TAP1
anti-TAP2
72
55
72
55
T
A
P
1
/
2
T
A
P
1
sol.
TAP1/2 TAP1
123 123
elution
*
anti-TAP1
anti-TAP2
72
55
72
55
T
A
P
1
/
2
T
A
P
1
sol.
TAP1/2 TAP1
123 123
elution
*
no additives
competitor
Fv
competitor
0
25
50
75
100
125
b
o
u
n
d
 
p
e
p
t
i
d
e
 
(
%
)
(a) (b) Results 
 
 
  100
RR(
125I)YQKSTEL at saturation concentration (1  µM). Interestingly, the Fv 
fragment could stabilize TAP to a similar extent as ATP (Figure  6-15). Even 
after 2  h 80% of the peptide-binding capacity of TAP was maintained. By 
contrast, in the absence of ATP and stabilizing Fv fragment the amount of 
peptide-receptive TAP decreased in a time-dependent manner with only 10% of 
bound peptide after 2 h. The decrease of peptide binding directly reflects the 
loss of peptide transport function as previously shown (van Endert et al., 1999). 
Importantly, the amount of peptides bound to the TAP complex in the presence 
and absence of the Fv fragment was comparable not only at saturating but also 
at half-maximal (non-saturating) peptide concentrations (Figure 6-14 (b)). Results 
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Figure 6-15. Stabilization of the TAP complex. TAP-containing microsomes (15 µg total protein) 
were preincubated with 3 mM of ATP or 5 µM of Fv fragment for the indicated periods at 27°C. 
Peptide binding was performed with 1  µM of radiolabeled peptide for 15  min at 4°C. TAP-
associated peptides were quantified by γ-counting. Measurements without ATP and Fv fragment 
(a), in the presence of ATP (b), and in the presence of Fv fragment but without ATP (c). Data 
represent the mean of triplicate measurements and were normalized to the peptide-binding data 
of TAP without additives (0 min). 
0 30 60 120
0
25
50
75
100
125
no additives
time (min)
b
o
u
n
d
 
p
e
p
t
i
d
e
 
(
%
)
0 30 60 120
0
25
50
75
100
125 ATP
time (min)
b
o
u
n
d
 
p
e
p
t
i
d
e
 
(
%
)
(a) 
(b) 
(c) 
0 30 60 120
0
25
50
75
100
125 Fv
time (min)
b
o
u
n
d
 
p
e
p
t
i
d
e
 
(
%
)Results 
 
 
  102
 
Since in peptide-binding experiments the recombinant antibody fragments 
displayed a stabilizing effect on the TAP complex with regard to peptide-binding 
(Figure 6-15), I also investigated the kinetics of substrate release by the TAP 
complex in the presence of the recombinant antibodies. Here, I used 
fluorescence polarization to analyze the kinetics of peptide association and 
dissociation in real time in the presence and absence of the recombinant 
antibody fragments. Interaction of the fluorescein-labeled peptide with the 
peptide-binding pocket of the TAP complex results in fluorescence quenching. 
This phenomenon is based on the characteristics of fluorescein, which is 
sensitive to polarity or pH changes of the surrounding (Neumann et al., 1999). 
The fluorescence quenching is caused by a structural rearrangement of the 
TAP-peptide complex moving a proton donor group in close proximity to the 
fluorophore (Neumann  et al.,  1999). Here, I analyzed the fluorescence 
quenching during the process of substrate binding and dissociation in the 
presence or absence of the Fab148.3 fragment. The addition of the affinity-
purified TAP complex to the buffer containing the fluorescein-labeled peptide 
resulted in a decrease of the fluorescence signal reaching equilibrium within 
8  min (Figure  6-16). A 100-fold molar excess of non-labeled peptide 
(competitor) resulted in the release of the bound fluorescein-labeled peptide. A 
time-dependent increase of the fluorescence signal approaching the initial 
fluorescence intensity was observed (Figure  6-16). All experiments were 
performed in the absence of ATP to exclude the possibility that the change of 
the fluorescence signal is due to ATP-dependent substrate transport instead of 
the formation and dissociation of the TAP-peptide complex. After pre-incubating 
the TAP complex with the Fab148.3 fragment, and adding the preformed 
complex to the buffer containing the fluorescein-labeled peptide a double 
decrease in the fluorescence signal was observed comparing to the decrease 
without the Fab fragment (Figure 6-16). Equilibrium was reached within 500 s 
and after addition of 100-fold molar excess of non-labeled peptide initial 
fluorescence intensity was restored. However, in the presence of the Fab 
fragment the fluorescence recovery was delayed indicating again that the 
recombinant antibody fragment stabilizes the TAP complex by inhibiting the 
dissociation of the TAP-peptide complex (Figure 6-16). Results 
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Figure 6-16. Fluorescence quenching of peptide bound to TAP. Time-dependent change of 
fluorescence emission was analyzed during the binding and dissociation of fluorescein-labeled 
peptide to TAP in the presence or absence of the Fab148.3 fragment. The fluorescence 
emission (λex/em=470/515 nm) was monitored with 80 nM of fluorescein-labeled peptide (C4F) in 
170 µL of HBS buffer at 10°C. After reaching a stable fluorescence emission signal, 30 µL of 
both, purified TAP1/TAP2 heterodimer or purified TAP1/TAP2 heterodimer preincubated with 
10 µM Fab148.3 fragment, were injected into the cuvette. When binding reached equilibrium, as 
indicated by a stable fluorescent emission signal, a 100-fold molar excess of non-labeled 
peptide (RRYQKSTEL) was added to compete for the bound fluorescent peptide. 
6.1.7.  Purification of the peptide-loading complex from a human 
B-lymphoblastoid cell line (Raji) 
In order to circumvent destruction by cytotoxic T cells of the adaptive immune 
system viruses in particular have evolved manifold strategies to interfere with 
the MHC  class  I antigen presentation pathway (Loch  et al., 2008, 
Lehner et al., 2003). Especially, shortly after infection, when antigenic peptides 
are presented at low frequency, time as well as efficiency in selection of those 
antigenic peptides for the recognition of the infected cell by the immune system 
plays a critical role. Thus MHC class I molecules being loaded with high-affinity 
peptides, depend on the optimal peptide supply by the PLC. Current evidence 
suggests that MHC class I molecules loaded with suboptimal peptides are later 
edited by the peptide-exchange mechanism provided by tapasin and ERp57 
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(Wearsch & Cresswell, 2007). But the detailed molecular mechanism of peptide-
binding and -editing is still under debate and needs further investigation of the 
PLC with respect to its function and structural subunits composition.  
Antibody fragments are widely used for the purification and crystallization of 
macromolecular protein complexes. Since the mAb148.3 allowed for the 
identification and isolation of the macromolecular PLC composed of TAP1, 
TAP2, tapasin, MHC class I heavy chain, β2-microglobulin, calreticulin, and 
ERp57 (Bangia,  et al., 2005;  Ortmann et al., 1997), I used the genetically 
engineered Fv and Fab fragments to purify the endogenous PLC from a human 
lymphoblastoid Raji cell line. The aim was to identify novel components of the 
PLC that could provide insight into the precise molecular mechanism of optimal 
peptide loading as well as peptide editing but also to get a more detailed view 
into the structural composition of the PLC. In contrast to the purification of the 
PLC with mAb148.3, where the PLC was eluted with a low pH buffer, the 
application of the recombinant antibody fragments, generated here, harboring 
C-terminal affinity-tags, allows for an elegant purification technique with regard 
to the mild elution conditions. I isolated the TAP complexes from digitonin-
solubilized microsomes of Raji cells and purified the Fab-TAP complexes via the 
C-terminal histidine-tag of the Fab fragment. The elution fraction was 
concentrated on StrataClean beads (Stratagene) and visualized on SDS-PAGE 
(coomassie-stained) (Figure 6-17 (a)). Subsequent analysis of the protein bands 
by MALDI mass spectrometry verified specific association of calreticulin 
(60  kDa), ERp57/PDI (57  kDa), tapasin (48  kDa), human lymphocyte antigen 
(HLA) class I heavy chain (44 kDa) with TAP1 (72 kDa) and TAP2 (70 kDa). 
Notably,  β2m (12  kDa) was missing, probably due to the non-covalent 
association with the class I heavy chain it was lost during the purification 
procedure. The MALDI-MS results are summerized in Table 6-3. The analysis of 
the 58 kDa protein band revealed that this band was a mixture of ERp57 and a 
novel factor, protein disulfide isomerase (PDI). PDI, a member of the protein 
disulfide isomerase family, is an enzyme in the endoplasmic reticulum of 
eukaryotes or periplasmic space of prokaryotes and mediates proper protein 
folding by acting on disulfide-bond oxidation, reduction, and isomerization. 
Unfortunately, shortly after our discovery Ahn and colleagues (Park et al., 2006) 
published the newly identified PDI as a novel factor of the PLC, describing its Results 
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editing function in the redox regulation of the MHC class I molecules facilitating 
selection of high-affnity peptides. They hypothesize that editing of the 
MHC class I peptide repertoire involves a rapid thiol disulfide exchange between 
PDI and the MHC class I α2 disulfide as well as a competition between peptides 
of various affinities for MHC class I binding. A prerequisite for peptide transfer to 
MHC class I peptide cleft by PDI, is the oxidation of the α2 disulfide bond of 
MHC  class  I molecules in the PLC. Binding of a high-affinity peptide to the 
MHC  class  I molecule stops the competition of peptides and induces a 
conformational change resulting in the release of the MHC class I-peptide from 
the PLC. 
An insight into the structural organization of the in vivo PLC composition would 
contribute greatly to the understanding of this macromolecular machinery. 
Single particle analysis (SPR) enables the analysis of quaternary structure and 
oligomerization state of protein complexes even with very low protein 
concentrations as already shown for TAP1/TAP2 (Velarde  et al., 2001). Here, 
Figure  6-17  (b) shows for the first time electron micrographs of negatively-
stained digitonin-solubilized endogenous PLC complexes obtained from a 
human lymphoblastoid Raji cell line. Unfortunately, the particles differed in their 
size, which made further analysis of the particles impossible. The reason for the 
heterogeneous population of the single particles may lie in the transient nature 
of the PLC, consequently leading to instability and further dissociation of single 
components during the purification procedure. The optimization of the 
purification procedure, for instance in the presence of cross-linkers to stabilize 
the complex, is still in progress. Results 
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Figure 6-17. Composition of the purified peptide-loading complex from Raji cells. Microsomes 
(5 mg/mL total protein) prepared from 10
10 Raji cells were solubilized with 2% digitonin. The 
PLC was co-purified via TAP1-specific Fab fragment affinity-coupled on Ni-NTA beads. The 
elution fraction was concentrated on StrataClean beads (Stratagene) and subjected to SDS-
PAGE (coomassie-stained). Molecular mass standard in kDa. (b) Single particle electron 
microscopy of digitonin-solubilized PLC particles. Electron micrographs of the negatively stained 
PLC elution fraction, with the protein density appearing white, were kindly provided by Dr. David 
Parcej (Institute of Biochemistry, Goethe-University).  
 
Table 6-3. Identification of the PLC components after separation on SDS-PAGE and analysis by 
MALDI-MS. Additional information about the databank acquisition number, the score (derived 
from ions scores as a non-probabilistic basis for ranking protein hits with a value of >70 being 
significant), number of identified peptides, the molecular weight and the isoelectric point (pI). 
Protein 
Databank 
acquisition 
number 
Score 
Number of 
identified 
peptides 
Molecular weight (Da)  pI 
TAP2  gi|62087486  100 18  76186 8.2 
TAP1 gi|549042  86  16  81427  6.9 
PDI gi|21361657 163  23  57146  6.0 
ERp57 gi|2245365  148  22  57143  6.2 
calreticulin gi|5031873  85  15  57798  6.3 
tapasin gi|57209901  46  9  47938  6.7 
MHC class I  gi|27657357  79  12  36508  5.3 
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6.2.  Tapasin and MHC class I molecules: Intrinsic modulators of 
the antigen peptide transporter TAP 
The macromolecular PLC displays an elaborated machinery of the immune 
system involved in the presentation of antigenic peptides to effector cells for 
rapid interference in case of an infection. However, the transient nature of the 
macromolecular PLC makes it difficult to look at single interactions in vivo. 
However, without structural information about the in vivo composition of the 
PLC, it is impossible to draw mechanistic conclusions. To date, little is known 
about the dynamic interaction within the PLC, including the reorganization of the 
PLC after formation of stabile MHC I-peptide complexes and their disassembly 
from the PLC ready to leave for the cell surface. And how does tapasin, the 
supposed peptide editor, come into play? Thus it is indispensable to establish 
an  in vitro platform for the investigation of individual interactions using 
recombinant proteins. To investigate the dynamic interaction between tapasin 
and MHC class I molecules in vitro, it is necessary to work with monodispersely 
purified and active proteins. This part of the work aims at establishing the 
expression, purification, as well as functional characterization of soluble tapasin 
and soluble MHC class I B44 alleles in insect cells. 
6.2.1.  Expression and purification of soluble tapasin in insect cells 
The cloning of the soluble tapasin in pFastBac1 was done by Stefan Ammer, 
Institute of Biochemistry, Goethe-University Frankfurt (PhD thesis). Tapasin 
lacking the cytosolic and the transmembrane domains (amino acids 1-384) was 
PCR-amplified introducing a His6-tag (3’-end) and the restriction sites BamH I 
(5’-end) and Hind  III (3’-end), which were subsequently used for cloning into 
pFastBacI (Figure  6-18  (a)). For biochemical characterization, theoretical 
parameters of the tapasin variant are summarized in Table 6-4.  
 
 
 Results 
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Table 6-4. Theoretical protein profile of tapasin (based on calculations with the ProtParam at 
www.expasy.ch). 
  Molecular weight (kDa)  pI  Extinction coefficient (M
-1cm
-1) 
(at 280 nm and pH 6.5) 
tapasin(1-384)  41.9 6.65  66,920 
 
Soluble tapasin was expressed in Tn5 cells for 72 h at 27°C. Since the cytosolic 
ER retention signal is deleted in the soluble tapasin, it is secreted into the 
medium. The recombinant tapasin with an apparent molecular mass of 42 kDa 
was detected after dialyzing the supernatant as shown by SDS-PAGE and 
immunoblotting with tag-specific antibodies  (Figure 6-18 (b)).  Tapasin  was 
purified by immobilized metal affinity chromatography (IMAC) using the C-
terminal His6-tag (Figure 6-18 (b)). Here, tapasin was purified to homogeneity in 
a single affinity chromatography step as shown by SDS-PAGE (coomassie-
stained) (Figure 6-18 (c)), yielding 100-200 µg of tapasin per liter of Tn5 culture. 
Correct folding and monodispersity of the purified tapasin was demonstrated by 
size exclusion chromatography (Figure 4-18 (d)). Tapasin eluted in a symmetric 
peak at a retention volume expected for the monomer. Bovine serum albumin 
with a molecular mass of 66 kDa was used as an internal standard. An aliquot of 
the elution fraction was also subjected to reducing and oxidizing SDS-PAGE 
(coomassie-stained) verifying minor differences in the running behaviour due to 
the intramolecular disulfide bridges (C7-C71, C292-C362) (Figure 6-18 (e)).  Results 
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Figure 6-18. Purification of soluble tapasin from Tn5 insect cells. (a) Schematic representation 
of the soluble tapasin gene cassette in the pFB1 plasmid. (b) 72 h post infection cells were 
harvested and the supernatant was dialyzed against 20 mM Tris/HCl (pH 8.0), 200 mM NaCl, 
changing the buffer at least three times every 8-10  h. Aliquots of the dialyzed supernatant 
(dialyzate), the flow through (ft), the washing steps (wash 1, wash 2, wash 3) and the elution 
fraction (elution) were analyzed by 12% SDS-PAGE and detected with a tapasin-specific 
antibody. (c) 1 µg of purified tapasin after concentration with an ultrafiltration device (Amicon, 
Millipore) analyzed on a SDS-PAGE (12%, coomassie-stained). (d) The affinity-purified tapasin 
(150  µg) was analyzed by size exclusion chromatography (Superdex  200  PC3.2/30) by 
monitoring at 280  nm. The void volume (V0  =  0.85), the total volume (Vt = 2.3 mL)  and 
calibration standard bovine serum albumin (BSA, 66 kDa) are indicated by arrows in the graph. 
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(e) 1  µg of purified tapasin were subjected to SDS-PAGE (12%, coomassie-stained) under 
reducing (red.) and oxidizing (oxid.) conditions. Molecular mass standard in kDa. Minor 
impurities after purification (*), (**).  
6.2.2.  Expression of single chain MHC class I conjugates in insect cells 
Human leukocyte antigen (HLA) -B4402 and -B4405 (amino acids 1-276) 
MHC class I alleles  lacking  their  transmembrane domains were linked N-
terminally to β2m  via an (SG4)3 linker resulting in soluble single chain 
B4402-β2m (scB4402-β2m) and soluble single chain B4405-β2m (scB4405-β2m) 
conjugates (Figure  6-19  (b)). A C-terminal TEV-cleavage site and a His6-tag 
alone or in combination with an N-terminal Strep-tag were introduced 
(Figure  6-19  (a)). For biochemical characterization the theoretical parameters 
were retrieved from the amino acid composition and are summarized in 
Table 6-5.  
 
Table 6-5. Theoretical protein profile of scB4402-β2m and scB4405-β2m (based on calculations 
with the ProtParam at www.expasy.ch.). 
  Molecular weight (kDa)  pI  Extinction coefficient (M
-1cm
-1) 
(at 280 nm and pH 6.5) 
scB4402-β2m 47.4  5.47  87,780 
scB4405-β2m 47.4  5.53  89,270 
 
To analyze the expression level of the conjugates, 0.5 x 10
6 insect cells from P2 
virus amplification of scB4402-β2m and scB4405-β2m were subjected to 
SDS-PAGE following imunoblotting (Figure 6-19 (c)).  Both  scB4402-β2m and 
scB4405-β2m were equally well expressed as detected by tag-specific 
antibodies.  Results 
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Figure 6-19. Expression of soluble MHC class I in insect cells. (a) Schematic representation of 
the soluble single chain MHC class I B4402 and B4405 expression cassette in pFastBac1. The 
cassette includes the polyhedrin promoter region (yellow), a newly introduced pro-melittin signal 
sequence (orange), the soluble B4402 (pink) and B4405 (pink) as well as β2m (pink) connected 
by a (SG4)3 linker (light yellow), a TEV cleavage site (blue), a His6-tag (green) at the 3’-end and 
a N-terminal strepII-tag (green) at the 5’-end. (b) Schematic representation of the single chain 
MHC class I conjugate. (c) Expression profile of scB4402-β2m and scB4405-β2m. 5 × 10
5 Sf9 
cells from P2 virus amplification were analyzed by reducing SDS-PAGE (12%). The scB44 
conjugates were detected with a histidine-tag specific antibody as demonstrated by the arrow. 
Molecular mass standard in kDa. 
6.2.3.  Purification of scB4405-β2m expressed in Tn5 insect cells  
For large scale expression, Tn5 insect cells were infected with 10% of the total 
culture volume with the respective baculovirus. 72 h - 96 h post infection, cells 
were harvested and culture supernatants dialyzed, changing buffer at least 3 
times  every  8 – 12 h.  Dialyzed  supernatant was applied on a Ni-NTA resin, 
washed and eluted finally with 200 mM histidine. The scB4405-β2m conjugate, 
with an apparent molecular mass of 49 kDa, was detected by SDS-PAGE and 
immunoblotting with an MHC  class  I-specific antibody (Figure  6-20  (a)). The 
scB4405-β2m conjugate was purified to homogeneity in a single affinity 
chromatography step as shown by SDS-PAGE (coomassie-stained) 
(Figure  6-20  (b)) with a yield of 100-200  µg  per liter of Tn5 culture. When 
subjected to oxidizing SDS-PAGE analysis the oxidized scB4405-β2m conjugate 
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migrated faster than the fully reduced conjugate (Figure 4-18 (c)). The higher 
migration rates of the oxidized protein suggest the presence of several 
intramolecular disulfide bonds. Size exclusion chromatography revealed a 
monodisperse peak for scB4405-β2m running at approximately 49 kDa with a 
minor dimer peak immediately after purification eluting shortly before the 
monomer (Figure 6-20 (d) black line). Storage of the scB4405-β2m conjugate for 
two weeks at 4°C lead to increase of the dimer peak, eluting shortly before the 
monomer, as shown by the dashed line (Figure 6-20 (d)).  
 
 
Figure 6-20. Purification of soluble single chain B4405-β2m from Tn5 insect cells. 72 h post 
infection cells were harvested and the supernatant was dialyzed against 20  mM Tris/HCl 
(pH 8.0), 200 mM NaCl, changing the buffer at least three times every 8-10 h. Aliquots of the 
72
55
43
34
95
130
26
72
55
43
34
95
130
26
(a) (b) 
scB4405-β2m 
scB4405-β2mred. 
scB4405-β2moxid. 
(c)  (d) 
scB4405-β2 
0,5 1,0 1,5 2,0 2,5
0,0
0,1
0,2
0,3
0,4
0,5
s
c
B
4
4
0
5
-
β
2
m
V
t
V
0
O
D
2
8
0
volume (mL)
72
55
42
33
24
100
130
170
red. oxid.
72
55
42
33
24
100
130
170
72
55
42
33
24
100
130
170
red. oxid.
55
42
33
24
72
100
130
anti-MHC I
dialyzate
ft
wash 2
wash 3
elution
55
42
33
24
72
100
130
anti-MHC I
55
42
33
24
72
100
130
anti-MHC I
55
42
33
24
72
100
130
55
42
33
24
72
100
130
anti-MHC I
dialyzate
ft
wash 2
wash 3
elutionResults 
 
 
  113
dialyzed supernatant (dialyzate), the flow through (ft), the washing steps (wash 2, wash 3) and 
the elution fraction (elution) were analyzed. (a) Purification profile of scB4405-β2m analyzed by 
12% SDS-PAGE and detected with an MHC  class  I-specific antibody. (b) 1  µg of purified 
scB4405-β2m after concentration with an ultrafiltration device (Amicon, Millipore) analyzed by 
SDS-PAGE (12%, coomassie-stained). (c) 1  µg of purified scB4405-β2m were subjected to 
SDS-PAGE (12%, coomassie-stained) under reducing (red.) and oxidizing (oxid.) conditions. (d) 
The affinity-purified scB4405-β2m (100 µg) was analyzed immediately after affinity-purification 
(black line) and after storage for two weeks at 4°C (250  µg, dashed line) by size exclusion 
chromatography (Superdex  200  PC3.2/30) by monitoring at 280  nm. The void volume 
(V0  =  0.85  mL), the total volume (Vt  =  2.3  mL) are indicated by arrows in the chromatogram. 
Molecular mass standard in kDa. 
6.2.4.  Purification of scB4402-β2m expressed in Tn5 insect cells 
The scB4402-β2m conjugate was also produced in Tn5 cells infected with 10% 
of the total culture volume with the respective baculovirus. The expression as 
well as the affinity purification was performed analogous to scB4405-β2m (for 
details see 6.2.3). The scB4402-β2m conjugate with an apparent molecular 
mass of 49 kDa was detected with an MHC class I-specific antibody by reducing 
and oxidizing SDS-PAGE and immunoblotting (Figure  6-21  (a)). The oxidized 
state of the conjugate showed the same migration behaviour as the 
scB4405-β2m conjugate, confirming proper folding (Figure 6-21 (a), oxid. lane). 
In comparison to the scB4405-β2m conjugate purification, the secretion of the 
scB4402-β2m conjugate into the media was drastically decreased together with 
the purity and the yield of approximately 20  µg per liter Tn5 culture. Size 
exclusion chromatography of the elution fraction revealed several peaks, which 
were subsequently analyzed by reducing SDS-PAGE (coomassie-stained) and 
immunoblotting with an MHC class I-specific antibody. The scB4402-β2m was 
however clearly detectable in the fraction A8-B2 by immunoblotting 
(Figure 6-21 (b)).   Results 
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Figure 6-21. Purification of soluble single chain B4402-β2m from Tn5 insect cells. 72 h post 
infection cells were harvested and the supernatant was dialyzed against 20  mM Tris/HCl 
(pH 8.0), 200 mM NaCl, changing the buffer at least three times every 8-10 h. Aliquots of the 
dialyzed supernatant (dialyzate), the flow through (ft), the washing steps (wash 2, wash 3) and 
the elution fraction (elution) were analyzed. (a) Purification profile of scB4402-β2m analyzed by 
reducing SDS-PAGE (12%) and detected with a MHC class I-specific antibody. An aliquot of the 
elution fraction was also submerged to oxidizing SDS-PAGE (12%) and immunoblotting. (b) The 
affinity-purified scB4402-β2m (*, 200  µg) was analyzed by size exclusion chromatography 
(Superdex 200 PC3.2/30) by monitoring at 280 nm. The void volume (V0 = 0.85 mL), the total 
volume (Vt  =  2.3  mL) are indicated by arrows in the graph. Aliquots of the fractions were 
subjected to reducing SDS-PAGE (12%, coomasie-stained) and scB4402-β2m was detected 
with an MHC class I-specific antibody. Molecular mass standard in kDa. 
0.5 1.0 1.5 2.0 2.5
0
20
40
60
80
100
120
140
160
V
t
V
0
O
D
2
8
0
volume (mL)
(b) 
scB4402-β2m 
24
33
42
55
72
100
130
anti-MHC I
dialyzate
ft
wash 1
wash 2
wash 3
24
33
42
55
72
100
130
anti-MHC I
dialyzate
ft
wash 1
wash 2
wash 3
oxid.
55
42
72
100
130
33
24
oxid.
oxid.
55
42
72
100
130
33
24
anti-MHC I
55
42
72
coomassie stain
55
72
100
130
42
33
24
A7 A8 A9 A10 A11 A12 B1 B2 B3
anti-MHC I
55
42
72
anti-MHC I
55
42
72
coomassie stain
55
72
100
130
42
33
24
A7 A8 A9 A10 A11 A12 B1 B2 B3
coomassie stain
55
72
100
130
42
33
24
A7 A8 A9 A10 A11 A12 B1 B2 B3
(a) 
* Results 
 
 
  115
6.2.4.1.  Peptide-binding to recombinant HLA-B44 
The analysis of peptide-binding by the recombinant scB4405-β2m and 
scB4402-β2m conjugates was performed to analyse their functionality. First, the 
pH sensitivity of peptide-binding by the conjugates was investigated. For this 
purpose the naturally occurring ligand peptide DPα46-54 (46EEFGRAFSF54) was 
chosen. This peptide, derived from HLA-DP and shared by HLA-B4402 and 
-B4405 molecules, has been isolated from immunoaffinity purified HLA-B44 
complexes and identified by MALDI-TOF MS (MacDonald  et al., 2002). This 
peptide was subsequently used as a matrix for the synthesis of cysteine variants 
(EEFGCAFSF, EEFGRCFSF, EEFGRACSF and EEFGRAFCF), which were 
used for fluorescein-labeling (see chapter 5.4.17).  Peptide-binding  by 
scB4405-β2m was first investigated at pH 8.0 and pH 6.5. Here, I confirmed that 
peptide-deficient scB4405-β2m expressed in insect cells as recombinant 
conjugates bind peptides efficiently and that peptide binding is pH dependent 
with a preference for basic pH (pH 8.0 was preferred compared to pH 6.5). A 
decrease of about 40% in peptide binding was observed at pH 6.5. Specificity of 
peptide binding was demonstrated by adding an excess of the non-labeled 
peptide as competitor (Figure 6-22). 
 
 
Figure 6-22. pH sensitivity of peptide binding by scB4405-β2m. Purified scB4405-β2m (1 µM) 
was pH-shocked with 0.1 M citric acid (pH 2.5) for 2 min on ice and neutralized with 1 M Tris/HCl 
(pH 9.0). Subsequently, buffer exchange was performed on Micro-Spin columns (Biorad) with 
20 mM  HEPES,  pH 8.0  or  pH 6.5,  supplemented with 140  mM NaCl. Peptide binding was 
performed with 500  nM of the fluorescein-labeled peptide EEFGC
(F)AFSF for 12  h at 16°C 
(green bars). Subsequently, free peptide was removed and buffer was exchanged again to 
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20 mM HEPES (pH 7.5), 140 mM NaCl. The specificity of peptide binding was determined by 
adding a 100-fold excess of the peptide EEFGRAFSF as competitor (grey bars). Data represent 
the arithmetic mean of triplicate measurements.    
 
Since the purity as well as the overall yield of scB4402-β2m differed drastically 
from scB4405-β2m, it was important to show whether the purified, peptide-
deficient scB4402-β2m conjugate is active in peptide-binding (Figure 6-23 (a)). 
Here, the elution fraction as well as the 20  mM washing step from the 
purification step (named 20 mM eluate), was analyzed, showing specific peptide 
binding when compared to the sample incubated additionally with a 100-fold 
excess of non-labeled peptide (Figure  6-23  (a)). Comparing the effective 
peptide binding of scB4402-β2m and scB4405-β2m at equal protein amount I 
could show that scB4402-β2m has roughly 95% reduced peptide binding activity.  Results 
 
 
  117
 
Figure 6-23. Peptide-binding to scB4405-β2m and scB4402-β2m.  (a) 1 µM  of purified 
scB4402-β2m molecules, from the elution with 200 mM histidine (eluat) and from the elution with 
20 mM histidine (20 mM eluate) were pH-shocked with 0.1 M citric acid (pH 2.5) for 2 min on ice 
and neutralized with 1 M Tris/HCl (pH 9.0). Peptide-deficient MHC I complexes were isolated on 
Micro-Spin columns (Biorad). Peptide-binding was performed with 500 nM of the fluorescein-
labeled peptide EEFGC
(F)AFSF for 12 h at 16°C (black bars). The specificity of peptide-binding 
was determined by adding a 100-fold excess of the peptide EEFGRAFSF as competitor (grey 
bars). (b) Peptide-binding of 1 µM purified scB4405-β2m in comparison to 1 µM scB4402-β2m, 
as described in (a). Data represent the mean of triplicate measurements.    
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6.2.4.2.  Monitoring MHC class I-peptide interactions in solution  
To examine the kinetics of peptide association with peptide-deficient 
scB4405-β2m conjugates, the binding of four fluorescein-labeled peptides 
derived from the naturally occurring ligand peptide DPα46-54 (46EEFGRAFSF54) 
was monitored by fluorescence anisotropy at 20°C (Figure  4-24). The 
scB4405-β2m conjugates were pH-shocked and immediately mixed with the 
appropriate peptide prior to measurement. The obtained anisotropy profiles 
were collected for 12 h and data up to 30 min reaching saturation were fitted to 
monophasic kinetics. All anisotropy profiles followed first-order kinetics and are 
summarized in Table 6-6.  
 
Table 6-6. Association kinetics of the natural ligand peptide DPα46-54 EEFGRAFSF to 
scB4405-β2m 
Peptides  Amplitude [x 10
-4]  τ [s]  ka [10
5 M
-1s
-1] 
EEFGRAFC
(F)F  0.09 (±2.4)  672 (±98)  0.75 (±0.02) 
EEFGRAC
(F)SF  0.04 (±3.3)  1157 (±126)  0.43 (±0.04) 
EEFGRC
(F)FSF  0.11 (±5.5)  300 (±27)  1.67 (±0.06) 
EEFGC
(F)AFSF  0.12 (±3.6)  458 (±76)  1.10 (±0.04) 
C
(F) denotes fluorescein-labeled cysteine; time constant (τ) defined as 1/kobs.  
 
The association rate constants (ka) of the recombinant scB4405-β2m conjugates 
were found to be between 0.43  ×  10
5 M
-1s
-1 and 1.67  ×  10
5 M
-1s
-1 at 20°C 
(Table  6-6) with an amplitude ranging between 0.04  and 0.12, and are 
comparable to published fluorescence polarization data of MHC class I-peptide 
interactions in solution (Chen  &  Bouvier,  2007;  Binz  et al., 2003; 
Dédier et al., 2001). Changes in the amplitude reflect the flexibility of the 
fluorophore: the mobile the fluorophore the less prominent are the changes in 
anisotropy. Here, the fluorescein-labeled peptide, which induced a change of 
0.12 in anisotropy, represents a rigid fluorophore coupled to the cysteine which 
is deeply anchored in the peptide-binding groove. On the contrary, an amplitude 
of 0.04, reflects a very flexible fluorophore coupled to a cysteine, which is not 
directly involved in the interaction with the peptide-binding groove. These results 
demonstrate the functionality of the generated recombinant scB4405-β2m 
conjugate. Interestingly, anisotropy measurements performed with refolded 
recombinant  MHC class I-β2m heterodimer by Gakamsky and colleagues Results 
 
 
  119
revealed that peptide binding to as well as peptide dissociation from the 
MHC  class I molecule are both biphasic processes (Gakamsky  et al., 2000). 
Binz and colleagues claim that peptide binding is a two-step process limited by 
the conformational rearrangement in the heavy chain/β2m heterodimer. They 
also propose two pathways to explain the biphasic peptide dissociation: (I) 
peptide dissociates and leaves the heavy chain/β2m heterodimer and (II) β2m 
dissociates first from the MHC  class  I-β2m-peptide complex, followed by the 
peptide (Binz et al., 2003). In my case, the recombinant HLA-B44 heavy chain 
molecule is linked via a (SG4)3 linker with β2m, preventing the dissociation of 
β2m and allowing measurements of monophasic peptide association and 
dissociation kinetics. For scB4405-β2m conjugates, which were not pH-shocked, 
the increase in anisotropy was less prominent, than for pH-shocked 
scB4405-β2m conjugates, proving the fact that the recombinant complexes must 
be loaded with suboptimal peptides, when secreted in insect cells 
(Figure  6-24  (b)). The anisotropy profiles were specific as demonstrated by 
adding a 100-fold excess of the non-labeled competitor peptide EEFGRAFSF 
(Figure 6-24 (c),  competition),  which reduced the anisotropy signal to 
background level corresponding to the anisotropy observed with the free 
fluorescein-labeled peptide in buffer (Figure 6-24 (c), peptide + buffer). Results 
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Figure 6-24. Kinetics of peptide association onto peptide-deficient scB4405-β2m molecules. (a) 
20  nM of fluorescein-labeled peptide EEFGRAFC
(F)F, EEFGRAC
(F)SF, EEFGRC
(F)FSF or 
EEFGC
(F)AFSF, were mixed with 1  µM of the peptide-deficient scB4405-β2m molecules in 
20 mM HEPES, 150 mM NaCl (pH 7.5). The time course of the reaction was monitored at 20°C. 
(b) EEFGRAFC
(F)F (20 nM) without (grey) or with (blue) EEFGRAFSF competitor peptide (1 µM) 
were mixed with 400  nM of peptide-deficient scB4405-β2m molecules (400  nM) in 20  mM 
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HEPES, 150 mM NaCl (pH 7.5). The time course of the association was monitored at 20°C. (c) 
EEFGRAFC
(F)F (20  nM) was mixed with peptide-deficient scB4405-β2m molecules (400  nM) 
(grey) or together with the competitor peptide EEFGRAFSF (400 nM) (blue), EEFGRAFC
(F)F 
(20 nM) alone in 20 mM HEPES, 150 mM NaCl (pH 7.5) (black). For (a), (b) and (c) data were 
collected for 12 h, data up to 2000 s were fitted to monophasic kinetics. Excitation and emission 
wavelengths were 470 and 515 nm, respectively. 
 
Since the MHC class I-peptide complex is very stable in regard to its half-life, 
the dissociation kinetics were obtained by measuring one single anisotropy 
profile for up to 50  h. To examine the kinetics of peptide dissociation from 
scB4405-β2m, the decay curves of two peptides, EEFGRAFC
(F)F and 
EEFGC
(F)AFSF, were monitored by fluorescence anisotropy (Figure 6-25). The 
decay curves followed simple first-order kinetics and are summarized in 
Table  6-7. For the EEFGRAFC
(F)F peptide a dissociation half-life (τ) of 4.5  h 
was determined, when data were collected for up to 14  h. The dissociation 
half-life changed to 17.5  h when the decay was monitored for 50  h. The 
corresponding amplitudes of 0.007 and 0.014, and the dissociation rate 
constants (kd) of 6.16  x  10
-5 s
-1 and 1.59  x  10
-5 s
-1, respectively, were 
determined by fitting to simple first-order kinetics. The EEFGC
(F)AFSF peptide 
displayed similar dissociation kinetics with a dissociation half-life of 6.8 h, an 
amplitude of 0.01 and a kd of 4.08 x 10
-5 s
-1. 
 
 
 
 
 
 
 Results 
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Figure 6-25. Kinetics of peptide dissociation from scB4405-β2m. (a), (b) scB4405-β2m (400 nM) 
loaded with the peptide EEFGRAFC
(F)F was added to a 10-mm cuvette containing 20  mM 
HEPES, 150 mM NaCl (pH 7.5). Peptide dissociation was monitored at 20°C. Excitation and 
emission wavelengths were monitored at 470 and 515  nm, respectively. Data points were 
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collected for 14  h. (b) Same set-up as in (a). Data points were collected for 50  h. (c) 
scB4405-β2m (400 nM) loaded with EEFGC
(F)AFSF was added to a 10-mm cuvette containing 
20 mM HEPES, 150 mM NaCl (pH 7.5). Peptide dissociation was monitored at 20°C for 12 h.  
 
Table 6-7. Dissociation kinetics of the natural ligand peptide DPα46-54 EEFGRAFSF from 
scB4405-β2m. 
Peptide  Amplitude [x 10
-4]  τ [h]  kd [10
-5s
-1] 
EEFGRAFC
(F)F  0.007 (±1.3)  4.5 (±1.2)  6.16 (±0.30) 
EEFGRAFC
(F)F (50 h)  0.014 (±2.2)  17.5 (±3.4)  1.59 (±0.08) 
EEFGC
(F)AFSF  0.01 (±3.6)  6.8 (±0.9)  4.08 (±0.08) 
C
(F) denotes fluorescein-labeled cysteine; time constant (τ) defined as 1/kd.  
 
6.2.5.  SPR interaction analysis of soluble tapasin and recombinant 
HLA-B44  
To date, the dynamic assembly and disassembly of MHC  class  I molecules 
within the PLC was investigated solely in vivo using cell-based methods. In 
order to quantitatively investigate differences between individual MHC  class  I 
molecules with respect to peptide loading and its association and dissociation 
kinetics as well as the interaction with single proteins of the PLC, for instance 
tapasin, an in vitro assay was required. Although the peptide repertoire as well 
as subtype-specific folding properties and the related dependency upon the 
PLC were investigated, dynamic properties of MHC class I molecules have so 
far received comparatively little attention. Here, an in vitro platform was 
established for measuring MHC class I-tapasin interactions on solid-supported 
biosensors using the SPR technology. To investigate the interaction between 
soluble tapasin and the scB44-β2m conjugates, a commercially available 
streptavidin-functionalized Biacore SA sensor chip (Biacore) was used. The 
Biacore SA chip was further functionalized to the multivalent chelator 
trisnitrilotriacetic acid biotin conjugated (
BTtris-NTA,  Figure 6-26 (a)) 
(Reichel et al., 2007), which allows a reversible biotinylation of histidine-tagged 
proteins  (Figure 6-26 (b)).  Subsequently, histidine-tagged tapasin was 
successfully immobilized at roughly 250 RUs (Figure 6-26 (c)) and the stability 
of the immobilization was monitored for 600 s at constant flow of HBS buffer. 
Due to the His6-tag of tapasin, drifting of about 100 RUs over 800  s was Results 
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observed. The weak interactive loss of surface could not be reversed by 
blocking the surface after tapasin immobilization, neither with maltose-binding 
protein (MBP) having a His6-tag nor with MBP bearing a His10-tag (data not 
shown).  
For probing the scB4405-β2m conjugate on the tapasin-immobilized sensor 
chip, the His6-tag at the C-terminus of the conjugate was successfully cleaved 
off by TEV protease (Figure  6-26  (a)). Immunoblotting against heavy chain 
MHC class I molecules revealed the presence of the conjugate before and after 
cleavage but absence of the His6-tag after TEV protease treatment. The 
conjugate lacking the histidine-tag was applied for 30  s with a flow rate of 
30  µL/min on the tapasin-immobilized sensor chip, displaying concentration-
dependent association and dissociation rate constants (Figure 6-26 (b)).  
 
 
 Results 
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Figure 6-26. Principle of functionalization of the Biacore SA sensor chip with 
BTtris-NTA. (a) 
Chemical structure of 
BTtris-NTA loaded with Ni
2+ ions. (b) Principle of the reversible biotinylation 
of histidine-tagged proteins according to Piehler and colleagues (Reichel  et al., 2007).  (c) 
Schematic representation of the SPR setup for the investigation of the MHC class I-tapasin 
interaction. (d) After functionalizing the Biacore SA chip with 100  nM 
BTtris-NTA (flow rate 
10 µL/min for 60 s), 100 nM tapasin with a C-terminal His6-tag (flow rate of 10 µL/min for 60 s) 
was immobilized. The stability of immobilization was monitored for 800 s. 
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Figure 6-27. Binding of scB4405-β2m to immobilized tapasin. (a) Detection of the scB4405-β2m 
conjugate (200 ng) by reducing SDS-PAGE and subsequent immunoblotting before (-) and after 
(+) TEV cleavage. (b) Binding of the scB4405-β2m conjugate after TEV cleavage to the 
immobilized tapasin at various concentrations (1.0, 2.5 and 5.0  µM) and binding of the 
scB4405-β2m conjugate (2.5 µM) after TEV cleavage to 
BTtris-NTA functionalized Biacore SA 
sensor chip without immobilized tapasin (w/o tapasin). (c) Fit and residuals for the association of 
the scB4405-β2m conjugate shown in (b). (d) Fit and residuals for the dissociation of the 
scB4405-β2m conjugate shown in (b). (e) Fit and residuals for the association of the 
scB4405-β2m conjugate to 
BTtris-NTA functionalized Biacore SA sensor chip without tapasin 
shown in (b). (f) Fit and residuals for the dissociation of the scB4405-β2m conjugate from 
BTtris-NTA functionalized Biacore SA sensor chip without tapasin shown in (b). 
 
The association and dissociation curves for probing immobilized tapasin with 
scB4405-β2m conjugate are summarized in Table 6-8. In detail, the association 
curves were fitted to a mono-exponential equation with ka  values of 
(4.93 ± 1.16) × 10
4 M
-1 s
-1  for  1 µM,  (6.59 ± 1.50) × 10
4 M
-1 s
-1 for 2.5  µM and 
(6.17 ± 1.83) × 10
4 M
-1 s
-1 for 5.0  µM of the scB4405-β2m conjugate. The 
dissociation curves were fitted to a bi-exponential equation with slow and fast kd 
values  of  (0.73 ± 0.02) × 10
-1 s
-1  and  (11.22 ± 1.11) × 10
-1 s
-1 for 1  µM, of 
(0.85 ± 0.01) × 10
-1 s
-1  and  (13.24 ± 0.63) × 10
-1 s
-1 for 2.5  µM and of 
(0.96 ± 0.01) × 10
-1 s
-1  and  (16.88 ± 0.70) × 10
-1 s
-1 for 5.0  µM of the 
scB4405-β2m conjugate. Since the SPR technique allows a quantification of 
chemical association rates of up to 10
5-10
6 M
-1 s
-1  and dissociation rates of 
between 10
-5 and 10
-1 s
-1, the fast kd value of 10
-1 s
-1 is very error prone. The 
dissociation phase deviated significantly from a single exponential decay, 
indicating rebinding (Figure 6-27 (d) and (f)). It can not be ruled out that the 
biphasic behaviour is also associated with the tapasin loss (drift) from the 
surface. The scB4405-β2m conjugate interacted also with the 
BTtris-NTA 
functionalized SA surface in the absence of tapasin, yielding a response of 
about 12  RUs  (Figure 6-27 (b),  w/o  tapasin). A divalent cation mediated 
non-specific interaction via a histidine cluster within the conjugate could not be 
ruled out, since both association and dissociation phases deviated strongly from 
the monoexponential model (Figure 6-27 (e) and (f))  with  a  ka value of 
(0.95 ± 0.02) × 10
4 M
-1s
-1 and kd value of 0.53 × 10
-1s
-1. Mass transfer limitations 
could be excluded by different immobilization levels of tapasin as well as 
different flow rates of the scB4405-β2m conjugate over the immobilized tapasin. Results 
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In conclusion, the scB4405-β2m conjugate showed a concentration-dependent 
interaction with immobilized tapasin. Unfortunately, biphasic dissociation 
kinetics did not allow a kinetically meaningful evaluation of the obtained data. 
 
Table 6-8. Association and dissociation rate constants for the scB4405-β2m-tapasin interaction. 
kd (10
-1s
-1) 
scB4405-β2m (µM)  ka (10
4M
-1s
-1) 
slow  fast 
1.0  4.93 (± 1.16)  0.73 (± 0.02)  11.22 (± 1.11) 
2.5  6.59 (± 1.50)  0.85 (± 0.01)  13.24 (± 0.63) 
5.0  6.17 (± 1.83)  0.96 (± 0.01)  16.88 (± 0.70) 
    
6.2.6.  SPR interaction analysis of tapasin and recombinant HLA-B27 
Analogous to the SPR interaction analysis of tapasin and the scB4405-β2m 
conjugate produced in insect cells, refolded soluble HLA-B2705 and HLA-B2709 
alleles were probed for interaction with tapasin. The HLA-B2705 and 
HLA-B2709 produced in E. coli and refolded in the presence of a high-affinity 
peptide and β2m were kindly provided by Rolf Misselwitz (Charité, Berlin). 
Likewise the HLA-B4405 and HLA-B4402 alleles, the HLA-B2705 and 
HLA-B2709 too, display distinct characteristics in regard to tapasin. The 
HLA-B27 is strongly associated to spondyloarthropathies, particularly 
ankylosing spondylitis (AS) (Khan, 2002; Ramos  &  Lopez de Castro, 2002). 
Interestingly, not all of the HLA-B27 subtypes are associated to AS. The 
difference between AS associated and non-associated HLA-B27 subtypes is 
determined mainly by very few amino acids, which predominantly affect peptide-
binding properties of the MHC class I molecule. The HLA-B2709 allele is very 
weakly associated to AS, whereas the HLA-B2705 is tightly associated with the 
disease. Both alleles differ only in one amino acid at position 116: in B2709 we 
find His116 and in B2705 Asp116 (D’Amato et al., 1995). These amino acids at 
position 116 are located within the peptide binding cleft at the floor of the F 
pocket. Furthermore, both alleles display different dependencies on tapasin: 
HLA-B2709 shows tapasin dependency for peptide presentation on the cell 
surface, whereas HLA-B2705 is tapasin-independent in regard to the 
presentation of peptides on the cell surface. Results 
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The interactions of tapasin with the HLA-B27 alleles were probed on the Biacore 
SA chip functionalized to the 
BTtris-NTA, which allows a reversible biotinylation 
of histidine-tagged proteins (for details see 6.2.5). Subsequently, 
histidine-tagged tapasin was successfully immobilized at roughly 40  RUs 
(Figure 6-28 (a)) and stability of the immobilization was monitored for 400 s at 
constant flow of HBS buffer. Following immobilization of tapasin, peptide-loaded 
and peptide-deficient HLA-B2709 and HLA-B2705 were probed, respectively, 
for interaction (Figure  6-28). The peptide-deficient HLA-B27 molecules were 
generated as described in chapter 5.4.18. As a result, binding of the 
tapasin-dependent HLA-B2709 to the immobilized tapasin was only detectable 
in its peptide-deficient state (Figure  6-28  (a) black curve) whereas peptide-
proficient molecules showed no interaction (Figure 6-28 (a), blue curve). This 
interaction was specific for the immobilized tapasin as confirmed by control 
experiments without tapasin on the surface (data not shown). Further, there was 
no measurable interaction of the tapasin-independent HLA-B2705 and tapasin 
neither in peptide-deficient nor -proficient state at 5  µM of HLA-B2705 
(Figure 6-28 (b)). Since it was not possible to determine Req from titration curves 
at various protein concentrations due to low concentrations of HLA-B2709, it 
was not possible to calculate a KD  value. Instead, the association and 
dissociation curves were fitted to a biphasic exponential equation which could 
also be a characteristic for changes in the refractive index. A slow and a fast ka 
value of (1.15 ± 0.7) × 10
4 M
-1 s
-1 and (1.52 ± 0.9) × 10
5 M
-1 s
-1 as well as a slow 
and a fast kd  value  of  0.13 ± 0.07 s
-1  and  1.60 ± 1.00 s
-1, respectively, were 
determined. Also here, since the SPR technique allows a quantification of 
chemical association rates of up to 10
5-10
6 M
-1 s
-1 and dissociation rates of 
between 10
-5 and 10
-1 s
-1, the fast kd value of 1.60 ± 1.00 s
-1 is error prone. It 
could not be excluded that the biphasic behaviour was due to the dissociation of 
the immobilized tapasin from the surface.  
ka (10
4M
-1s
-1)  kd (10
-1s
-1) 
B2709 (µM) 
slow  fast  slow  fast 
5.0  1.15 (±0.7)  15.20 (±0.9) 0.13 (± 0.07)  1.60 (± 1.0) 
      
 Results 
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Figure 6-28. Binding of HLA-B2709 and HLA-B2705 to immobilized tapasin on a functionalized 
BTtris-NTA sensor chip. (a) The BIAcore SA chip was functionalized with 100 nM 
BTtris-NTA, with 
a flow rate of 10 µL/min for 60 s, following immobilization of 50 nM tapasin with a C-terminal 
His6-tag with a flow rate of 10  µL/min for 60  s. Stability of the tapasin immobilization was 
monitored for 400  s. Binding of peptide-deficient (black) and peptide-proficient (blue) 
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HLA-B2709 (5  µM; (b)) and HLA-B2705 (5  µM;  (c)) to immobilized tapasin or to 
BTtris-NTA 
functionalized Biacore SA sensor chip without immobilized tapasin (peptide-deficient B2709 w/o 
tapasin, peptide-deficient B2705 w/o tapasin ((b), (c), magenta). (d) Fit and residuals of the 
association of the peptide-deficient B2709 to the tapasin-immobilized 
BTtris-NTA functionalized 
sensor chip. (e) Fit and residuals of the dissociation of the peptide-deficient B2709 from the 
tapasin-immobilized 
BTtris-NTA functionalized sensor chip. 
7.2.7.  Influence of tapasin on the peptide dissociation from HLA-B44 
The analysis of the MHC class  I-tapasin interaction by SPR spectroscopy 
revealed difficulties in quantification due to transient, low affinity interaction, and 
consequently limitation in protein amount. Additionally, surface-exposed 
clusters of two histidines within the heavy chain MHC  class  I molecules 
contributed to non-specific interaction with the 
BTtris-NTA chelator groups. Thus 
the influence of tapasin on peptide dissociation from the scB4405-β2m 
conjugate was monitored in real-time by simultaneous total internal reflection 
fluorescence spectroscopy (TIRFS) and reflectance interferometry (RIf) 
detection (Gavutis et al., 2005) on lipid bilayers fused to a glass substrate to 
ensure lateral mobility, in cooperation with Dirk Paterok und Jacob Piehler 
(Institute of Biochemistry, Goethe University). The proper formation and 
thickness of the bilayer was monitored by RIf system before conditioning 
(imidazole, EDTA, Ni
2+). Here, the scB4405-β2m conjugate loaded with 
fluorescein-labeled peptide (EEFGC
FAFSF) was immobilized via the C-terminal 
His6-tag on a chelatorlipid mimicking the anchoring by the transmembrane 
domain, and the stability of immobilization was monitored for about 350 s before 
tapasin was injected. After 300  s non-labeled high affinity peptide 
(EEFGRAFSF) was injected and the peptide dissociation was monitored in the 
TIRFs channel (Figure 6-29). Results 
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Figure 6-29. Influence of tapasin on peptide exchange by the scB4405-β2m conjugate. (a) 
Schematic model of a co-immobilization experiment consisting of the generation of a fluid lipid 
bilayer by fusing unilaminar vesicles to the surface, (b) after immobilization of MHC  class  I 
molecules loaded with fluorescein-labeled peptide, (c) tapasin is probed. (d) Interference signal 
(black) and fluorescence signal (red) during immobilization of scB4405-β2m (I, 150 nM), stability 
of immobilization (II), tapasin injection (III, 500  nM), buffer flow after tapasin injection (IV), 
EEFGRAFSF peptide injection (V, 100 µM), buffer flow after EEFGRAFSF peptide injection (VI). 
 
Table 6-9. Dissociation kinetics of the fluorescence signal 
  kd (10
-4s
-1)  τ [h] 
II  6.42 (±0.31)  0.43 (±0.21) 
III  8.23 (±0.26)  0.33 (±0.13) 
IV  6.32 (±0.38)  0.44 (±0.15) 
V  4.63 (±0.41)  0.60 (±0.20) 
VI  6.78 (±0.60)  0.41 (±0.19) 
 
In the simultaneous TIRFS-RIfs system fluorescence-labeled as well as label-
free detection of interacting molecules is advantageous in comparison to the 
(d) 
(a)  (b)  (c)
600 900 1200 1500 1800
3.0
4.5
6.0
7.5
9.0
-10
-5
0
5
10
15
20
c
h
a
n
g
e
 
i
n
 
r
e
f
l
e
c
t
i
v
i
t
y
 
(
m
V
)
time (s)
VI IV II V III I
 
f
l
u
o
r
e
s
c
e
n
c
e
 
i
n
t
e
n
s
i
t
y
 
(
m
V
/
1
0
0
)Results 
 
 
  133
SPR spectroscopy, where interaction of proteins is solely based on mass 
changes on the sensor surface. Here, the role of tapasin, as peptide editor, on 
the fluorescein-labeled peptide loaded onto the scB4405-β2m conjugate was 
further investigated. Unfortunately, no significant differences in the peptide 
dissociation rates were observed, neither during or after tapasin injection nor 
during or after non-labeled peptide was injected as depicted from the 
fluorescence signal (red curve) shown in Figure  6-29. The kd  values derived 
from fitting the fluorescence signal to a mono-exponential decay are 
summarized in Table 6-9 and are 10-fold faster than the peptide dissociation 
kinetics obtained by anisotropy measurements. It is reasonable that a tapasin-
dependent MHC class I allele is needed to further investigate the peptide-editing 
role of tapasin. Unfortunately, the tapasin-dependent scB4402-β2m I generated, 
was not secreted properly and therefore not available for further tapasin 
interaction studies. Furthermore, recombinant and refolded HLA-B27 molecules 
are tag-less and were also not available for probing with tapasin. Recently, 
Wearsch and colleagues reported in a cell-free system, that recombinant 
soluble tapasin was ineffective in recruiting  MHC class I  molecules  and 
facilitating peptide binding. However, they showed, that recombinant tapasin-
ERp57 conjugates accomplished not only both of the above mentioned 
functions but also were capable to edit the repertoire of bound peptides to 
increase their affinity (Wearsch & Cresswell, 2007). The investigation of peptide 
dissociation kinetics in the presence of the tapasin-ERp57 conjugate, instead of 
tapasin alone, may shed light on the dynamics of reassembly of the 
subcomplex. 
 Discussion 
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7.  Discussion 
7.1.  Recombinant antibodies as extrinsic modulators of the 
antigen peptide transporter TAP 
The major and rather unexpected finding of this systematic study is that the 
peptide transport of human TAP can be inhibited by antibodies that specifically 
recognize a discrete linear epitope comprised of the very last five C-terminal 
amino acid residues of TAP1 (
744ADAPE
748). In addition, these antibodies 
strongly stabilize the heterodimeric TAP complex against rapid thermal 
inactivation in the absence of ATP. Since no other region within TAP was 
recognized by the antibodies both effects are exclusively linked to the 
C-terminus of TAP1. 
7.1.1.  Expression, purification and characterization of the recombinant 
antibodies 
Here, I generated recombinant Fv, scFv and Fab fragments by genetic 
engineering from hybridoma cells expressing the mAb148.3. First, the 
recombinant antibody fragments were heterologously expressed in E. coli. Both 
the Fv and Fab fragments from E. coli, were purified to homogeneity and 
monodispersity as demonstrated by SDS-PAGE, immunoblotting, and size 
exclusion chromatography (Figure 6-3). However the low yield, especially of the 
Fab fragment, supported the decision to choose an alternative strategy, and 
switch to Sf9 insect cells as expression host. As for other eukaryotic expression 
systems, insect cells provide their own eukaryotic chaperones mediating correct 
folding in the endoplasmatic reticulum (ER) as well as posttranslational 
modification similar to those found in mammalian cells. In this work a novel 
expression strategy for recombinant antibodies in insect cells was successfully 
established. The combination of the advantages of genetic engineering in 
baculovirus together with the processing machinery of the Sf9 secretion 
pathway provided an efficient expression system for recombinant antibodies. Discussion 
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The expression vectors pFastBac  1 and pFastBacDual were modified by 
inserting a leader peptide from the pro-melittin gene of honeybee for secretion 
of the recombinant proteins. The scFv as well as the Fab fragments were 
expressed and secreted into the insect cell medium. They were subsequently 
purified to homogeneity and monodispersity as demonstrated by SDS-PAGE, 
immunoblotting, and size exclusion chromatography (Figure  6-4). Moreover, 
successful formation of disulfide bonds in the immunoglobulin domains was 
confirmed by oxidizing SDS-PAGE (Figure 6-4 (a)). The yield of 2-4 mg/L cell 
culture was an increase by a factor of 10-20 for the scFv and by a factor of 
100-200 for the Fab fragment compared to expression in the periplasm of 
E. coli.  
7.1.2.  Characterization of the antigen-antibody interaction 
Based on kinetic and thermodynamic analysis, the epitope-paratope interaction 
was characterized in detail and compared with the parental antibody 
demonstrating nanomolar affinity of the monovalent antibody fragments for 
TAP1. The equilibrium binding constants of the recombinant antibodies as well 
as of the mAb148.3 were determined by ELISA (Figure 6-5;  Figure 6-6)  and 
SPR using the isolated NBD and the C-terminal epitope peptide 
CYWAMVQAPADAPE of TAP1, respectively, as antigen (Figure 6-7). The KD 
values for the monovalent recombinant Fv and Fab fragments are very similar. 
Moreover, the KD of the monovalent proteolytic Fab fragment of the mAb148.3 
for the NBD of TAP1 is in the same range as for the recombinant antibody 
fragments.  
7.1.3.  Dissection of the inhibition mechanism  
Surprisingly, the recombinant Fv fragment inhibits TAP-dependent peptide 
translocation into the ER similar to viral factors such as ICP47 of herpes simplex 
virus or US6 of human cytomegalovirus. Transport inhibition of the monovalent 
Fv fragment and the intact mAb148.3 was equally efficient (Figure 6-13). This 
observation demonstrates that inhibition results from a direct interaction of the 
paratopes with the C-terminus of TAP1 and not from steric effects caused by the Discussion 
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Fc regions of the intact antibodies or cross-linking of adjacent TAP heterodimers 
because of the bivalent interactions of the mAb148.3. To elucidate the inhibition 
mechanism I considered interference with ATP or peptide binding to the TAP 
complex. However, I could not detect an adverse effect on ATP or peptide 
binding in the presence of the Fv fragment, illustrating that the overall integrity of 
the heterodimeric TAP complex is maintained (Figure  6-14). Strikingly, the 
recombinant antibody fragments stabilize the TAP complex similar to ATP. The 
peptide-binding capacity of TAP was maintained over 2 h, whereas only 10% of 
remaining TAP activity was observed in the absence of Fv fragment (Figure 6-
15). Moreover, the presence of antibody fragments decelerated peptide 
dissociation kinetics from the purified TAP complex, inhibiting the dissociation of 
the TAP complex (Figure 6-16). These results are reminiscent of observations 
made during characterization of the recently identified TAP-specific viral 
inhibitor UL49.5 from bovine herpesvirus 1 (BHV-1). This protein employs two 
mechanisms to inhibit peptide translocation: (I) arrest of the transporter in a 
functionally incompetent conformation and (II) induction of proteasomal 
degredation of components of the peptide-loading complex 
(Koppers-Lalic et al., 2005). However, this effect could be explained by either 
protection from proteolytic degradation or stabilization of the TAP complex.  
By binding to the C-terminus of TAP1, the antibodies presented in my study, 
arrest TAP in a transport-incompetent state. Several lines of argumentation 
have to be considered: The X-ray crystal structure of the isolated NBD of human 
TAP1 bound to ADP-Mg
2+ was solved at a resolution of 2.5  Å 
(Gaudet et al., 2001). However, the structure of the last six C-terminal amino 
acid residues, which contain the epitope of the mAb148.3, was not resolved, 
indicating high flexibility of this region in the ADP-bound monomeric state of the 
NBD. Based on truncation studies and chimeras of rat TAP1 and TAP2, Knittler 
and colleagues could show that the C-terminal tails of TAP1 and TAP2 are 
non-equivalent (Bouabe et al., 2003). It became also evident that the control of 
nucleotide interaction in the NBD of TAP1 is more complex than in the NBD of 
TAP2. Although nucleotide binding to the NBDs can be modulated by both 
C-terminal tails, the exchange of ADP to ATP within the NBD of TAP1 is 
restricted to the intrinsic C-terminal tail. Interestingly, the C-terminal tail of the 
NBD of TAP1 can force the NBD of TAP2 to adapt the same ATP binding Discussion 
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properties as the NBD of TAP1, and the transporter containing two C-terminal 
tails of TAP1 has a remaining peptide transport activity of only 30% when 
compared to wild-type TAP (Bouabe  et al., 2003). More recently, it was 
suggested that the so-called α6/β10-loops close to the C-termini of TAP1 and 
TAP2 determine the non-synonymous nucleotide binding of the two NBDs 
(Ehses et al., 2005). However there is no indication from structural or 
biochemical studies that the α6/β10-loop region makes direct contact with 
bound ATP or ADP, suggesting that the α6/β10-loops contribute to the 
regulation of nucleotide binding in a conformational rather than a 
sequence-specific manner. 
The recombinant antibody fragments generated here did not affect ATP binding 
to TAP. However, peptide translocation was significantly inhibited. Considering 
the potential importance of the α6/β10-loop, the distance between this region 
and the epitope of the antibodies at the C-terminus of TAP1 might be too large 
to fully disturb the intramolecular cross-talk within the NBD of TAP1. Inhibition of 
peptide transport was highly specific, since the mAb435.3 directed against 
TAP2 showed absolutely no effect on peptide transport even at a concentration 
of 10 µM. If the affinity of mAb435.3 were to be 1,000-fold lower than that of 
mAb148.3 I would still have expected to see an effect on peptide transport. 
Furthermore, the fact that mAb435.3 is widely used in co-immunoprecipitation 
studies of TAP and the peptide-loading complex, demonstrates that the native 
conformation of TAP2 is recognized with a reasonable affinity. Notably, the 
TAP-specific viral inhibitor ICP47, which displays a similar equilibrium binding 
constant (50  nM, Beinert  et al., 1997) to the Fv fragment (32  nM), inhibits 
peptide translocation to a similar extent (75%) when used at a concentration of 
10 µM. 
It is commonly accepted that ATP binding to the NBDs of ABC-transporters 
induces the formation of a composite dimer, which in turn is required for 
productive ATP hydrolysis (Jones et al., 2004). Several sequence motifs of both 
NBD monomers contribute to dimer formation, most importantly the Walker A 
motif and the C-loop (Zaitseva  et al., 2005, Smith  et al., 2002, 
Chen et al., 2003). The crystal structure of the HlyB-NBD dimer bound to 
ATP-Mg
2+ provides evidence that also the C-terminus of the NBDs contributes Discussion 
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to the dimer interface (Zaitseva  et al., 2005). This suggests one possible 
explanation of the data presented here, namely that the antibody-mediated 
inhibition of the TAP-dependent peptide transport is due to interference with the 
formation of a stable dimer interface between the NBDs of TAP1 and TAP2. 
Notably, alignment of HlyB and TAP1 shows little conservation of the C-terminal 
20 residues. However, of the few dimeric NBD structures of ABC transporters 
available, HlyB is the closest relative to TAP. At this stage, therefore, I can only 
suggest a direct contribution of the C-terminus of TAP1 to the dimer interface. In 
order to provide strong experimental proof we have to rely on high-resolution 3D 
structures of a TAP heterodimer, which are not available yet. 
Within the current study, a detailed analysis of the inhibition mechanism of TAP-
dependent peptide transport is provided (peptide binding, ATP binding). The 
only open issue is whether TAP is inhibited by steric hindrance of the 
recombinant antibody fragments or by neutralizing a possible direct functional 
role of the C-terminus of TAP1. Therefore, studies with the isolated NBDs would 
be required. However, nobody in the field has so far managed to form a 
non-artificial heterodimer of the NBDs of TAP1 and TAP2 in solution. Finally, 
even if available, it remains questionable whether the isolated NBD dimer 
represents a valid model system for the TAP heterodimer within the ER 
membrane. 
In conclusion, the recombinant antibody fragments generated here proved 
useful to analyze the functional importance of the very last amino acid residues 
at the C-terminus of TAP1. Moreover, the antibodies represent valuable tools to 
modulate TAP function and might prove useful in the structural analysis and 
3D-crystallization of the TAP complex. Discussion 
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7.2.  Tapasin and MHC class I molecules: Intrinsic modulators of 
the antigen peptide transporter TAP  
The presentation of endogenous peptides by major histocompatibility complex 
(MHC) class I molecules to cytotoxic T-lymphocytes (CD8
+) on the surface of 
nucleated cells is a prerequisite for eliminating infected or malignantly 
transformed cells (Lehner  et al., 2004, Yewdell  &  Haeryfar,  2005). The highly 
regulated process of high-affinity loading of an optimized pool of peptides onto 
MHC  class I involves the interplay of specialized proteins including the lectin 
chaperones calnexin and calreticulin, the class  I-specific accessory molecule 
tapasin, the thiol-disulfide oxidoreductase ERp57, the protein disulfide 
isomerase (PDI), and the heterodimeric peptide transporter TAP1/2 within the 
endoplasmic reticulum (ER) (Paulsson & Wang, 2004,  Antoniou et al., 2003; 
Ahn et al., 2006). To dissect this elaborate pathway and to develop a 
mechanistic understanding of peptide loading and peptide selectivity, including 
the necessary interplay of other components of the PLC, an in vitro assay is 
indespensable. The prerequisite for performing functional in vitro-based assays 
is the establishment of an efficient expression and purification system for the 
recombinant proteins. In the current study, I report for the first time human 
MHC class I molecules engineered as single chain MHC class I-β2m complexes 
including a honeybee secretion signal sequence for the secretion in insect cells. 
Moderate yields of purified functional MHC  class  I scB44-β2m conjugates as 
well as tapasin were achieved. Furthermore, a peptide-binding assay as well as 
a homogenous assay to monitor MHC class I-peptide assembly in solution was 
established to verify functionality of the recombinant MHC  class  I molecules. 
Last but not least, an in vitro platform for probing MHC class I-tapasin 
interactions on biosensors was developed. Two recombinant MHC class I 
alleles, HLA-B27 and HLA-B44, as well as tapasin were probed for interaction 
by SPR and TIRF spectroscopy.  Discussion 
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7.2.1.  Expression, purification, and characterization of single chain B44 
conjugates 
The choice of an expression system for heterologous expression of human 
proteins very often demands a compromise between yield and functionality. The 
heterologous expression of recombinant proteins in E. coli, the working horse 
for recombinant protein production, is very often associated with high 
expression yields but mostly the proteins are insoluble and therefore inactive. 
Hence, elaborate refolding methods have to be established. Besides the tedious 
refolding process bacteria lack also the post-translational modification 
machinery, often needed for protein-protein interactions, which is present in 
eukaryotic organisms (Sambrook et al., 1998). Here, the insect cell expression 
system was applied, which is widely used to produce high quantities of post-
translationally modified human soluble as well as transmembrane proteins. 
Selecting the insect cells as hosts for the production of human recombinant 
MHC  class  I molecules, the functionality of the recombinant proteins was a 
major criterion, which was addressed. Hence, for the biochemical and the 
biophysical characterization it was necessary that the heterologously expressed 
recombinant MHC  class  I molecules could be loaded with defined peptides, 
designed here. Additionally a fluorescence-based peptide-binding assay was 
necessary to verify the functionality of the recombinant MHC class I molecules 
as well as a fluorescence polarization-based assay to directly monitor the 
kinetics of peptide-binding to the recombinant MHC class I molecules. 
Here, I successfully expressed HLA-B4402 and HLA-B4405 fused to β2m via a 
(SG4)3 linker, resulting in single chain conjugates. The leader peptide from the 
pro-melittin gene of the honeybee was employed for secretion of the 
recombinant MHC class I conjugates (Figure 6-19). The scB4405-β2m conjugate 
was purified to homogeneity in a single step purification yielding 100-200 µg/L 
cell culture. Size exclusion chromatography revealed a monodisperse protein 
peak running at approximately 49  kDa (Figure  6-20). Peptide binding and 
anisotropy measurements verified the functionality of the scB4405-β2m 
conjugate, thus demonstrating insect cells as the appropriate expression host 
(Figure  6-22; 6-23; 6-24; 6-25). Kinetic studies of scB4405-β2m-peptide 
complexes carried out with variants of the naturally occurring ligand peptide Discussion 
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EEFGRAFSF (with introduced cysteines at various positions (position 5-8)), 
revealed no significant changes in the association and dissociation rate 
constants (Figure 6-24; 6-25). Thus by substituting define amino acids in the 
ligand peptide EEFGRAFSF to cysteines and subsequent fluorescein-labeling, I 
did not succeed in generating short-lived peptide for suboptimal loading of the 
scB44-β2m conjugates for direct comparison with optimal loaded molecules. 
The association and dissociation rate constants (10
5 × M
-1s
-1 and 10
-5 × s
-1) of 
the scB4405-β2m conjugate are comparable to those published ones 
(Chen et al., 2007). However, the obtained dissociation rate constant may be 
error prone due to the stability of the complex and consequently the slow 
dissociation rate constant as well as the experimental setup monitoring the 
dissociation for up to 50 h. The scB4402-β2m conjugate was also successfully 
expressed (Figure 6-19 (c)) but the secretion into the medium was drastically 
decreased with the immediate consequence that it was very difficult to purify. 
The purified scB4402-β2m conjugate, as shown by coomassie-stained 
SDS-PAGE and verified by immunoblotting, represented only a minor portion of 
the abundant proteins in the eluate (Figure  6-21). Furthermore, in the size 
exclusion chromatography the scB4402-β2m conjugate was distributed over 
several fractions, as detected by immunoblotting, indicating polydisperse 
behaviour of the protein. This is indicative for misfolded, unstable, or unfolded 
proteins. However, unfolded scB4402-β2m conjugate would not display different 
running behaviour under reducing and oxidizing conditions as detected by 
immunoblotting (Figure 6-21, oxid. lane). When testing for functionality it was 
clearly demonstrated that it showed peptide-binding activity, however 
representing only 10% of the scB4405-β2m conjugate activity (Figure  6-23). 
Taking into account the fact that both molecules display great differences in 
their purity may reflect the difference in peptide-binding activity. Since both 
proteins, scB4405-β2m and scB4402-β2m, differ only in one amino acid it is very 
surprising how drastically this might affect the secretion, thus providing an 
insight into the intrinsic instability and therefore sequestration within the ER. It is 
known, that single MHC class I alleles differ in their selectivity of peptide loading 
depending on tapasin. While some HLA-alloforms are barely presented on the 
cell surface of tapasin
-/--cells, others show only minor differences in comparison 
to tapasin
-/--cells transfected with tapasin (Greenwood  et al., 1994, Discussion 
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Ortmann et al., 1997, Peh et al., 1998, Lewis et al., 1998, Barnden et al., 2000). 
A direct comparison showed that HLA-B2705 and HLA-A202, tapasin-
independent alleles, are present at the cell surface of .220-cells, a tapasin 
deficient cell line. By contrast, the expression of HLA-B4402, highly tapasin-
dependent allele, was drastically impaired in those cells. The HLA-B8 allele 
presented an average dependency on tapasin (Peh  et al., 1998). Based on 
these results the original hypothesis was that some HLA-alloforms, for instance 
HLA-B2705, were loaded with high affinity peptides in the absence of tapasin 
and that individual MHC  class  I molecules were affected differently by the 
tapasin editing function. Further investigation of HLA-B2705 in the presence and 
absence of tapasin revealed major differences in loaded peptides. It was 
observed that HLA-B2705 loaded with a viral peptide was presented to cytotoxic 
T cells in the absence of tapasin within a time-lag. In tapasin
-/--cells the 
HLA-B2705 molecules were prone to thermally induced instability as well as 
shortened half-life on the cell surface. In addition, they were loaded with a 
different peptide repertoire as in tapasin positive cells (Purcell  et al., 2000, 
Purcell et al., 2001, Tan  et al., 2002). Consequently, the peptide loading of 
HLA-B2705 was subject to quality control by tapasin. However, the HLA-B2705 
is also peptide stabilized in the absence of tapasin albeit to a lesser extent. This 
was one of the criteria why besides the HLA-B4402 and HLA-B4405, also 
HLA-B2705 and HLA-B2709 were chosen to directly probe the interaction of 
tapasin and MHC class I molecules.  
Besides the peptide supply, further factors must influence the 
tapasin-independent maturation. It is conceivable that a high intrinsic stability of 
an MHC class I allele promotes maturation. Also, a differential retention impact 
retains certain MHC class I alleles in the ER. In the absence of peptides the 
interaction of the HC with β2m determines the stability and probably also the 
export of MHC  class  I molecules from the ER (Neefjes  &  Ploegh,  1998, 
Shields et al., 1999). One can speculate whether the weak scB4402-β2m 
conjugate secretion in insect cells is due to the loss of bound peptide on the way 
to the cell surface, resulting in HC/β2m unfolding. It is important to mention that 
in tapasin-deficient cells the ER export of HLA-B4402 is very weak when 
compared to tapasin-proficient cells (Tan  et al., 2001). This supports the 
assumption that the HLA-B44 allele has a decreased intrinsic stability in the ER, Discussion 
 
 
  143
than for instance the HLA-B27 allele, leading to a decrease ER export. Alleles 
such as HLA-B2705 and HLA-B4405 show reduced tapasin dependencies 
(Peh et al., 1998, Williams  et al., 2002, Park  et al., 2003, Zernich  et al., 2004), 
implying that these alleles can mature through a pathway that bypasses 
equilibria at which tapasin can associate either with the peptide-deficient, open 
(active) conformation or with the peptide-filled, closed conformation. This in turn 
implies that the open forms of HLA-B2705 and HLA-B4405 molecules possess a 
binding cleft that is intrinsically more stable relative to the more tapasin-
dependent alleles. An increased stability could be achieved, for example, by 
engineering a peptide-binding cleft displaying a more intrinsic conformational 
maturity. As a consequence, it is expected that the open forms of peptide-
deficient HLA-B2705 and HLA-B4405 molecules show more specificity in the 
initial capture of peptides relative to tapasin-dependent alleles, which I 
suggested above to be more permissive in their initial selection of peptides. In 
other words, it is possible that allele-specific tapasin dependencies may be 
rooted by differences in intrinsic conformational maturity and maybe also by 
differences in peptide association kinetics. The question arises whether it is 
possible that peptide-binding to the highly tapasin-dependent alleles, including 
the scB4402-β2m conjugate, does not take place at all or is slowed down in the 
absence of tapasin. Although this remains to be examined experimentally, a role 
for MHC residues 114 and 116 (Williams  et al., 2002, Park  et al., 2003, 
Zernich et al., 2004) may be considered to influence the intrinsic conformational 
maturity of the class I binding cleft.  
The question remains how to improve the secretion of scB4402-β2m? 
Co-expression with soluble tapasin did not solve the problem (data not shown), 
which was also confirmed by the work of Everett and Edidin, who showed that 
tapasin increases the efficiency of MHC  class  I assembly but did not affect 
MHC class I stability at the cell surface (Everett & Edidin, 2007). Though, one 
would expect an increased retention of scB4402-β2m in the ER. Another idea 
would be to co-express scB4402-β2m together with a tapasin-ERp57 conjugate 
(Wearsch & Cresswell, 2007). Here again, in case the appropriate peptide is the 
missing link, I would still lack a high affinity peptide needed for loading and 
secretion since insect cells lack TAP expression, the supplier of the needed 
peptide pool. The simultaneous expression of scB4402-β2m, tapasin/ERp57 and Discussion 
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TAP together with the appropriate peptide is a very tedious task to perform, 
since all three viruses have to infect one cell at the same time. One would have 
to analyze single expression pattern of all three proteins and quantify their 
expression pattern at the same level. This could be solved using the MultiBac 
system where up to five separate genes are cloned for insect cell expression 
and expressed simultaneously. Furthermore, the expression of the ligand 
peptide itself, as a mini-gene construct, is another possibility but will not solve 
the problem if the tapasin-dependent HLA-B4402 displays slower peptide 
association kinetics and is dependent on other components of the PLC. Flutter 
and colleagues demonstrated that covalently linked HLA-B4402 heavy chain to 
β2m (B44-β2m) is efficiently expressed inside as well as on the surface of 
human cells (Flutter et al., 2007). However, the linked B44-β2m molecule is not 
expressed on the surface of a murine fibroblast, although it is expressed inside 
the cell. The authors showed that the lack of appearance on the surface is not 
due to degradation of unloaded B44-β2m molecules, since provision of 
HLA-B4402 binding peptide could not rescue impaired surface expression. 
Furthermore, they showed that co-expression with human tapasin does not 
rescue the cell surface expression either. But since human A2-β2m, a tapasin 
independent allele, was successfully expressed on the cell surface of these 
murine fibroblasts, it is obviously an allele-specific phenomenon to be further 
investigated. 
7.2.2.  MHC-tapasin interaction 
So far, the function of tapasin was characterized almost entirely by in-vivo 
studies. These experiments are primarily based on the analysis of tapasin
-/--
cells, mutagenesis, and co-immunoprecipitation studies. Only recently, Chen 
and Bouvier examined for the first time interactions in a soluble 
tapasin / HLA-B0801 complex to gain mechanistic insights into the functions of 
tapasin. By fusing the ER-luminal domains of tapasin and HLA-B0801 heavy 
chain at their C-termini to Jun and Fos peptides, respectively, they increased 
the intrinsic affinity of both proteins, succeeding in detecting interaction in 
solution by anisotropy measurements. Furthermore, they suggest that tapasin 
influences presentation of antigenic peptides by excluding peptides from the Discussion 
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repertoire that are unable to conformationally disengage tapasin from 
class I molecules (Chen & Bouvier, 2007).  
Within the current PhD-thesis, I investigated the MHC class I-tapasin interaction 
for the first time on solid-supported surfaces using SPR as well as RIfs-TIRF 
spectroscopy. To investigate association and dissociation kinetics of the 
MHC  class  I-tapasin interaction, a commercially available streptavidin-coated 
sensor chip was used. This biosensor was further functionalized to the 
BTtris-
NTA, which allows a reversible biotinylation of histidine-tagged proteins 
(Figure  6-26). The setup used here, allowed an immobilization of soluble 
tapasin via the C-terminal His6-tag for subsequent probing with the recombinant 
MHC class I molecules. Generating recombinant proteins for biochemical and 
biophysical analysis always bears the risk that the introduced modifications, for 
instance in case of tapasin the deletion of the transmembrane domain and the 
introduction of an affinity-tag, of rendering the recombinant protein non-
functional and unstable. This is the reason why modifications regarding the 
protein structure should always be as non-invasive as possible. Here, for the 
recombinant tapasin a hexa- instead of a His10-tag was chosen. In the following 
interaction analysis however, the immobilization via the His6-tag of tapasin, 
turned out to be the achilles’ heel of the system. Due to the C-terminal His6-tag 
and the decrease affinity towards the tris-NTA moieties on the sensor surface 
compared with His10-tag (Lata et al., 2005), tapasin drifted from the 
BTtris-NTA 
functionalized SA sensor surface over time, making it impossible for quantitative 
analysis. Blocking the tapasin-immobilized surface additionally with MBP, 
bearing a His10- or a His6-tag, did not eliminate background binding. On the 
contrary, tapasin, or tapasin together with MBP, were drifiting from the surface. 
This can be explained by the fact that the His10-tag of MBP of course competes 
for the His6-tag of tapasin for binding sites. Due to the drifting effects the 
obtained dissociation curves for scB4405-β2m were fitted best to biphasic 
kinetic, which make a qualitative evaluation in regard to actual rate constants 
impossible. After tapasin immobilization, first the scB4405-β2m conjugate, 
lacking the C-terminal His6-tag, was probed at different concentrations. From 
anisotropy measurements it became evident, that the purified scB4405-β2m 
conjugate was already loaded with a peptide, which could be competed out with 
the high-affinity ligand peptide EEFGRAFSF  (Figure 6-24 (b)).  This  loaded Discussion 
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peptide may represent a suboptimal peptide, allowing the interaction with 
tapasin (Figure 6-27 (b)). The observed interaction of scB4405-β2m-tapasin was 
concentration-dependent and tapasin specific (Figure 6-27 (b)) but followed a 
biphasic dissociation kinetic. Consequently, leaking of the surface affected the 
obtained dissociation curves for the scB4405-β2m conjugate, which made a 
qualitative evaluation in regard to the actual rate constants impossible. Since an 
increase of the flow rate as well as different levels of tapasin immobilization did 
not automatically change the association and dissociation kinetics, the biphasic 
behaviour may reflect the leaking of the surface. Even a more prominent 
drawback for the applied measurements of the MHC class I-tapasin interaction 
is the low protein amount relative to the transient low-affinity interaction. 
Transient, low-affinity interactions can be calculated from the equilibrium values 
derived from the kinetic data at different concentrations. Here, concentrations at 
least up to 10-100-fold higher than 5  µM should have been applied, which 
represent protein amounts not achievable with the shaking cultures of insect 
cells. The recombinant HLA-B27 molecules were also probed for interaction 
with tapasin. Peptide-loaded as well as peptide-deficient tapasin-independent 
HLA-B2705 and the tapasin-dependent HLA-B2709 were probed on the tapasin-
immobilized sensor surface (Figure  6-28). In contrast to the tapasin-
independent scB4405-β2m conjugate produced in insect cells and loaded with a 
sub-optimal peptide as stated above, the HLA-B2705 produced in E. coli and 
refolded in the presence of a high-affinity ligand peptide, showed neither a 
peptide-proficient nor a peptide-deficient tapasin-specific interaction 
(Figure 6-28 (c)). Since the refolded heavy chain-β2m molecules disintergrate in 
the absence of a ligand peptide, it is obvious that the pH shock, used to 
generate peptide-deficient MHC  class  I molecules, resulted in non-functional 
HLA-B27. However, tapasin-dependent HLA-B2709 displayed tapasin-specific 
interaction in the peptide-deficient state (Figure  6-28  (b)). Thus it cannot be 
ruled out, that the obtained plasmon shift is rather due to changes in refractive 
index, than to protein-protein interaction. As already mentioned for the scB4405-
β2m conjugate, the association and dissociation rate constants followed 
biphasic kinetics. Low-affinity interaction resulting in the limited protein amount 
available hindered concentration-dependent analysis. Discussion 
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Because the transient, low-affinity interaction of the MHC  class  I-tapasin 
complex and the low protein amounts available, the SPR measurements proved 
not to be the optimal method for evaluating these interactions. The TIRF-RIfs 
system was applied instead. The advantage to the SPR technology lies in the 
immobilization of proteins on chelated lipid bilayer surface, allowing for lateral 
mobility of the immobilized proteins. Another advantage to the mass-sensitive 
channel is the simultaneous monitoring of the fluorescence-labeled probe in the 
fluorescence channel. Here, the scB4405-β2m conjugate loaded with the 
fluorescein-labeled peptide as well as tapasin were immobilized on the chelated 
lipid bilayer via their C-terminal histidine-tags. Stable immobilization of both 
proteins was observed (Figure 6-29). Since the MHC class I-peptide association 
is slow as shown by the anisotropy measurements (Figure  6-24), only the 
tapasin editing function on the peptide dissociation kinetics was investigated. 
Unfortunately, immobilization of tapasin did not affect peptide dissociation 
kinetics. As already mentioned above the HLA-B4405 is rather a tapasin-
independent allele which may not necessarily be edited by tapasin when 
already loaded with a high affinity peptide. To my knowledge there is no 
endogenous suboptimal ligand peptide known for the HLA-B44 allele, which 
could be used for the investigation of the tapasin influence on peptide kinetics. 
However, the high-affinity peptide used here could be further modified by 
scanning the N-terminal amino acids (position 1 to 4) for a low-affinity 
interaction with the MHC class I peptide-binding cleft. Also, a tapasin-dependent 
MHC class I allele is important to further investigate the peptide-editing role of 
tapasin. 
Conclusively, the recombinant MHC class I molecules generated here, proved 
useful to analyze MHC class I-tapasin interaction as well as further interactions 
within the macromolecular PLC. Here, I presented for the first time an in vitro 
platform based on the SPR technology for measuring protein-protein 
interactions within the PLC. The heavily discussed question, whether or not 
tapasin serves as peptide-editor on preloaded  MHC class I  molecules,  still 
remains open. Only biochemical data exist, supporting tapasin’s editing 
function. Here, I applied the TIRF-RIfs system, immobilizing tapasin and pre-
loaded MHC  class  I molecules for the first time on chelated lipid bilayer to Discussion 
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ensure lateral mobility of the immobilized proteins, and to further investigate 
tapasin’s function in detail.  Abbreviations 
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8.  Abbreviations 
ABC     ATP-binding  cassette 
ADCC     antibody dependent cellular cytotoxicity 
ADP     adenosine  5’-diphosphate 
AHT     anhydrotetracycline 
Amp     ampicillin 
APC     antigen  presenting  cell 
APS     ammonium  persulfate 
ATP     adenosine  5’-triphosphate 
Bap      B cell associated protein 
BiP      immunoglobulin binding protein 
bp     base  pair(s) 
BSA      bovine serum albumin 
CCL2     chemotactic protein 
CDC     complement-dependent cytotoxicity 
cDNA     complementary DNA 
CDR      complementarity determing region 
CLIP      class II-associated invariant chain peptide 
Con A     Concanavalin A 
COP      coat protein complex 
CPM      counts per minute 
CTP     cytidine  5’-triphosphate 
DMF      dimethylformamide                    
DMSO  dimethyl  sulfoxide 
DNA     deoxyribonucleic  acid 
DTT     1,4-dithiothreitol 
dNTP     deoxynucleotide triphosphate Abbreviations 
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dsFv       disulfide-stabilized Fv fragment 
E. coli     Escherichia coli 
ECL       enhanced chemiluminescence 
EDTA     ethylene diamine tetraacetic acid 
ELISA     enzyme-linked immunosorbent assay 
ER       endoplasmic reticulum 
Fc     fragment  crystallizable 
Fv     fragment  variable 
Fab      fragment antigen binding 
g       gravity 
GM-CSF    granulocyte and macrophage colony-stimulating factor 
GTP     guanosine  5’-triphosphate 
HABA     (2-(4-hydroxyphenylazo)benzoic acid 
HBS      HEPES buffered saline 
HC     heavy  chain 
HLA     human  leukocyte  antigen 
hsFv      helix-stabilized Fv fragment 
IDA     iodo-diacetic  acid 
IFN     interferon 
IL     interleukin 
IgG     immunglobulin  G 
IMAC     immobilized metal affinity chromatography 
IPTG     isopropyl  β-D-thiogalactopyranoside 
ka      association rate constant 
kDa     kilo  Dalton 
KD     dissociation constant 
kd      dissociation rate constant 
L             liter Abbreviations 
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LB       lysogeny broth 
mAb     monoclonal  antibody 
MBP     maltose-binding  protein 
MHC      major histocompatibility complex 
min        minute 
mRNA    messenger  RNA 
NBD       nucleotide-binding domain 
Ni-NTA    nickel nitrilotriacetic acid 
NO     nitric  oxide 
OD      optical density  
PAGE     polyacrylamide gel electrophoresis 
PBS       phosphate buffered saline 
PCR      polymerase chain reaction 
pI       isoelectric point 
PI-Mix     protease inhibitor mix 
Rif(s)     reflectance  interference  spectroscopy 
RNA         ribonucleic acid 
RNase     ribonuclease 
rpm     rounds  per  minute 
RT     room  temperature 
RT-PCR    reverse transcription polymerase chain reaction 
s         second 
scFv       single chain Fv fragment  
SDS      sodium dodecyl sulfate 
SEC      size exclusion chromatography 
Sf9     Spodoptera  frugiperda  9 
Sm         streptomycin  
SOPC     stearoyl-oleoyl phosphatidylcholine Abbreviations 
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SPR      surface plasmon resonance   
T. ni      Trichoplusia ni    
TAE        Tris-acetate-EDTA buffer 
TAP        transporter associated with antigen processing 
TAPBP    TAP binding protein 
Taq     Thermophilus  aquaticus 
TBS       Tris-buffered saline 
TEMED   N,N,N’,N’-tetramethylethylenediamine 
TIRFS      total internal reflection fluorescence spectroscopy 
TMD     transmembrane  domain 
TMH     transmembrane  helix 
Tris        2-amino-2-hydroxymethyl-propane-1,3-diol 
TY       tryptone yeast 
U     unit 
V       Volt 
v/v       volume per volume 
w/v     weight  per  volume 
WT       wild type 
X-Gal     5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
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10.  Appendix 
Sequence of the XbaI-HindIII fragment of pASK68-Fv148.3 
 
TCTAGATAACGAGGGCAAAAAATGAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCT 
                       M  K  K  T  A  I  A  I  A  V  A  L  A 
GGTTTCGCTACCGTAGCGCAGGCCGAAGTTAAACTGCAGGAGACTGGTGGAGGATTGGTG 
  G  F  A  T  V  A  Q  A  E  V  K  L  Q  E  T  G  G  G  L  V 
CAGCCTAAAGGGTCATTGCAACTCTCATGTGCAGCCTCTGGATTCACCTTCAATACCATT 
  Q  P  K  G  S  L  Q  L  S  C  A  A  S  G  F  T  F  N  T  I 
GCCATGAACTGGGTCCGCCAGGCTCCAGGAAAGGGTTTGGAATGGGTTGCTCGCATAAGA 
  A  M  N  W  V  R  Q  A  P  G  K  G  L  E  W  V  A  R  I  R 
AGTAAAAGTAATAATTATGCAGCGTATTATGCCGATTCAGTGAAAGACAGGTTCACCATC 
  S  K  S  N  N  Y  A  A  Y  Y  A  D  S  V  K  D  R  F  T  I 
TCCAGAGATGATTCACAAAGCATCCTCTATCTGCAAATGAACAACTTGAAAACTGAGGAC 
  S  R  D  D  S  Q  S  I  L  Y  L  Q  M  N  N  L  K  T  E  D 
ACTGCCATGTATTACTGTGTGAGGGGTGCTTACGAGGGGGGTGCTATGGACTACTGGGGT 
  T  A  M  Y  Y  C  V  R  G  A  Y  E  G  G  A  M  D  Y  W  G 
CAAGGAACCTCGGTCACCGTCTCCTCAGCGTGGAGGCATCCACAGTTCGGAGGCTAATAA 
  Q  G  T  S  V  T  V  S  S  A  W  R  H  P  Q  F  G  G       
CCATGGAGAAAATAAAGTGAAACAAAGCACTATTGCACTGGCACTCTTACCGTTACTGTT 
                  M  K  Q  S  T  I  A  L  A  L  L  P  L  L   
TACCCCTGTGACAAAAGCCGACATCGAGCTCACTCAGGCTGCACCCTCTGTCTCTGTCAA 
F  T  P  V  T  K  A  D  I  E  L  T  Q  A  A  P  S  V  S  V   
TCCTGGAGAGTCAGTATCCATCTCCTGCAGGTCTAGTAGGAGTCTCCTGCATATTAATGG 
N  P  G  E  S  V  S  I  S  C  R  S  S  R  S  L  L  H  I  N   
CAACACTTTCTTATATTGGTTCCTACAGAGGCCAGGCCAGTCTCCTCAGCTCCTGATATA 
G  N  T  F  L  Y  W  F  L  Q  R  P  G  Q  S  P  Q  L  L  I   
TCGGATGTCCAACCTTGCCTCAGGAGTCCCAGACAGGTTCAGTGGCAGTGGGTCAGGAAT 
Y  R  M  S  N  L  A  S  G  V  P  D  R  F  S  G  S  G  S  G   
TGCTTTCACACTGAGAATCAGTAGAGTGGAGGCTGAGGATGTGGGTGTTTATTACTGTAT 
I  A  F  T  L  R  I  S  R  V  E  A  E  D  V  G  V  Y  Y  C   
GCAACATCTAGAATATCCGCTCACGTTCGGTGCTGGGACCAAGCTCGAGATCAAACGGGA 
M  Q  H  L  E  Y  P  L  T  F  G  A  G  T  K  L  E  I  K  R   
ACAAAAACTCATCTCAGAAGAGGATCTGAATTAATAATGATCTAAGCTT 
E  Q  K  L  I  S  E  E  D  L  N 
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Sequence of the XbaI-HindIII fragment of pASK85-Fab148.3 
 
TCTAGATAACGAGGGCAAAAAATGAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCT 
                       M  K  K  T  A  I  A  I  A  V  A  L  A 
GGTTTCGCTACCGTAGCGCAGGCCGAAGTTAAACTGCAGGAGACTGGTGGAGGATTGGTG 
  G  F  A  T  V  A  Q  A  E  V  K  L  Q  E  T  G  G  G  L  V 
CAGCCTAAAGGGTCATTGCAACTCTCATGTGCAGCCTCTGGATTCACCTTCAATACCATT 
  Q  P  K  G  S  L  Q  L  S  C  A  A  S  G  F  T  F  N  T  I 
GCCATGAACTGGGTCCGCCAGGCTCCAGGAAAGGGTTTGGAATGGGTTGCTCGCATAAGA 
  A  M  N  W  V  R  Q  A  P  G  K  G  L  E  W  V  A  R  I  R 
AGTAAAAGTAATAATTATGCAGCGTATTATGCCGATTCAGTGAAAGACAGGTTCACCATC 
  S  K  S  N  N  Y  A  A  Y  Y  A  D  S  V  K  D  R  F  T  I 
TCCAGAGATGATTCACAAAGCATCCTCTATCTGCAAATGAACAACTTGAAAACTGAGGAC 
  S  R  D  D  S  Q  S  I  L  Y  L  Q  M  N  N  L  K  T  E  D 
ACTGCCATGTATTACTGTGTGAGGGGTGCTTACGAGGGGGGTGCTATGGACTACTGGGGT 
  T  A  M  Y  Y  C  V  R  G  A  Y  E  G  G  A  M  D  Y  W  G 
CAAGGAACCTCGGTCACCGTCTCCTCAGCAAAGACCACTCCTCCGTCTGTTTACCCTCTG 
  Q  G  T  S  V  T  V  S  S  A  K  T  T  P  P  S  V  Y  P  L 
GCTCCTGGTTCTGCGGCTCAGACTAACTCTATGGTGACTCTGGGATGCCTGGTCAAGGGC 
  A  P  G  S  A  A  Q  T  N  S  M  V  T  L  G  C  L  V  K  G 
TATTTCCCTGAGCCAGTGACAGTGACCTGGAACTCTGGATCCCTGTCCAGCGGTGTGCAC 
  Y  F  P  E  P  V  T  V  T  W  N  S  G  S  L  S  S  G  V  H 
ACCTTCCCAGCTGTCCTGCAATCTGACCTCTACACTCTGAGCAGCTCAGTGACTGTCCCC 
  T  F  P  A  V  L  Q  S  D  L  Y  T  L  S  S  S  V  T  V  P 
TCCAGCACCTGGCCCAGCGAGACCGTCACCTGCAACGTTGCCCACCCGGCTTCTAGCACC 
  S  S  T  W  P  S  E  T  V  T  C  N  V  A  H  P  A  S  S  T 
AAAGTTGACAAGAAAATCGTACCGCGCGACTGCCATCACCACCATCACCATTAATAACCA 
  K  V  D  K  K  I  V  P  R  D  C  H  H  H  H  H  H 
TGGAGAAAATAAAGTGAAACAAAGCACTATTGCACTGGCACTCTTACCGTTACTGTTTAC 
               M  K  Q  S  T  I  A  L  A  L  L  P  L  L  F   
CCCTGTGACAAAAGCCGACATCGAGCTCACTCAGGCTGCACCCTCTGTCTCTGTCAATCC 
T  P  V  T  K  A  D  I  E  L  T  Q  A  A  P  S  V  S  V  N   
TGGAGAGTCAGTATCCATCTCCTGCAGGTCTAGTAGGAGTCTCCTGCATATTAATGGCAA 
P  G  E  S  V  S  I  S  C  R  S  S  R  S  L  L  H  I  N  G   
CACTTTCTTATATTGGTTCCTACAGAGGCCAGGCCAGTCTCCTCAGCTCCTGATATATCG 
N  T  F  L  Y  W  F  L  Q  R  P  G  Q  S  P  Q  L  L  I  Y   
GATGTCCAACCTTGCCTCAGGAGTCCCAGACAGGTTCAGTGGCAGTGGGTCAGGAATTGC 
R  M  S  N  L  A  S  G  V  P  D  R  F  S  G  S  G  S  G  I   
TTTCACACTGAGAATCAGTAGAGTGGAGGCTGAGGATGTGGGTGTTTATTACTGTATGCA 
A  F  T  L  R  I  S  R  V  E  A  E  D  V  G  V  Y  Y  C  M   
ACATCTAGAATATCCGCTCACGTTCGGTGCTGGGACCAAGCTCGAGCTGAAGCGCGCTGA Appendix 
 
 
  176
Q  H  L  E  Y  P  L  T  F  G  A  G  T  K  L  E  L  K  R  A   
TGCTGCACCGACTGTATCCATCTTCCCACCATCCAGTGAGCAGTTAACATCTGGAGGTGC 
D  A  A  P  T  V  S  I  F  P  P  S  S  E  Q  L  T  S  G  G   
CTCAGTCGTGTGCTTCTTGAACAACTTCTACCCCAAAGACATCAATGTCAAGTGGAAGAT 
A  S  V  V  C  F  L  N  N  F  Y  P  K  D  I  N  V  K  W  K   
TGATGGCAGTGAACGACAAAATGGCGTCCTGAACAGTTGGACTGATCAGGACAGCAAAGA 
I  D  G  S  E  R  Q  N  G  V  L  N  S  W  T  D  Q  D  S  K   
CAGCACCTACAGCATGAGCAGCACCCTCACGTTGACCAAGGACGAGTATGAACGACATAA 
D  S  T  Y  S  M  S  S  T  L  T  L  T  K  D  E  Y  E  R  H   
CAGCTATACCTGTGAGGCCACTCACAAGACATCAACTTCACCCATTGTCAAGAGCTTCAA 
N  S  Y  T  C  E  A  T  H  K  T  S  T  S  P  I  V  K  S  F   
CAGGAATGAGTGTTAGAGACAAAGGTCCTGATGCTGCTGATAGCAGGTAAGCTT 
N  R  N  E  C 
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Sequence of the EcoRI-HindIII fragment of pFastBac1-scFv148 
 
GAATTCCCCGGGGGATCCTCTAGAAACTCCTAAAAAACCGCCACCATGAAATTCTTAGTC 
                                              M  K  F  L  V 
 
AACGTTGCCCTTGTCTTTATGGTCGTATACATTTCTTACATCTATGCCGGCGACATCGAG 
 N  V  A  L  V  F  M  V  V  Y  I  S  Y  I  Y  A  G  D  I  E 
 
CTCACTCAGGCTGCACCCTCTGTCTCTGTCAATCCTGGAGAGTCAGTATCCATCTCCTGC 
 L  T  Q  A  A  P  S  V  S  V  N  P  G  E  S  V  S  I  S  C 
 
AGGTCTAGTAGGAGTCTCCTGCATATTAATGGCAACACTTTCTTATATTGGTTCCTACAG 
 R  S  S  R  S  L  L  H  I  N  G  N  T  F  L  Y  W  F  L  Q 
 
AGGCCAGGCCAGTCTCCTCAGCTCCTGATATATCGGATGTCCAACCTTGCCTCAGGAGTC 
 R  P  G  Q  S  P  Q  L  L  I  Y  R  M  S  N  L  A  S  G  V 
 
CCAGACAGGTTCAGTGGCAGTGGGTCAGGAATTGCTTTCACACTGAGAATCAGTAGAGTG 
 P  D  R  F  S  G  S  G  S  G  I  A  F  T  L  R  I  S  R  V 
 
GAGGCTGAGGATGTGGGTGTTTATTACTGTATGCAACATCTAGAATATCCGCTCACGTTC 
 E  A  E  D  V  G  V  Y  Y  C  M  Q  H  L  E  Y  P  L  T  F 
 
GGTGCTGGGACCAAGCTCGAGATCAAACGGGGTGGCGGTGGCTCTGGTGGCGGCGGTTCT 
 G  A  G  T  K  L  E  I  K  R  G  G  G  G  S  G  G  G  G  S 
 
GGCGGTGGCGGTTCTGCCGGCGAAGTTAAACTGCAGGAGACTGGTGGAGGATTGGTGCAG 
 G  G  G  G  S  A  G  E  V  K  L  Q  E  T  G  G  G  L  V  Q 
 
CCTAAAGGGTCATTGCAACTCTCATGTGCAGCCTCTGGATTCACCTTCAATACCATTGCC 
 P  K  G  S  L  Q  L  S  C  A  A  S  G  F  T  F  N  T  I  A 
 
ATGAACTGGGTCCGCCAGGCTCCAGGAAAGGGTTTGGAATGGGTTGCTCGCATAAGAAGT 
 M  N  W  V  R  Q  A  P  G  K  G  L  E  W  V  A  R  I  R  S 
 
AAAAGTAATAATTATGCAGCGTATTATGCCGATTCAGTGAAAGACAGGTTCACCATCTCC 
 K  S  N  N  Y  A  A  Y  Y  A  D  S  V  K  D  R  F  T  I  S 
 
AGAGATGATTCACAAAGCATCCTCTATCTGCAAATGAACAACTTGAAAACTGAGGACACT 
 R  D  D  S  Q  S  I  L  Y  L  Q  M  N  N  L  K  T  E  D  T  
 
GCCATGTATTACTGTGTGAGGGGTGCTTACGAGGGGGGTGCTATGGACTACTGGGGTCAA 
 A  M  Y  Y  C  V  R  G  A  Y  E  G  G  A  M  D  Y  W  G  Q 
 
GGAACCTCGGTCACCGTCTCCTCACACCATCACCATCACCATTAATGACCATGGAAGCTT 
 G  T  S  V  T  V  S  S  H  H  H  H  H  H  - 
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Sequence of the BamHI-HindIII fragment (VLCL) of pFastBacDual-Fab148.3 
 
GGATCCTCTAGAAACTCCTAAAAAACCGCCACCATGAAATTCTTAGTCAACGTTGCCCTT 
                                  M  K  F  L  V  N  V  A  L 
 
GTCTTTATGGTCGTATACATTTCTTACATCTATGCCGGCGACATCGAGCTCACTCAGGCT 
 V  F  M  V  V  Y  I  S  Y  I  Y  A  G  D  I  E  L  T  Q  A 
 
GCACCCTCTGTCTCTGTCAATCCTGGAGAGTCAGTATCCATCTCCTGCAGGTCTAGTAGG 
 A  P  S  V  S  V  N  P  G  E  S  V  S  I  S  C  R  S  S  R 
 
AGTCTCCTGCATATTAATGGCAACACTTTCTTATATTGGTTCCTACAGAGGCCAGGCCAG 
 S  L  L  H  I  N  G  N  T  F  L  Y  W  F  L  Q  R  P  G  Q 
 
TCTCCTCAGCTCCTGATATATCGGATGTCCAACCTTGCCTCAGGAGTCCCAGACAGGTTC 
 S  P  Q  L  L  I  Y  R  M  S  N  L  A  S  G  V  P  D  R  F 
 
AGTGGCAGTGGGTCAGGAATTGCTTTCACACTGAGAATCAGTAGAGTGGAGGCTGAGGAT 
 S  G  S  G  S  G  I  A  F  T  L  R  I  S  R  V  E  A  E  D 
 
GTGGGTGTTTATTACTGTATGCAACATCTAGAATATCCGCTCACGTTCGGTGCTGGGACC 
 V  G  V  Y  Y  C  M  Q  H  L  E  Y  P  L  T  F  G  A  G  T 
 
AAGCTCGAGCTGAAGCGCGCTGATGCTGCACCGACTGTATCCATCTTCCCACCATCCAGT 
 K  L  E  L  K  R  A  D  A  A  P  T  V  S  I  F  P  P  S  S 
 
GAGCAGTTAACATCTGGAGGTGCCTCAGTCGTGTGCTTCTTGAACAACTTCTACCCCAAA 
 E  Q  L  T  S  G  G  A  S  V  V  C  F  L  N  N  F  Y  P  K 
 
GACATCAATGTCAAGTGGAAGATTGATGGCAGTGAACGACAAAATGGCGTCCTGAACAGT 
 D  I  N  V  K  W  K  I  D  G  S  E  R  Q  N  G  V  L  N  S 
 
TGGACTGATCAGGACAGCAAAGACAGCACCTACAGCATGAGCAGCACCCTCACGTTGACC 
 W  T  D  Q  D  S  K  D  S  T  Y  S  M  S  S  T  L  T  L  T 
 
AAGGACGAGTATGAACGACATAACAGCTATACCTGTGAGGCCACTCACAAGACATCAACT 
 K  D  E  Y  E  R  H  N  S  Y  T  C  E  A  T  H  K  T  S  T 
 
TCACCCATTGTCAAGAGCTTCAACAGGAATGAGTGTTAGAGACAAAGGTCCTGATGCTGC 
 S  P  I  V  K  S  F  N  R  N  E  C  -   
 
TGATAGCAGGTAAGCTT 
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Sequence of the XmaI-NcoI fragment (VHCH) of pFastBacDual-Fab148.3 
 
CCCGGGGGATCCTCTAGAAACTCCTAAAAAACCGCCACCATGAAATTCTTAGTCAACGTT 
                                        M  K  F  L  V  N  V 
 
GCCCTTGTCTTTATGGTCGTATACATTTCTTACATCTATGCCGGCGAAGTTAAACTGCAG 
 A  L  V  F  M  V  V  Y  I  S  Y  I  Y  A  G  E  V  K  L  Q 
 
GAGACTGGTGGAGGATTGGTGCAGCCTAAAGGGTCATTGCAACTCTCATGTGCAGCCTCT 
 E  T  G  G  G  L  V  Q  P  K  G  S  L  Q  L  S  C  A  A  S 
 
GGATTCACCTTCAATACCATTGCCATGAACTGGGTCCGCCAGGCTCCAGGAAAGGGTTTG 
 G  F  T  F  N  T  I  A  M  N  W  V  R  Q  A  P  G  K  G  L 
 
GAATGGGTTGCTCGCATAAGAAGTAAAAGTAATAATTATGCAGCGTATTATGCCGATTCA 
 E  W  V  A  R  I  R  S  K  S  N  N  Y  A  A  Y  Y  A  D  S 
 
GTGAAAGACAGGTTCACCATCTCCAGAGATGATTCACAAAGCATCCTCTATCTGCAAATG 
 V  K  D  R  F  T  I  S  R  D  D  S  Q  S  I  L  Y  L  Q  M 
 
AACAACTTGAAAACTGAGGACACTGCCATGTATTACTGTGTGAGGGGTGCTTACGAGGGG 
 N  N  L  K  T  E  D  T  A  M  Y  Y  C  V  R  G  A  Y  E  G 
 
GGTGCTATGGACTACTGGGGTCAAGGAACCTCGGTCACCGTCTCCTCAGCAAAGACCACT 
 G  A  M  D  Y  W  G  Q  G  T  S  V  T  V  S  S  A  K  T  T 
 
CCTCCGTCTGTTTACCCTCTGGCTCCTGGTTCTGCGGCTCAGACTAACTCTATGGTGACT 
 P  P  S  V  Y  P  L  A  P  G  S  A  A  Q  T  N  S  M  V  T 
 
CTGGGATGCCTGGTCAAGGGCTATTTCCCTGAGCCAGTGACAGTGACCTGGAACTCTGGA 
 L  G  C  L  V  K  G  Y  F  P  E  P  V  T  V  T  W  N  S  G 
 
TCCCTGTCCAGCGGTGTGCACACCTTCCCAGCTGTCCTGCAATCTGACCTCTACACTCTG 
 S  L  S  S  G  V  H  T  F  P  A  V  L  Q  S  D  L  Y  T  L 
 
AGCAGCTCAGTGACTGTCCCCTCCAGCACCTGGCCCAGCGAGACCGTCACCTGCAACGTT 
  S  S  S  V  T  V  P  S  S  T  W  P  S  E  T  V  T  C  N  V 
 
GCCCACCCGGCTTCTAGCACCAAAGTTGACAAGAAAATCGTACCGCGCGACTGCCATCAC 
  A  H  P  A  S  S  T  K  V  D  K  K  I  V  P  R  D  C  H  H 
 
CACCATCACCATTAATAACCATGG 
 H  H  H  H  -  
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Sequence of the EcoRI-HindIII fragment of pFastBac1-scMHC-B4402 
 
GGAATTCAAAGGCCTACGTCGACGAGCTCACTAGTCGCGGCCGCTTTCGAATCTAGAAAC 
TCCTAAAAAACCGCCACCATGAAATTCTTAGTCAACGTTGCCCTTGTCTTTATGGTCGTA 
                   M  K  F  L  V  N  V  A  L  V  F  M  V  V 
TACATTTCTTACATCTATGCCGGCATCCAGCGTACTCCAAAGATTCAGGTTTACTCACGT 
 Y  I  S  Y  I  Y  A  G  I  Q  R  T  P  K  I  Q  V  Y  S  R 
CATCCAGCAGAGAATGGAAAGTCAAATTTCCTGAATTGCTATGTGTCTGGGTTTCATCCA 
 H  P  A  E  N  G  K  S  N  F  L  N  C  Y  V  S  G  F  H  P 
TCCGACATTGAAGTTGACTTACTGAAGAATGGAGAGAGAATTGAAAAAGTGGAGCATTCA 
 S  D  I  E  V  D  L  L  K  N  G  E  R  I  E  K  V  E  H  S 
GACTTGTCTTTCAGCAAGGACTGGTCTTTCTATCTCTTGTACTACACTGAATTCACCCCC 
 D  L  S  F  S  K  D  W  S  F  Y  L  L  Y  Y  T  E  F  T  P 
ACTGAAAAAGATGAGTATGCCTGCCGTGTGAACCATGTGACTTTGTCACAGCCCAAGATA 
 T  E  K  D  E  Y  A  C  R  V  N  H  V  T  L  S  Q  P  K  I 
GTTAAGTGGGATCGAGACATGGGTGGCGGAGGTAGTGGTGGCGGTGGCTCCGGTGGTGGC 
 V  K  W  D  R  D  M  G  G  G  G  S  G  G  G  G  S  G  G  G 
GGATCCGGCTCCCACTCCATGAGGTATTTCTACACCGCCATGTCCCGGCCCGGCCGCGGG 
 G  S  G  S  H  S  M  R  Y  F  Y  T  A  M  S  R  P  G  R  G 
GAGCCCCGCTTCATCACCGTGGGCTACGTGGACGACACGCTGTTCGTGAGGTTCGACAGC 
 E  P  R  F  I  T  V  G  Y  V  D  D  T  L  F  V  R  F  D  S 
GACGCCACGAGTCCGAGGAAGGAGCCGCGGGCGCCATGGATAGAGCAGGAGGGGCCGGAG 
 D  A  T  S  P  R  K  E  P  R  A  P  W  I  E  Q  E  G  P  E 
TATTGGGACCGGGAGACACAGATCTCCAAGACCAACACACAGACTTACCGAGAGAACCTG 
 Y  W  D  R  E  T  Q  I  S  K  T  N  T  Q  T  Y  R  E  N  L 
CGCACCGCGCTCCGCTACTACAACCAGAGCGAGGCCGGGTCTCACATCATCCAGAGGATG 
 R  T  A  L  R  Y  Y  N  Q  S  E  A  G  S  H  I  I  Q  R  M 
TACGGCTGCGACGTGGGGCCGGACGGGCGCCTCCTCCGCGGGTATGACCAGGACGCCTAC 
 Y  G  C  D  V  G  P  D  G  R  L  L  R  G  Y  D  Q  D  A  Y 
GACGGCAAGGATTACATCGCCCTGAACGAGGACCTGAGCTCCTGGACCGCGGCGGACACC 
 D  G  K  D  Y  I  A  L  N  E  D  L  S  S  W  T  A  A  D  T 
GCGGCTCAGATCACCCAGCGCAAGTGGGAGGCGGCCCGTGTGGCGGAGCAGGACAGAGCC 
 A  A  Q  I  T  Q  R  K  W  E  A  A  R  V  A  E  Q  D  R  A 
TACCTGGAGGGCCTGTGCGTGGAGTCGCTCCGCAGATACCTGGAGAACGGGAAGGAGACA 
 Y  L  E  G  L  C  V  E  S  L  R  R  Y  L  E  N  G  K  E  T 
CTGCAGCGCGCGGACCCCCCAAAGACACATGTGACCCACCACCCCATCTCTGACCATGAG 
 L  Q  R  A  D  P  P  K  T  H  V  T  H  H  P  I  S  D  H  E Appendix 
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GTCACCCTGAGGTGCTGGGCCCTGGGCTTCTACCCTGCGGAGATCACACTGACCTGGCAG 
 V  T  L  R  C  W  A  L  G  F  Y  P  A  E  I  T  L  T  W  Q 
CGGGATGGCGAGGACCAAACTCAGGACACCGAGCTTGTGGAGACCAGACCAGCAGGAGAT 
 R  D  G  E  D  Q  T  Q  D  T  E  L  V  E  T  R  P  A  G  D 
AGAACCTTCCAGAAGTGGGCAGCTGTGGTGGTGCCTTCTGGAGAAGAGCAGAGATACACA 
 R  T  F  Q  K  W  A  A  V  V  V  P  S  G  E  E  Q  R  Y  T 
TGCCATGTACAGCATGAGGGGCTGCCGAAGCCCCTCACCCTGAGATGGGAGCCGGTCGAC 
 C  H  V  Q  H  E  G  L  P  K  P  L  T  L  R  W  E  P  V  D 
GAGAACCTGTACTTCCAGTCTCATCACCATCACCATCACTAATGAAAGCTT 
 E  N  L  Y  F  Q  S  H  H  H  H  H  H  -  
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